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Abstract
The accumulation of misfolded proteins has profoundly toxic consequences for organisms and has
been linked to over 40 human disorders. Pregnancy is a unique physiological state involving
elevated stresses that are capable of inducing protein misfolding and aggregation. However,
essentially nothing is known about how the maternal body adapts during the stresses of pregnancy
to maintain protein homeostasis (proteostasis). Uncovering how the maternal body maintains
extracellular proteostasis during gestation is important, because the accumulation of misfolded
proteins in biological fluids has been reported as a pathological feature of the pregnancy-specific
disorder, pre-eclampsia. Pregnancy zone protein (PZP) and plasminogen activator inhibitor type2 (PAI-2), are two enigmatic proteins attributed with various biological functions that are
upregulated in pregnancy and in non-pregnancy associated inflammatory states. Both proteins are
known for their protease inhibitory activity in vitro, but there are indications that they potentially
contribute to extracellular proteostasis via other mechanisms including holdase-type chaperone
activity. Thus, the overarching goal of this project was to provide the first evidence of a pregnancyassociated extracellular chaperone network by characterising the novel holdase-type chaperone
activity of PZP and extracellular glycosylated PAI-2 in vitro.
The work described in Chapter 3 includes strategic attempts to optimise the purification of
endogenous PZP from human pregnancy plasma. The newly devised procedure operates under
non-denaturing conditions, allowing for the purification of native PZP with 40–75% increased
yield compared to previously published approaches. Given that pregnancy plasma is technically
and ethically challenging to acquire, novel attempts to produce recombinant PZP in human cells
are also described in this chapter. The results showed that 6His-tagged recombinant PZP could be
produced in HEK293-based cell lines in vitro, which was of a similar size to the endogenous form
of PZP found in pregnancy plasma as assessed by native Western blot analysis. However, there
were some issues with the quality of recombinant PZP-6His obtained, which was heterogeneous
and exhibited formation of undesirable disulfide bonds with other proteins constitutively secreted
by the HEK293-based expression systems.
Using purified PZP derived from human pregnancy plasma, the work described in Chapter 4
demonstrates that PZP can inhibit the fibrillar aggregation and cytotoxicity of the pre-eclampsiaand Alzheimer’s-associated amyloid beta 1–42 peptide (Aβ1–42) in vitro. Furthermore, the holdasetype chaperone activity of PZP also inhibited the amorphous aggregation of creatine
phosphokinase (CPK), and putative inhibition of misfolded proteins by PZP was observed in heatvi

stressed pregnancy plasma. Interestingly, analysis of plasma samples showed that the level of PZP
was significantly reduced (P = 0.012) in women with pre-eclampsia (mean ± standard deviation
(SD) = 0.16 ± 0.14 mg/mL, n = 32), compared to matched controls experiencing uncomplicated
pregnancy (0.28 ± 0.20 mg/mL, n = 32). Other proposed functions of PZP including its potential
role in immunomodulation are also considered in this chapter, with the present study identifying a
novel binding interaction between PZP and tumor necrosis factor alpha (TNFα).
Finally, the results described in Chapter 5 show that PAI-2 can inhibit the aggregation and
cytotoxicity of Aβ1–42 in vitro. Notably, the holdase-type chaperone activity of extracellular
glycosylated PAI-2 was markedly superior to that of intracellular non-glycosylated PAI-2.
Additional work in this chapter shows that both the chaperone and protease inhibitory activities of
PAI-2 are uniquely resistant to modification by inflammation-associated hypochlorite oxidation
unlike the protease inhibitory activity of PAI-1, which is likely to be important for considering the
relative contributions of PAI-2 to fibrinolysis and proteostasis during inflammation in vivo.
Taken together, the results presented in this thesis support the idea that PZP and PAI-2 may provide
significant contributions to the maintenance of extracellular proteostasis during pregnancy and
non-pregnancy associated inflammatory states, through stabilising misfolded proteins, and
inhibiting protein aggregation and cytotoxicity. This represents the first mechanistic explanation
of how the maternal body adapts to handle protein-misfolding stresses induced by human
gestation. Further understanding of PZP and PAI-2 functions including their chaperone activity
may lead to novel diagnostic or therapeutic strategies for numerous human disorders, including
Alzheimer’s disease and pre-eclampsia.
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1 Introduction
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1.1 Overview
All life is critically dependent upon the ability of proteins to correctly fold into their biologically
active, 3-dimensional conformation. Unfortunately, the process of protein folding is imperfect, and
is challenged by the existence of environmental stresses and molecular aberrations including
mutations. Proteins that misfold can lose their function and accumulate in proteinacious aggregates
containing amorphous or fibrillar structures. The process of protein misfolding and aggregation
has profoundly toxic consequences for organisms and has been linked to over 40 human disorders.
Concomitantly, a great deal of cellular machinery and energy is dedicated to protein folding quality
control (PFQC) in vivo. Although we possess quite a detailed understanding of intracellular PFQC
systems, our knowledge of corresponding extracellular PFQC mechanisms is still relatively
limited. The molecular mechanisms underlying PFQC is an important area of investigation that
has the potential to inform the development of novel therapeutic strategies for combatting human
disorders which exhibit protein misfolding and aggregation.
Pregnancy is a unique physiological state involving elevation of stresses that are capable of
inducing protein misfolding and aggregation. Remarkably, virtually nothing is known about how
the maternal body adapts during the stresses of pregnancy to maintain extracellular protein
homeostasis (proteostasis). This is important, because the accumulation of misfolded proteins
occurs in the pregnancy-specific disorder, pre-eclampsia. PZP and PAI-2 are two proteins that are
dramatically upregulated in pregnancy and in non-pregnancy associated inflammatory states. Both
proteins are known for their protease inhibitory activity, but there are indications that they
potentially contribute to extracellular proteostasis via other mechanisms including holdase-type
chaperone activity. Further characterisation of the functions of PZP and PAI-2 in vitro will shed
much needed light on their true biological importance.

2

1.2 Protein folding, misfolding, aggregation and disease
1.2.1

Mechanisms of protein folding

Polypeptides can adopt countless conformations over an immense amount of time, however, in
biological systems polypeptides fold into a highly specific structure within seconds (the “Levinthal
paradox”) (Levinthal 1969). This observation indicates the existence of an effective mechanism of
protein folding and although it has been the subject of fifty years of research, it is still not fully
understood. Seminal studies demonstrated that protein folding was a spontaneous and reversible
process, dependent solely upon the unique amino acid sequence of a polypeptide (Anfinsen 1973;
Anfinsen et al. 1961). As random searching through all available conformations would take an
astronomical length of time, it was suggested that folding occurred sequentially along a folding
pathway (Levinthal 1968, 1969). This suggestion led to the currently accepted model of protein
folding, which proposes that proteins achieve the native conformation through a multitude of
folding routes and intermediate conformations which converge on the most thermodynamically
favourable energy state (Baldwin 1995; Dill & Chan 1997; Karplus 1994). This is often graphically
represented as a free energy folding funnel (Figure 1.1). Key forces that contribute to the
production of the native state are believed to be (i) hydrophobic collapse, through which non-polar
residues become internally shielded from the solvent, forming a molten globule state (Ptitsyn et
al. 1990) and (ii) the formation of ~ 20 amino acid folding domains or “foldons”, in which localised
folding drives the assembly of the larger molecule (Englander & Mayne 2014). While small
proteins (< 100 amino acids) fold efficiently within milliseconds directly to the native state without
any observable intermediates, larger proteins (> 100 amino acids; the majority of all proteomes)
fold inefficiently to the native state through a pathway which is populated by many possible
intermediates and aggregation-prone misfolded conformations (Balchin et al. 2016). Chaperones
are defined as proteins that stabilise misfolded proteins, and may subsequently facilitate their
correct folding or unfolding. Chaperones interactively assist larger proteins in achieving the native
conformation and in preventing off-pathway misfolding and aggregation. However, despite the
involvement of chaperones, proteins can still become misfolded and trapped on the off-pathway
as protein aggregates.
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Figure 1.1 Folding funnel depicting free energy landscapes of protein folding, misfolding and aggregation.
Unfolded proteins travel through a multitude of on-pathway folding routes down an energy landscape (green) to reach
the most thermodynamically favourable state, which is known as the native state. Partially folded intermediates can
become trapped in low energy folding states or may undergo aberrant intermolecular reactions in off-pathway folding
(red), which can lead to the formation of stable aggregates (amorphous, oligomeric or fibrillar). Chaperones assist
folding intermediates to achieve the native state along the on-pathway and prevent aberrant intermolecular reactions
along the off-pathway. Adapted from Balchin et al. (2016).

1.2.2

Protein misfolding and aggregation

Proteins which assume abnormal or incorrect confomations are defined as misfolded. A range of
environmental stressors can contribute to the misfolding of native and newly synthesised proteins,
including (i) extremes of pH and temperature (Azuaga et al. 2002; Vetri et al. 2007), (ii) ionic,
shear and oxidative stress (Hill et al. 2006; Mantyh et al. 1993; Rakhit et al. 2002), hypochloriteinduced modification (discussed further in Section 1.2.4) and (iii) macromolecular crowding (Van
den Berg et al. 1999). Mutations or errors in DNA sequences can also structurally destabilise
proteins and contribute to their misfolding. For example, gene mutations have been linked to the
misfolding and subsequent aggregation of (i) amyloid beta (Aβ) precursor protein in Alzheimer’s
disease (Julia & Goate 2017), (ii) superoxide dismutase in amyotrophic lateral sclerosis (Banci et
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al. 2008) and (iii) transthyretin in systemic amyloidosis (Adams et al. 2019). Once misfolded,
proteins are prone to aggregation via intermolecular hydrogen bonding and non-polar interactions
between newly exposed hydrophobic regions (Rajan et al. 2001). These stabilising associations
result in proteins entering the off-pathway of protein aggregation. Depending on a range of factors
(such as the environmental conditions, rate of aggregation and identity of the protein), the offfolding pathway produces distinct types of protein aggregates, including disordered amorphous
aggregates and ordered amyloid fibrils (Figure 1.1) (Ecroyd & Carver 2008).
Amorphous aggregates are produced by the random and rapid clumping together of misfolded
proteins, which is a process that is rate-dependent upon the surface area of the aggregate (Borgia
et al. 2013; Stranks et al. 2009). It has been suggested that some large, insoluble aggregates consist
of local β-sheet arrangements, yet these do not contribute to the overall structure, which remains
disordered (Fink 1998). Despite being responsible for numerous human diseases and causing
significant problems in the wine making and pharmacological industries, amorphous protein
aggregation has received little attention in comparison to amyloid fibril research (Stranks et al.
2009).
Amyloid fibrils form more slowly than amorphous aggregates through a highly ordered,
nucleation-dependent polymerisation mechanism which follows sigmoidal kinetics in vitro
(Knowles et al. 2014). Briefly, the initial nucleation or “lag” phase is believed to be the primary
rate-determining step, in which misfolded intermediates of the protein associate together to form
a stable nucleus. During the polymerisation or “elongation” phase, monomeric, misfolded
intermediates sequentially add to the growing ends of the soluble oligomeric protofibril. However,
fragmentation and secondary nucleation may also contribute to the formation and generation of
protofibrils during the lag and elongation phases. The final termination or “plateau” phase is
characterised by termination of the elongated “protofilament”. X-ray fiber diffraction studies have
revealed that protofilaments are linear unbranched chains, consisting of cross-β structures (from
separate monomers) stacked perpendicular to the fibril axis (Saiki et al. 2005; Sunde & Blake
1997). Up to 6 of these protofilaments may associate to form a mature amyloid fibril (Serpell et
al. 2000). Mature amyloid fibrils are insoluble structures that are highly resistant to denaturation
and degradation by proteases, which may contribute in part to the difficulty the body encounters
in eliminating fibrillar aggregates. Strikingly, the formation of fibrillar aggregates has been
established to be an inherent property of polypeptide chains, as a diverse range of proteins (even
those not implicated in disease) are capable of forming amyloid-like structures (Chiti & Dobson
2006).
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1.2.3

Diseases of protein misfolding and aggregation

Protein misfolding has been linked to a plethora of human disorders. In general, protein misfolding
induces disease because the misfolded protein loses its normal function and/or gains a toxic
function. A subset of human protein misfolding disorders in which proteins misfold and
subsequently aggregate, often forming proteinacious deposits in bodily tissues, are collectively
known as protein deposition disorders (PDDs). Deposits of amorphous or fibrillar aggregates
(either intra- or extracellular) have been implicated in the pathology of over 40 PDDs (some
examples are provided in Table 1.1).

Table 1.1 Examples of PDDs and major protein aggregates implicated in their pathology.

Disease

Major protein aggregate(s)

Deposit
morphology

Localisation

Alzheimer’s disease

Amyloid beta
Tau

Fibrillar
Fibrillar

Extracellular
Intracellular

Amyotrophic lateral sclerosis

Superoxide dismutase

Fibrillar

Intracellular

Certain corneal dystrophies

Kerato-epithelin

Amorphous

Extracellular

Dialysis-related amyloidosis

Beta-2-microglobulin

Fibrillar

Extracellular

Huntington

Huntington

Fibrillar

Intracellular

Parkinson’s disease

Alpha-synuclein

Fibrillar

Intracellular

Pre-eclampsia1

Albumin
Alpha-1 antitrypsin
Amyloid beta
Ceruloplasmin
IgG K-free light chains
Transthyretin

Fibrillar
Fibrillar
Fibrillar
Fibrillar
Fibrillar
Fibrillar

Extracellular
Extracellular
Extracellular
Extracellular
Extracellular
Extracellular

Senile systemic amyloidosis

Transthyretin

Fibrillar

Extracellular

Spongiform encephalopathies

Prion protein

Fibrillar

Extracellular

Table compiled from Buhimschi et al. (2014); Kalkunte et al. (2013); Korvatska et al. (1999); Muchowski and Wacker
(2005); Rambaran and Serpell (2008); Sherman and Goldberg (2001); Soto (2001); Stefani (2004); Yerbury et al.
(2005b).
1
See Section 1.2.5 for further review.

Depending on the specific protein and the physiological context of its function, protein misfolding
and aggregation can result in a toxic loss of function. For example, mutations which impair the
folding of the cystic fibrosis transmembrane conductance regulator, a cyclic-AMP regulated
plasma membrane chloride channel, results in the lethal disease cystic fibrosis (Lukacs & Verkman
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2012). However, it is generally accepted that the toxic gain of function elicited by misfolded
proteins and their aggregates is the major contributor to disease pathogenesis in the PDDs.
Although, the precise mechanism(s) by which the process of protein misfolding and aggregation
evokes toxicity in many human disorders remains largely unknown. Induction of pro-inflammatory
responses, mitochondrial dysfunction, aberrant calcium signalling, membrane perforation,
oxidative stress, synaptic dysfunction and disruption to regular cellular functions such as
transcription have all been described as cytotoxic properties of misfolded proteins and their
aggregates (Merlini & Bellotti 2003; Sweeney et al. 2017). Part of the problem in understanding
how misfolded proteins and their aggregates elicit a toxic function in vivo lies in the diversity of
the heterogeneous protein species that form along the off-folding aggregation pathway (Bemporad
& Chiti 2012). For example, in the case of Alzheimer’s disease and “the amyloid hypothesis”, it
was initially thought that insoluble Aβ plaques were the primary inducer of pathogenicity in
Alzheimer’s disease. However, Aβ plaque deposition correlates poorly with disease severity and
clinical trials which involved drugs that reduced Aβ plaque production or aggregation were
unsuccessful in ameliorating the disease (Karran et al. 2011; Kayed & Lasagna-Reeves 2013). In
contrast, the amount of soluble Aβ oligomers from brain tissue correlates strongly with disease
severity and soluble Aβ oligomers are more toxic than insoluble Aβ fibrils in vitro (Ono & Tsuji
2020; Sengupta et al. 2016; Tomic et al. 2009). In the light of these findings, the amyloid
hypothesis has since been modified and it is now believed that soluble oligomers and other smaller
species formed early in the off-folding aggregation pathway are most likely to be the primary toxic
species responsible for Alzheimer’s disease (Reiss et al. 2018; Selkoe & Hardy 2016), and possibly
other PDDs. Overall, solving the precise mechanism(s) by which misfolded proteins and their
aggregates contribute to disease pathogenesis in PDDs remains a complex problem which is the
subject of ongoing investigation. Solving the latter problem is critical for the invention of effective
PDD therapeutics.

1.2.4

Hypochlorite-induced protein misfolding and disease

Hypochlorite (chemical formula OCl–) is produced during inflammation by cells of the innate
immune system (such as neutrophils, macrophages, and microglia) through the myeloperoxidaseH2O2-chloride system (Klebanoff 2005). Hypochlorite is a powerful oxidant and chlorinating agent
that is highly toxic to foreign microbes, which is therefore commonly used as the active ingredient
in many disinfectants. It has been previously suggested that the toxicity of hypochlorite is largely
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due to its ability to induce protein misfolding and aggregation (Winter et al. 2008). Hypochlorite
reacts far more rapidly with protein amino acids than other biological molecules (Hawkins et al.
2003; Pattison & Davies 2001). In terms of protein identity, this reactivity is non-specific and so
when hypochlorite is generated in vivo, it causes damage to proteins containing susceptible amino
acids regardless of whether they are of host or pathogenic origin. Hypochlorite-damaged proteins
have been implicated in the pathology of a wide range of human disorders including Alzheimer’s
disease (Green et al. 2004), atherosclerosis (Hazell et al. 1994), kidney disease (Malle et al. 1997),
rheumatoid arthritis (Stamp et al. 2012), osteoarthritis (Steinbeck et al. 2007) and chronic lung
disease (Buss et al. 2003). Several hypochlorite-activated chaperone systems have now been
described, including bacterial heat shock protein (HSP) 33 and RidA (Müller et al. 2014; Winter
et al. 2008), as well as human alpha-2-macroglobulin (A2M) and potentially other blood plasma
proteins including human serum albumin (Ulfig et al. 2019; Wyatt et al. 2014). The existence of
hypochlorite-activated proteostasis machinery strongly suggests that hypochlorite is an important
biological protein misfolding agent.

1.2.5

Pre-eclampsia: a pregnancy-associated disorder involving protein misfolding and
aggregation

Pre-eclampsia is a pregnancy-specific disorder of unknown etiology which affects approximately
5% of pregnancies worldwide (Abalos et al. 2013). It is a complex heterogeneous syndrome that
is characterised by new-onset hypertension and proteinuria, or new-onset hypertension co-morbid
with maternal organ dysfunction (e.g. haematological complications, intrauterine growth
restriction, liver damage and/or neurological complications) (Brown et al. 2018). Early-onset (<
34 weeks) and late-onset (≥ 34 weeks) forms of pre-eclampsia have been described (Von
Dadelszen et al. 2003). Abnormal placentation due to poor spiral artery invasion perfusion,
resulting in placental ischemia and angiogenic imbalances, are considered to be the underlying
pathological hallmarks of early-onset pre-eclampsia (Burton et al. 2019; Gathiram & Moodley
2016; Uzan et al. 2011). Late-onset pre-eclampsia is believed to arise from maternal endothelial
dysfunction and a systemic inflammatory response to placental oxidative stress (Phipps et al.
2016). In either case, delivery of the placenta constitutes the only effective treatment. Early-onset
or late-onset pre-eclampsia can be further sub-classified based on the severity of the disease and
other symptoms (Mammaro et al. 2009). However, the complex and heterogeneous nature of preeclampsia makes it difficult to accurately classify, and the latter practice is perhaps of limited
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usefulness given overlap is common between classifications (Brown et al. 2018). Due to the
adverse pathology, which in some cases can rapidly deteriorate into seizures, coma and severe
cardiovascular events, pre-eclampsia is a major cause of maternal and neonatal morbidity and
mortality worldwide, with 10–15% of maternal deaths directly attributed to the disorder (Duley
2009). Pre-eclampsia poses a significant health threat in developing countries where the majority
of worldwide maternal deaths occur, often due to poor diagnosis and late intervention (Osungbade
& Ige 2011). In addition, affected mothers and their children are at an increased risk of developing
further health issues later in life, including diabetes mellitus and cardiovascular complications
(O’Tierney-Ginn & Lash 2014). Due to the complex nature of the disorder, intensive multidisciplinary research is required to combat the formidable global health challenge presented by
pre-eclampsia.
Recent studies suggest that pre-eclampsia can be classified as a PDD. Pathophysiological features
of pre-eclampsia that underpin this classification are summarised in Figure 1.2. Misfolded protein
assemblies, including fibrillar amyloid-like structures, have been identified to accumulate in the
urine, serum and placenta of women with pre-eclampsia (Buhimschi et al. 2014; Kalkunte et al.
2013; Millen et al. 2018). The identity of misfolded proteins in pre-eclampsia patients includes
proteoforms of Aβ, albumin, alpha-1 antitrypsin, ceruloplasmin, IgG k-free light chains and
transthyretin (Buhimschi et al. 2014; Buhimschi et al. 2008; Kalkunte et al. 2013; Tong et al.
2017). Packaging of transthyretin aggregates into extracellular vesicles has been reported, and it
has been proposed the latter may be a general mechanism by which misfolded proteins are
transported in the maternal circulation to other organs (Schuster et al. 2020; Tong et al. 2017). It
has also been postulated that intracellular proteostasis mechanisms are impaired during preeclampsia, concomitant with elevations in cellular stresses which induce protein misfolding and
aggregation (Cheng 2014; Cheng et al. 2016; Gerasimova et al. 2019). For example, ischemia,
hypoxia and inflammation, are all capable of inducing intracellular endoplasmic reticulum stress
(Azfer et al. 2006; Jian et al. 2008; Yan et al. 2018). Indeed, high levels of endoplasmic reticulum
stress have been observed in the placenta of pre-eclampsia patients (Burton et al. 2009; Burton &
Yung 2011; Lian et al. 2011; Yung et al. 2008), which has been linked to impaired autophagy
(Nakashima et al. 2019a; Nakashima et al. 2019b; Nakashima et al. 2013) and dysregulation of
the unfolded protein response (Burton et al. 2009; Burton & Yung 2011; Gao et al. 2012). The
latter stresses and disruptions to intracellular proteostasis represent possible mechanisms by which
proteins may misfold and aggregate in pre-eclampsia. Hypochlorite-induced stress is potentially a
further mechanism by which proteins misfold in pre-eclampsia, because myeloperoxidase (the
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Figure 1.2 Pathophysiology of pre-eclampsia exhibiting protein misfolding and aggregation. Pre-eclampsia is a
complex heterogeneous disorder of unknown etiology. Common pathological hallmarks of pre-eclampsia at the
placenta are narrow spiral arteries (SA) with reduced extravillous trophoblast (EVT) invasion, resulting in
hypoperfusion of the placental intervillous space (IVS). Consequential placental ischemia produces oxidative stress,
inflammation, angiogenic imbalances and cytotoxicity, contributing to clinical manifestations of pre-eclampsia (high
blood pressure, organ dysfunction and/or proteinuria). Protein aggregates (PA) with fibrillar amyloid-like structure
are found in serum, placenta and urine of pre-eclampsia patients. Genetic and environmental stresses during pregnancy
that contribute to pre-eclampsia may also contribute to protein misfolding and aggregation. Oxidative stress and
inflammation arising as a result of pre-eclampsia-associated placental ischemia may also contribute to protein
misfolding and aggregation.

enzyme responsible for hypochlorite production) and advanced oxidation protein products
(produced by the reaction of proteins with hypochlorite), are elevated in maternal plasma and at
the placenta of women with pre-eclampsia (D’souza et al. 2017; Gandley et al. 2008; Huang et al.
2013). Similar to other PDDs, protein aggregates formed during pre-eclampsia are expected to
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cause cytotoxic effects in vivo. Supporting this idea, human transthyretin aggregates have been
found to deposit in the placenta of a humanised mouse model of pre-eclampsia and induce
apoptosis (Kalkunte et al. 2013). However, the overall role of protein aggregation in the
pathophysiology of pre-eclampsia remains unclear. Considering the vast majority of pre-eclamptic
aggregates are extracellular, characterisation of corresponding protective extracellular proteostasis
networks is of high interest.

1.3 Proteostasis
To mitigate the detrimental effects of protein misfolding, organisms have evolved complex PFQC
networks that function to maintain proteostasis. It has been demonstrated that the effectiveness of
PFQC networks declines with age (Ben-Zvi et al. 2009; Hipp et al. 2019; Kaushik & Cuervo
2015). Concomitantly stresses that promote protein misfolding are enhanced (Brehme et al. 2014;
Jones et al. 2002; Kikis et al. 2010). This collapse in proteostasis systems and corresponding
elevation of physiological stresses throughout life is believed to underpin the age-related nature of
many PDDs. Further study and complete elucidation of proteostasis systems could be the key to
understanding why PDDs occur and may aid in the identification of novel therapeutic strategies.

1.3.1

Intracellular proteostasis

The intracellular environment presents many challenges to proteins attempting to reach the native
fold. Nascent and incompletely folded polypeptides are prone to inappropriate interactions with
other proteins in the crowded environment of the cell, while proteins must also routinely unfold
and fold during cellular trafficking (Dobson 2003). Genetic mutations and other environmental
stressors can further contribute to the propagation of incompletely folded proteins (as discussed in
Section 1.2.2). Taken together, the potential for protein misfolding and aggregation within the cell
is high. Correspondingly, there exists a number of complex PFQC networks that function to
maintain intracellular proteostasis by mitigating protein misfolding and aggregation. At a glance,
some of the key players in the maintenance of intracellular proteostasis include molecular
chaperones, the ubiquitin-proteasome system (UPS) and the autophagosome-lysosome pathway
(ALP) (Figure 1.3).
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Figure 1.3 Simplified model depicting mechanisms of intracellular and extracellular proteostasis. Genetic
mutations or physiological stresses can cause proteins to misfold in the intracellular and extracellular compartments
of multicellular organisms. Specialised organelles, chaperone/co-chaperone networks, signalling pathways and
regulatory responses all help maintain intracellular proteostasis. Some key pathways of intracellular proteostasis are
summarised. (1) Molecular chaperones may stabilise and/or refold misfolded proteins, assisting in achievement of the
native conformation. Molecular chaperones may also assist in the degradation of misfolded proteins via interaction
with pathways 2 and 3. (2) Intracellular misfolded proteins may be tagged with ubiquitin and delivered to the
proteasome for proteolytic degradation. (3) Protein aggregates may be sequestered and internalised in autophagosomes
for proteolytic degradation via lysosome fusion. Outside the intracellular proteostasis network, (4) extracellular
chaperones may stabilise misfolded proteins and facilitate their disposal via receptor-mediated endocytosis and
lysosomal degradation. Alternatively, large complexes of extracellular insoluble misfolded proteins of amorphous or
fibrillar structure may undergo degradation by extracellular proteases into smaller soluble fragments and become
sequestered by extracellular chaperones.
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Molecular chaperones interact non-covalently with the exposed hydrophobic regions of
incompletely folded proteins and subsequently facilitate their stabilisation and/or refolding. Many
intracellular chaperones have been identified, all of which display varying functions vital to the
maintenance of proteostasis. Some key intracellular chaperones include (i) HSP60 and HSP70,
which are ATP-dependent chaperones that refold or promote the folding of non-native proteins
and (ii) small HSPs, which are ATP-independent holdase chaperones that bind to non-native
proteins for stabilisation (Hartl et al. 2011). In addition, HSPs may also promote the degradation
of misfolded proteins by interacting with the UPS and ALP. By stabilising, refolding and targeting
misfolded proteins for degradation, chaperones prevent protein aggregation and are thus vital to
the maintenance of intracellular proteostasis.
The UPS is involved in a broad array of cellular functions, including the ATP-dependent
proteolytic degradation of misfolded proteins. Initially, misfolded proteins are covalently tagged
with ubiquitin by a suite of ligases and subsequently, the ubiquitin-tagged protein is recognised by
a proteasome and degraded (Lecker et al. 2006). Misfolded proteins which bear ubiquitin tags (that
are non-specific for proteasomal degradation) and larger protein aggregates which are unable to
be degraded by the UPS may instead be targeted for sequestration in autophagosomes (Bjørkøy et
al. 2005; Pankiv et al. 2007). Following fusion of the latter with a lysosome, the sequestered
misfolded aggregates are proteolytically degraded. By disposing of misfolded and aggregated
proteins, the UPS and ALP work together to prevent the accumulation of toxic protein aggregates
and thus assist in maintaining intracellular proteostasis.
Further to the key players outlined here, cells possess many other tools (such as an extensive
network of chaperones and co-chaperones), regulatory pathways (such as the heat shock and
unfolded protein response) and specialised organelles (such as the endoplasmic reticulum), among
others, which can all contribute to maintenance of intracellular proteostasis. These are reviewed
extensively elsewhere (Díaz-Villanueva et al. 2015; Klaips et al. 2018).

1.3.2

Extracellular proteostasis

Once secreted from the tightly regulated confines of the cell, proteins are exposed to a variety of
stresses that are capable of inducing their misfolding. Protein misfolding can be induced by the
oxidising conditions of the extracellular environment (Go & Jones 2008) and the shear stress
induced by blood circulation (Hill et al. 2006; Ker & Chen 1998). In counteracting extracellular
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protein misfolding, intracellular mechanisms of PFQC are ineffective due to spatial separation and
lower extracellular concentrations of molecular chaperones, UPS components and ATP (which is
required for function of the former) (Farias et al. 2005; Filali et al. 2014; Martin-Ventura et al.
2007). Instead, a small group of normally secreted extracellular proteins with holdase type, ATPindependent chaperone activity has been identified. Currently, only a handful of extracellular
chaperones are reasonably well characterised, including clusterin, A2M and haptoglobin (French
et al. 2008; Humphreys et al. 1999; Poon et al. 2002a; Poon et al. 2002b; Wyatt et al. 2013b;
Wyatt et al. 2014; Wyatt & Wilson 2010, 2013; Wyatt et al. 2013c; Yerbury et al. 2009; Yerbury
et al. 2005a; Yerbury & Wilson 2010). Other extracellular chaperones of potential physiological
relevance include human serum albumin, lipocalins, serum amyloid P, apolipoproteins, fibrinogen,
caseins, secreted DNAJB11 and osteonectin (Carrotta et al. 2012; Coker et al. 2000; Emerson et
al. 2006; Evans et al. 1995; Finn et al. 2012; Genereux & Wiseman 2015; Janciauskiene et al.
1995; Kanekiyo et al. 2007; Koldamova et al. 2001; Marini et al. 2005; Morgan et al. 2005; Naiki
et al. 1997; Tang et al. 2009; Thorn et al. 2009; Wyatt et al. 2013c; Zsila 2010). In general,
extracellular chaperones selectively bind to and stabilise misfolded proteins, and in some cases
facilitate their disposal by receptor-mediated endocytosis (Figure 1.3) (Wyatt et al. 2013c). In this
way, it has been shown that extracellular chaperones (i) inhibit amorphous and fibrillar protein
aggregation (French et al. 2008; Poon et al. 2002a; Wyatt et al. 2013a; Yerbury et al. 2009;
Yerbury et al. 2007; Yerbury et al. 2005a) and (ii) protect cells against aggregate-related toxicity,
by binding to and disposing of soluble toxic oligomers (Bell et al. 2007; Fabrizi et al. 2001; Narita
et al. 1997; Qiu et al. 1999; Wyatt et al. 2014; Yerbury & Wilson 2010). This knowledge has
greatly increased our understanding of how secreted chaperones maintain extracellular
proteostasis. However, knowledge of extracellular proteostasis mechanisms remains quite limited
compared to our understanding of intracellular proteostasis. This is disturbing, given the number
of currently untreatable disorders that arise from the misfolding and aggregation of extracellular
proteins. Enhancing our understanding of extracellular proteostasis has the potential to fuel the
development of novel PDD therapies and central to this is the identification and characterisation
of extracellular chaperones.
Apart from the action of extracellular chaperones, there is evidence that circulating proteases may
also help maintain extracellular proteostasis by proteolytically degrading large insoluble protein
deposits which cannot otherwise be effectively cleared (Figure 1.3). For example, a wide array of
denatured proteins have been found to stimulate the activation of plasmin via tissue plasminogen
activator (tPA) (Ellis et al. 2002; Kinston et al. 1995; Machovich & Owen 1997; Radcliffe 1983;
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Radcliffe & Heinze 1981). Plasmin has been shown to directly degrade fibrillar aggregates of Aβ
(Tucker et al. 2000a; Tucker et al. 2000b), as well as amorphous aggregates of ovotransferrin or
superoxide dismutase (Constantinescu et al. 2017). It has been further reported that extracellular
chaperone are capable of sequestering and reducing the cytotoxicity of small hydrophobic peptides
released by plasmin-mediated degradation of protein aggregates (Constantinescu et al. 2017).

1.3.3

The challenge of maintaining proteostasis in pregnancy

Normal healthy pregnancy involves elevations in physiological stresses which are capable of
inducing protein misfolding and aggregation. For example, oxidative stresses are markedly
enhanced during pregnancy (Gitto et al. 2002), which contributes to a quantifiable increase in the
oxidation of maternal plasma proteins (Zusterzeel et al. 2000). In particular, the placenta is a major
contributor to the generation of reactive oxygen species due to its high metabolic activity (Myatt
& Cui 2004). The placenta also appears to experience mild endoplasmic reticulum stress during
pregnancy (Kyathanahalli et al. 2015), which can become severe in pregnancy disorders like preeclampsia (as discussed in Section 1.2.5). Furthermore, a systemic inflammatory response
underlies pregnancy, as heightened hypochlorite generation has been reported in pregnancy plasma
and at the placenta (Fialova et al. 2006; Hammer et al. 2001), with even higher amounts of
hypochlorite generation identified in the plasma and placenta of women with pre-eclampsia
(Gandley et al. 2008). Additionally, there is a slight elevation in maternal body temperature
throughout pregnancy (Buxton & Atkinson 1948), and a tremendous 40–45% increase in blood
volume during gestation promotes shear stress (Rodríguez & González 2014; Sanghavi &
Rutherford 2014; Sprague et al. 2010). Given these unfavourable conditions, it is tempting to
speculate that pre-eclampsia may thus be a disorder manifested of exacerbated protein misfolding
stresses and impaired proteostasis during pregnancy. Remarkably, however, virtually nothing is
known about how the maternal body adapts to handle the unique proteostasis challenges of
pregnancy.

1.3.4

Potential mechanisms of extracellular proteostasis in pregnancy

To counteract the marked elevations in stresses that can induce protein misfolding and aggregation,
it is hypothesised that the capacity of the maternal proteostasis network is normally bolstered
during pregnancy. Of particular interest are mechanisms by which the maternal body maintains
extracellular proteostasis, due to the observation that protein aggregates accumulate in the
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extracellular fluids and tissues of women with pre-eclampsia (as discussed in Section 1.2.5). In
this regard, extracellular chaperones are likely to play an important role in stabilisation of
misfolded proteins. However, plasma levels of currently well characterised chaperones, including
clusterin, A2M and haptoglobin, do not increase during pregnancy (Areekul et al. 1975; Dombai
et al. 2017; Tayade et al. 2005). As such, it is plausible that other proteins which are specifically
upregulated during pregnancy can function as extracellular chaperones. Of particular interest is
PZP, which is quantitatively the most abundant of all the plasma proteins that are specifically
upregulated during pregnancy, and PAI-2, which is expressed in high amounts at the placenta. The
reasons for the interest in PZP and PAI-2 as members of the extracellular proteostasis network
during pregnancy, as well as features of these proteins in general, are explored in the remainder of
this chapter.

1.4 Pregnancy zone protein
1.4.1

Structure

PZP belongs to the highly conserved alpha-macroglobulin family of protease inhibitors and
complement components, which are found in the plasma of vertebrates and hemolymph of some
invertebrates. Typical alpha-macroglobulin protease inhibitors including PZP are composed of one
or more ~ 180 kDa subunits, each containing a series of macroglobulin domains, a bait region, a
reactive thioester bond and a receptor binding site (Figure 1.4) (Sottrup-Jensen 1989). In PZP, the
receptor binding site is specific for the low-density lipoprotein receptor-related protein 1 (LRP1)
receptor and is exposed upon a conformational change that is induced by reaction with proteases
or small nucleophiles including ammonium chloride or methylamine (Björk & Fish 1982;
Chiabrando et al. 2002; Sanchez et al. 2001; Van Leuven et al. 1986). The PZP gene (12p12–13,
36 exons) encodes a 4615 bp mRNA transcript, which is translated as a 1482 amino acid monomer.
During synthesis and secretion, the 1482 amino acid monomer folds into a highly glycosylated (~
10% glycosylation by mass), 180 kDa monomer which is linked by disulfide bonds to another
monomer, producing the native 360 kDa homodimer (Devriendt et al. 1989; Sand et al. 1985).
Remarkably, PZP shares 71% of its amino acid sequence with A2M, with all cysteines conserved
and 82% of the amino acids being chemically similar between the two proteins (Devriendt et al.
1991). Comparatively, A2M (the constitutively abundant alpha-macroglobulin in humans) is a
homotetramer (720 kDa) formed by the non-covalent association of two disulfide-linked 360 kDa
dimers (Jensen & Sottrup-Jensen 1986). Current information on the multi-domain fold of PZP is
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limited; at best, its structure can be estimated from homology modelling a low resolution (4.3-Å)
crystal structure of a transformed, “fast” conformation of A2M that closely resembles the proteasebound form (Figure 1.4) (Marrero et al. 2012).

Figure 1.4 Structure and known domains of PZP. Structure of a PZP dimer based on homology modelling, and
schematic diagram of human monomeric PZP (180 kDa) showing amino acid (aa) positions of the signal sequence,
bait region, thioester and receptor binding domain. PZP monomers (180 kDa) are disulfide bonded to form the native
and functionally active 360 kDa homodimer. Image shows a 3D homology model built with SWISS-MODEL using a
crystal structure of A2M in the transformed, fast conformation from PDB ID: 4ACQ (Marrero et al. 2012), lacking
the receptor binding domain. This is currently the best estimate of PZP tertiary structure. Macroglobulin domains
(M1–M6) are predicted using InterPro (EMBL-EBI). Hashtags denote N-glycosylation sites (Asn54, Asn69, Asn246,
Asn392, Asn406, Asn753, Asn875, Asn932, Asn997 and Asn1430). Schematic diagram is adapted from Wyatt et al. (2016).
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The biochemical similarities between PZP and A2M present some challenges for studying these
proteins independently. For example, monoclonal antibodies have been shown to display crossreactivity (Carlsson et al. 1985), and even modern proteomic techniques do not always distinguish
the two proteins given their high amino acid sequence similarity (Blumenstein et al. 2009). PZP
is normally purified from human pregnancy plasma during the period when it is highly upregulated
(~ 30 weeks gestation). Considering that A2M is also constitutively abundant at 2–4 mg mL in
human blood plasma independent of pregnancy (Tayade et al. 2005; Tunstall et al. 1975), purified
preparations of PZP are easily contaminated with A2M during purification (Arbelaéz & Stigbrand
1997; Chiabrando et al. 1997; Sand et al. 1985). This raises questions regarding the suitability of
the PZP standards used in past investigations to estimate levels of PZP in biological fluids
(Petersen et al. 1990). Contamination with A2M, as well as the tendency for PZP to form tetramers
following extended periods of storage or following reaction with protease (Bonacci et al. 2000;
Christensen et al. 1989), led to early propositions that native PZP was a tetramer (Sottrup-Jensen
et al. 1984).

1.4.2

Mechanism of protease inhibition

PZP has been shown to inhibit proteases using a unique trapping mechanism in vitro (Figure 1.5).
Within each PZP monomer, the bait region and thioester bond are crucial for protease inhibition.
The bait region is a mobile element of 51 amino acids located in the middle of each 180 kDa
subunit, which presents itself as a substrate for proteolytic cleavage by a range of proteases
(Sottrup-Jensen et al. 1989). Much of the bait region sequence of PZP is non-homologous with the
corresponding region of A2M, which explains why they inhibit a different range of proteases
(Sottrup-Jensen et al. 1989). Proteolytic cleavage of the bait region of PZP induces a major
conformational change and results in the exposure of the intramolecular β-cysteinyl-γ-glutamyl
thioester. Reaction of the thioester bond with a nucleophilic amino acid of the protease results in
covalent attachment of the protease to PZP via an ε-lysyl-γ-glutamyl cross-link (Sottrup-Jensen
1989). Covalent trapping of the protease by PZP results in the formation of a dimeric PZP-protease
complex. The dimeric PZP-protease complex is an inefficient inhibitor of the protease because it
provides only partial steric hindrance, with the functional active site of the protease remaining
mostly solvent accessible for reaction with further substrates. The bound protease of the dimeric
PZP-protease complex can therefore cleave and covalently associate with another PZP dimer,
forming a 1:1 complex of tetrameric PZP-protease. This tetrameric cage is a much more effective
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steric inhibitor of the protease than dimeric PZP (Christensen et al. 1989; Jensen & Stigbrand
1992). The conformational change triggered by protease binding also results in the presentation of
a C-terminal receptor-recognition site for LRP1 (Chiabrando et al. 2002). PZP-protease complexes
are rapidly cleared from the circulation (within minutes in vivo) by LRP1-mediated endocytosis
and degraded by lysosomes in cell types such as hepatocytes, monocytes and placental
syncytiotrophoblasts (Imber & Pizzo 1981; Jensen et al. 1988; Petersen 1993).

Figure 1.5 Graphic depicting the currently accepted model of PZP protease inhibition. Proteolytic cleavage of
the bait region of PZP induces a conformational change exposing the internal thioester. The attacking protease is
covalently bound to PZP via the exposed thioester bond of PZP, forming a dimeric PZP-protease complex. The latter
is a poor inhibitor of the protease, as the protease is only partially sterically hindered by PZP, and the protease active
site remains functionally intact and mostly solvent accessible for reaction with further substrates. The protease from
the dimeric PZP-protease complex can cleave and covalently associate with an additional PZP dimer, resulting in the
formation of a tetrameric PZP-protease complex. Tetrameric PZP-protease is a more efficient steric inhibitor of the
protease than dimeric PZP-protease. A C-terminal LRP1 binding site is exposed in PZP following the conformational
change induced by proteolytic cleavage, resulting in clearance of dimeric or tetrameric PZP-protease complexes by
LRP1-mediated endocytosis (not shown).

1.4.3

Regulation, expression and levels in biological fluids

PZP is secreted by numerous cell types and tissues, including endothelium, epithelium, uterus,
ovary, placenta, breast, testis, kidney, leukocytes, brain and liver, with the latter three believed to
be the major synthesisers of PZP in vivo (Petersen 1993; Tayade et al. 2005). Typically, PZP is
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found in blood plasma at levels of < 0.01 mg/mL in healthy men and 0.01–0.03 mg/mL in healthy
non-pregnant women (Folkersen et al. 1981; Petersen et al. 1990). During pregnancy, however,
the level of PZP in blood plasma markedly increases to 0.25–3 mg/mL (Ekelund & Laurell 1994;
Petersen et al. 1990). PZP has also been detected in a number of other extracellular fluids,
including cerebrospinal fluid (Macron et al. 2020), synovial fluid (Balakrishnan et al. 2014),
sputum (Finch et al. 2019; Smith et al. 2017) and amniotic fluid (Zhao et al. 2018). Reduced levels
of PZP in pregnancy plasma have been reported in spontaneous abortion (Than et al. 1976) and
pre-eclampsia (Auer et al. 2010; Griffin 1983; Horne et al. 1972; Nguyen et al. 2019; Rasanen et
al. 2010). On the other hand, conflicting results have been presented which show no correlation
between the maternal plasma PZP level and pre-eclampsia (Armstrong et al. 1986; Blumenstein
et al. 2009). Given these discrepancies, there is a need to revisit investigations of the level of PZP
in pre-eclampsia plasma, with attention given to ruling out A2M cross-reactivity and ensuring an
adequate sample size for statistical significance.
Estrogens are thought to be the main drivers of PZP expression through a hormonally-induced
promoter (Damber et al. 1976; Helgason et al. 1982), with the level of PZP rising steadily
throughout pregnancy and falling post-partum (Stimson 1975). However, other promoters are
thought to exist, given that PZP is reportedly upregulated in a variety of inflammatory disorders
such as Alzheimer’s disease (IJsselstijn et al. 2011; Nijholt et al. 2015), rheumatoid arthritis
(Horne et al. 1979), bronchiectasis (Smith et al. 2017), autoimmune thyroid disease (Scott et al.
1985), Behcet’s syndrome (Thomson et al. 1981), hepatitis (Zarzur et al. 1986; Zarzur et al. 1989)
and HIV-1 (Sarcione & Biddle 2001). Indeed, interferon response and steroid response elements
have been reported to exist in the promoter region of PZP (Tayade et al. 2005). Others have
suggested that PZP may have usefulness as a tumour marker (Bauer 1981; Bauer et al. 1979;
Wilking et al. 1984), but conflicting results have brought this proposal under scrutiny (Müller et
al. 1982; Petersen et al. 1990). Due to its upregulation in inflammation, it has been proposed that
PZP is the acute-phase alpha-macroglobulin in humans, a role shared by other alphamacroglobulins in animals, but not by human A2M (Sand et al. 1985). Taken together, the
upregulation of PZP during inflammation and pregnancy is consistent with PZP playing a currently
undefined role in homeostasis in response to physiological stress.
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1.4.4

Proposed biological functions

Early research into the biological role of PZP suggested that PZP potentially functions as an
immunosuppressive molecule which protects the allogenic foetus from destruction by the maternal
immune system (Stimson 1976; Von Schoultz et al. 1973). More recently, PZP has been shown to
bind placental protein-14 (PP14) and synergistically inhibit T-helper 1 (Th1) cell activation in
vitro, which is indeed supportive of the initial proposition that PZP may function to suppress
maternal immune surveillance (Skornicka et al. 2004). Additionally, PZP reportedly inhibits IL-2
production (Saito et al. 1990) and allograft rejection (Svendsen et al. 1978). However, clear
mechanistic insight into how PZP achieves its immunosuppressive activity is lacking. Perhaps a
clue to the immunomodulatory activity of PZP lies with studies which have shown that PZP can
non-covalently bind in vitro to neurotrophins (NGF, BDNF and NT-3) (Skornicka et al. 2002) and
growth factors (TGFβ1 and TGFβ2) (Philip et al. 1994). Considering that A2M binds a plethora
of growth factors and cytokines in vitro (Barcelona & Saragovi 2015; Crookston et al. 1994;
Gonias et al. 2000; LaMarre et al. 1991; Westwood et al. 2001; Wolf & Gonias 1994; Wollenberg
et al. 1991; Wu et al. 1998), analogous interactions of PZP with a range of cytokines could be one
of the avenues by which PZP elicits immunomodulatory effects. In any case, the biological
significance of possible PZP-cytokine interactions, and moreover how this relates directly to the
observed immunosuppressive properties of PZP, remains largely unknown. To this end, studies
which elucidate the broader cytokine binding profile of PZP and clarify the mechanistic
significance of its non-covalent cytokine interactions are needed.
It is a commonly accepted view that PZP has biological importance as a protease inhibitor, but the
precise biological importance of PZP-induced protease inhibition has not yet been established
owing mainly to the lack of confirmed endogenous targets. Inhibition of chymotrypsin, the most
studied substrate of PZP protease inhibition (Christensen et al. 1989; Jensen & Stigbrand 1992;
Sand et al. 1985), is not considered to be physiologically relevant given the spatial separation
between chymotrypsin and PZP in digestive and vascular fluids, respectively. Instead, it has been
proposed that PZP is specifically upregulated during conditions of inflammation and increased
cellular turnover (such as pregnancy) to control the excessive activity of potentially destructive
proteases such as elastase, which is inhibited by PZP (Sand et al. 1985). Preliminary evidence
suggests human tissue kalikrein (Arbelaez et al. 1995), matrix metalloproteinases-1, -2 and -9
(Arbeláez et al. 1997; Sottrup-Jensen & Birkedal-Hansen 1989) and tPA (Sánchez et al. 1998a)
are also possible targets of PZP protease inhibition, although there are conflicting results whether
PZP inhibits tPA (Arbelaez et al. 1995). The major problem with all proposed targets of PZP
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protease inhibition is that more abundant and/or efficient inhibitors already exist, including alpha1 antitrypsin (elastase), kalistatin (tissue kalikrein), tissue inhibitors of metalloproteinases (matrix
metalloproteinases) and plasminogen activator inhibitor type-1 (PAI-1)/PAI-2 (tPA) (Brantly et
al. 1988; Janoff 1972; Kruithof et al. 1986; Murphy 2011; Thorsen et al. 1988; Vaughan 2005;
Zhou et al. 1992). In particular, the higher abundance of A2M (present at 2–4 mg/mL in human
plasma) diminishes the potential role for PZP in endogenous protease inhibition, given A2M is a
more efficient inhibitor of all proposed protease targets of PZP (Arbelaez et al. 1995; Arbeláez et
al. 1997; Christensen et al. 1989; De Boer et al. 1993; Jensen & Stigbrand 1992; Sottrup-Jensen
& Birkedal-Hansen 1989; Virca & Travis 1984). Due to a lack of known endogenous targets,
several sources have suggested that alpha-macroglobulin family proteins like PZP may constitute
ancient parts of the innate immune system, which protect the host by inactivating the secreted
proteases of pathogens in vivo (Araujo-Jorge et al. 1992; Armstrong & Quigley 2001; De Boer et
al. 1993). Again, this is a role more suited to A2M than PZP. For example, due to the amino acid
sequence differences in the bait region, PZP (i) is not a broad spectrum protease inhibitor like A2M
(e.g. demonstration of PZP’s protease trapping activity is limited to few protease classes in vitro,
whereas A2M can inhibit all classes of proteases) and (ii) its mechanism of protease inhibition is
much less efficient (e.g. two separate molecules of PZP must interact to achieve satisfactory
inhibition of a protease, compared to one molecule of A2M) (Jensen & Stigbrand 1992; Sand et
al. 1985). The bait region of PZP is also much poorer as a substrate for proteolytic cleavage than
the bait region of A2M, considering that it contains only one arginine which is not easily cleaved
by arginine-specific proteases given it is followed by a proline (Arbelaez et al. 1995). In summary,
owing to the presence of more constitutively abundant and/or efficient protease inhibitors, it is
unlikely that the physiological importance of PZP is exclusively related to its protease inhibitory
activity.
Ultimately, despite being discovered over 60 years ago (Smithies 1959), the biological function of
PZP remains very poorly understood. This is especially true in comparison to A2M, which has
much better characterised biological functions. A Scopus search of articles (2020) containing
“alpha 2 macroglobulin” versus “pregnancy zone protein” (including alternative names
"pregnancy associated alpha 2 glycoprotein", or "pregnancy associated alpha 2 globulin", or
"pregnancy associated alpha 2 macroglobulin" or "alpha 2 pregnoglobulin”) in the title, abstract
or keywords returned 7, 312 and 399 documents, respectively. This research discordance is in part
likely to be due to the complexities associated with purifying PZP for study in vitro, which requires
late-pregnancy plasma (Arbelaéz & Stigbrand 1997; Chiabrando et al. 1997; Sand et al. 1985).
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A2M, on the other hand, can be isolated from normal plasma using very simple purification
protocols. The high similarity between A2M and PZP entails that the two proteins share many
overlapping functions, but there are important differences to consider. It is plausible that PZP has
a unique biological role in humans that is not fulfilled by A2M, but this remains to be elucidated.

1.4.5

Evidence for possible function as an extracellular chaperone

A2M inhibits the stress-induced aggregation of a range of proteins (French et al. 2008) and
amyloidogenic peptides in vitro (Yerbury et al. 2009), via holdase-type chaperone activity.
Furthermore, A2M has been shown to (i) inhibit the formation of Aβ amyloid fibrils and (ii) protect
against Aβ-induced cytotoxicity by binding to Aβ and facilitating its clearance via LRP1-mediated
endocytosis in vitro and in vivo (Cascella et al. 2013; Fabrizi et al. 2001; Hughes et al. 1998;
Narita et al. 1997). Although this has generated much interest in the potential role of A2M in
preventing Alzheimer’s disease, A2M is also found co-localised with misfolded protein deposits
in dialysis-related amyloidosis (Motomiya et al. 2003), atherosclerosis (Hollander et al. 1979) and
the spongiform encephalopathies (Adler & Kryukov 2007), which is suggestive of a broadly
important biological role as an extracellular chaperone.
Given the high structural similarity between PZP and A2M, it is feasible to surmise that PZP might
also function as a holdase-type chaperone. This is strengthened by the observation that when
tetrameric A2M is induced to dissociate into dimers (e.g. analogous to the quaternary structure of
native PZP), A2M’s ability to inhibit protein aggregation is dramatically increased (Wyatt et al.
2014). Considering that holdase-type chaperones interact with misfolded proteins largely through
hydrophobic interactions, it is interesting that PZP displays enhanced surface-exposed
hydrophobicity in comparison to native A2M (Birkenmeier et al. 1989; Chiabrando et al. 1997).
In addition, co-localisation of Aβ and PZP has been observed in immunohistochemical studies of
the Alzheimer’s disease brain and it has been proposed that PZP could be involved in clearing
toxic Aβ from the circulation via LRP1-mediated endocytosis (Nijholt et al. 2015). PZP is also one
of a small number of proteins proposed as a plasma biomarker for pre-symptomatic Alzheimer’s
disease (IJsselstijn et al. 2011). It is tempting to speculate that the upregulation of PZP in this
disease is a specific attempt to prevent the accumulation of Aβ. Given that no prior study has
directly looked at the ability of PZP to influence Aβ aggregation, clearly, investigations into the
chaperone activity of PZP are warranted.
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1.5 Plasminogen activator inhibitor type-2
1.5.1

Structure

The serine protease inhibitors (serpins) are a highly conserved and functionally diverse
superfamily of proteins found in the kingdoms of bacteria, archaea and eukarya (Law et al. 2006).
PAI-2/SerpinB2 is a member of the ovalbumin serpin (ov-serpin) subfamily, which is
phylogenetically classified into clade B. The ov-serpins notably include the widely studied
ovalbumin (also known as SerpinB14), which shares a striking degree of homology with PAI-2 in
terms of amino acid sequence and gene structure (Remold-O'Donnell 1993; Ye et al. 1989). PAI2 and other serpins adopt a well-conserved tertiary structure known as the serpin fold (Figure 1.6)
(Silverman et al. 2001), which consists of nine α-helices (A-I), three β-sheets (A-C) and a highly
mobile reactive center loop (RCL) tethered between β-sheets A and C (Harrop et al. 1999).
However, unique to PAI-2 and some of the other ov-serpins, PAI-2 features a highly mobile, 33
amino acid loop between helices C and D (the “CD-loop”) which is able to translocate ~ 40 Å
between the side and bottom of the molecule (Lobov et al. 2004).
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Figure 1.6 Structure and known domains of PAI-2. Human monomeric PAI-2 3D structure model and schematic
diagram showing amino acid (aa) positions of the internal secretion signals, a unique to PAI-2 inter-helical domain
between helices C and D (CD-loop) and the reactive center loop (RCL) which contains the protease recognition site
involving cleavage of the P1(Arg380)-P1’(Thr381) bond. The major form of intracellular PAI-2 is non-glycosylated
(PAI-2NG; 47 kDa), whereas the major extracellular form is glycosylated (PAI-2G; 60 kDa). Hashtags denote Nglycosylation sites found in PAI-2G (Asn75, Asn115 and Asn339). Image shows the 3D structure of PAI-2 in the relaxed
conformation using a peptide mimicking the reactive center loop, based on PDB ID: 1JRR (Jankova et al. 2001). PAI2 conforms to the general tertiary structure conserved across all known serpins and matches to the serpin domain fold
when analysed by InterPro (EMBL-EBI). The CD-loop and RCL are highly mobile or disordered regions and have
not been structurally resolved. Schematic diagram is adapted from Wyatt et al. (2016).

Under oxidising conditions, C79 (of the translocatable CD-loop) forms a disulfide bond with C161
(of helix F), which opens β-sheet A (Lobov et al. 2004; Wilczynska et al. 2003b). This bond
converts PAI-2 to a conformation which readily self-oligomerises via RCL insertion of one
monomer into the open β-sheet A of another monomer (Lobov et al. 2004). The biological
importance of PAI-2 oligomers remains unknown and unlike other oligomeric human serpins (such
as alpha-1 antitrypsin, C1-inhibitor, alpha-1 antichymotrypsin, and neuroserpin), PAI-2
oligomerisation has not been implicated in the causation of any serpinopathies (Belorgey et al.
25

2007). Reduction of the C79-C161 disulfide bond closes β-sheet A and converts PAI-2 to a stable
monomeric conformation (Lobov et al. 2004). Conversion between the oxidised (oligomeric) and
reduced (stable monomeric) conformations is fully reversible, making PAI-2 an example of a
redox-regulated protein which undergoes major (yet reversible) conformational changes in vitro
(Lobov et al. 2004; Wilczynska et al. 2003b).
The PAI-2 gene (18q21-23, 8 exons) encodes a 1884 bp mRNA transcript which is translated as a
415 amino acid monomer (Ye et al. 1989). This monomer contains an inefficient internal signal
sequence (Von Heijne et al. 1991). As a result, PAI-2 is found predominantly as an intracellular
non-glycosylated 47 kDa protein (PAI-2NG), but also as a secreted 60 kDa glycoprotein (PAI-2G)
(Wohlwend et al. 1987). However, both forms are found in extracellular fluids including
pregnancy plasma (Kruithof et al. 1987). This may be via secretion of intracellular PAI-2NG by
microparticles (Guller et al. 2011) or inflammation-induced exosomes (Boncela et al. 2013).
Overwhelmingly, studies of PAI-2 to date have focused on characterising the non-glycosylated
form given that large quantities can be produced relatively easily using bacterial expression
systems (Cochran et al. 2009; Lobov et al. 2004).

1.5.2

Mechanism of protease inhibition

PAI-2 inhibits tPA and urokinase plasminogen activator (uPA) by an irreversible suicide-substrate
mechanism common to the serpins (Figure 1.7) (Silverman et al. 2001). Native PAI-2 and other
serpins exist in a metastable stressed conformation analogous to an unsprung “mouse trap” and
are thus a rare exception to Anfinsen’s proposal that native proteins exist in their most
thermodynamically stable state (Whisstock et al. 2000). Proteolytic cleavage of the mobile RCL
via a specific protease “springs the trap”, with the RCL translocating ~70 Å into the center of βsheet A with the covalently attached protease (Huntington et al. 2000). This translocation
physically distorts the active site of the covalently attached protease by compressing it against βsheet A (rendering it inactive), while correspondingly the serpin enters a more thermodynamically
relaxed state (Huntington et al. 2000). The irreversible stressed-relaxed transition results in the
formation of a covalent SDS-stable 1:1 complex of serpin-to-protease, neither of which are capable
of further activity (Huntington et al. 2000). Protease-PAI-2 complexes, including cell surface
bound uPA and tPA, are rapidly cleared from the extracellular space by LRP1 or mannose
receptor-mediated endocytosis (Al-Ejeh et al. 2004; Lee et al. 2010; Narita et al. 1995; Orth et al.
1992; Otter et al. 1991). Given PAI-2 lacks a recognition site for these receptors, PAI-2 must form
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a complex with uPA or tPA in order to be internalised via these receptors (Medcalf 2011).
Glycosylation does not appear to influence the protease inhibitory activity of PAI-2, as both PAI2G and PAI-2NG are capable of efficiently inhibiting uPA and tPA (Genton et al. 1987; Mikus et al.
1993).

Figure 1.7 Graphic depicting the “molecular mousetrap” mechanism of PAI-2 protease inhibition. PAI-2 exists
in a metastable conformation analogous to that of an “unsprung mouse trap”. Cleavage in the reactive center loop
(RCL) by an attacking protease results in covalent attachment of the protease to the RCL. The cleaved RCL then
translocates or “snaps” into the open β-sheet A, carrying with it the covalently attached protease. The latter event
results in deformation of the protease and its active site, causing a loss of protease activity.

1.5.3

Regulation, expression and levels in biological fluids

A large number of different cell types and tissues are capable of producing PAI-2, including
neurons, keratinocytes, fibroblasts, epithelium and monocytes (Lee et al. 2011; Medcalf 2011;
Medcalf & Stasinopoulos 2005). PAI-2 is normally undetectable in the plasma of healthy nonpregnant individuals, but rises to a concentration of 260 ng/mL during pregnancy (Kruithof et al.
1987). The increased expression of PAI-2 during pregnancy has been attributed to trophoblast cells
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of the placenta (Hofmann et al. 1994; Jonasson et al. 1989). High amounts of PAI-2 are also
detectable independent of pregnancy in extracellular fluids including gingival crevicular fluid
(Brown et al. 1995; Kinnby et al. 1991), saliva (Virtanen et al. 2006), pleural effusions (Aleman
et al. 2003), tears (Csutak et al. 2008) and peritoneal fluid (Scott‐Coombes et al. 1995).
Intracellular PAI-2 is distributed within the nucleus and cytoplasm, and can remarkably constitute
as much as ~ 0.27% of the total cellular protein (Maurer & Medcalf 1996).
Increased PAI-2 expression has also been reported in tumors and tumor-associated stromal cells
such as macrophages and fibroblasts (Shiomi et al. 2000; Umeda et al. 1997). Increased expression
of PAI-2 is thought to play a protective role in the host response to tumor growth and metastasis
by inhibiting tumor-associated uPA, which is needed for plasmin activation and degradation of the
extracellular matrix (Croucher et al. 2008). Favourable patient outcomes have been observed for
a variety of different cancers which exhibited increased PAI-2 expression (Croucher et al. 2008),
and PAI-2 has been shown to inhibit tumor growth and metastasis in rodent models (Mueller et al.
1995; Praus et al. 1999). Taken together, these findings suggest that PAI-2 plays an important
protective role in cancer as a classical inhibitory serpin and this has raised interest in PAI-2 as a
potential cancer therapeutic.
PAI-2 expression can be induced by a plethora of primarily pro-inflammatory stimuli and other
biological agents (Lee et al. 2011; Medcalf & Stasinopoulos 2005; Schroder et al. 2011b). For
example, increased PAI-2 expression has been observed following treatment with proinflammatory cytokines (TNFα, interferon-γ, IL-1β, IL-2, IL-13, G-CSF, M-CSF), pathogenic
stimuli (lipopolysaccharide, dengue virus, Legionella pneumophila, Mycobacterium avium,
Borrelia burgdorferi), steroids (EGF, glucocorticoids), tumor promoters (phorbol 12-myristate 13acetate) and vasoactive agents (angiotensin II) (Antalis & Dickinson 1992; Costelloe et al. 1999;
Feener et al. 1995; Gan et al. 1995; George et al. 1990; Gyetko et al. 1992; Gyetko et al. 1993;
Haile et al. 2006; Hamilton et al. 1993; Krishnamurti et al. 1989; Losick & Isberg 2006; Medcalf
et al. 1988; Scarpati & Sadler 1989; Schwartz & Bradshaw 1992; Woodruff et al. 2007).
Interestingly, microglia exhibit enhanced expression of PAI-2 when co-localised with amyloid
plaques in Alzheimer’s disease brain (Akiyama et al. 1993). The increased expression of PAI-2
under mostly pro-inflammatory conditions, as well as the observation that PAI-2 is one of the most
upregulated genes in activated macrophages (Schroder et al. 2010), is strongly suggestive that
PAI-2 may have a currently under-recognised protective function in inflammation.
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1.5.4

Proposed biological functions

Despite its discovery some 50 years ago (Kawano et al. 1970), PAI-2 is considerably less studied
than other members of the serpin superfamily and its precise biological importance remains an
enigma. Part of the complication in describing a biological role for PAI-2 lies in its bi-topological
distribution in the intracellular and extracellular compartments. Correspondingly, a myriad of
functions for PAI-2 have been suggested in intracellular and extracellular contexts. The majority
of evidence supports the idea that PAI-2 functions as a classical extracellular serpin which inhibits
the plasminogen activators (PAs) (Croucher et al. 2008; Schroder et al. 2019a). The PAs, including
uPA and tPA, are responsible for the proteolytic activation of plasmin from plasminogen (Vassalli
et al. 1991). To prevent excessive plasmin-mediated proteolysis and fibrinolysis, the PA system is
tightly regulated. One aspect of regulation is by inhibition of PAs by the plasminogen activator
inhibitors (PAIs), PAI-1 and PAI-2 (Kruithof et al. 1995). PAI-2 has been shown to (i) inhibit uPA
and tPA (Thorsen et al. 1988), (ii) form SDS-stable complexes with uPA and tPA (Sprengers &
Kluft 1987), (iii) mediate rapid disposal of cell-surface bound uPA and tPA via LRP1-mediated
endocytosis in vitro (as discussed in Section 1.5.2) and (iv) exist as SDS-stable complexes with
tPA in gingival crevicular fluid (Brown et al. 1995). Mutations in PAI-2 have been linked to
disorders including thrombic pneumonia (Palafox-Sánchez et al. 2009), antiphospholipid
syndrome (Mercado et al. 2007) and myocardial infarction (Buyru et al. 2003; McCarthy et al.
2004), which is further supportive of a possible role for PAI-2 in hemostasis. On the other hand,
the biological importance of PAI-2 as a genuine protease inhibitor under normal conditions is
questionable, owing mostly to the inefficient secretion of PAI-2 under non-inflammatory
conditions and the observation that PAI-1 is a more abundant and efficient inhibitor of uPA and
tPA (Thorsen et al. 1988; Vaughan 2005). An exception to this is during pregnancy, when the
level of PAI-2 can increase from undetectable in normal plasma to 260 ng/mL at term in pregnancy
plasma, which is higher than the increase observed for PAI-1 (50 ng/mL in normal plasma to 140
ng/mL at term in pregnancy plasma) (Kruithof et al. 1987). Given the marked upregulation of PAI2 during pregnancy, it has been proposed that PAI-2 is important for protecting against premature
placental separation and securing haemostasis at parturition by counteracting the activity of uPA
and tPA, which increase in concentration by 200% and 50% in blood plasma over the course of
pregnancy, respectively (Astedt et al. 1997; Brenner 2004; Kruithof et al. 1995; Kruithof et al.
1987; Reith et al. 1993). Others have suggested that PAI-2 is upregulated during inflammation to
control excessive uPA and tPA-induced proteolysis, because PAI-1 (but not PAI-2) is highly
sensitive to hypochlorite-induced oxidative inactivation (Baker et al. 1990; Strandberg et al.
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1991). Indeed, in vitro cellular models support the idea that PAI-2 may out-compete PAI-1 for
uPA inhibition during conditions of inflammation and pregnancy, where the level of PAI-2 is
elevated (Lobov & Ranson 2011).
Other lesser-studied functions proposed for PAI-2 include inhibition of apoptosis (Dickinson et al.
1995; Dickinson et al. 1998; Kumar & Baglioni 1991) and regulation of adaptive immunity by
Th1 cell suppression (Schroder et al. 2010). The latter is a biological function that has also been
proposed for PZP-PP14 complexes (as discussed in Section 1.4.4). In addition, PAI-2 has been
shown to bind to a diverse set of ligands predominantly via its CD-loop domain, including
retinoblastoma protein, vitronectin, interferon regulatory factor-3, fibrin, annexins (I, II, IV, V),
and the proteasome (Darnell et al. 2003; Fan et al. 2004; Jensen et al. 1996; Radtke et al. 1990;
Ritchie et al. 1999; Zhang et al. 2003). In most cases the exact functional significance of these
binding interactions is unknown. Interestingly, a recent line of work showing that PAI-2 can reduce
bacterial protease activity suggests that the upregulation of PAI-2 in numerous pro-inflammatory
states is part of the innate immune response, whereby PAI-2 protects the host by inactivating
secreted pathogenic proteases in vivo (Neilands et al. 2016). In any case, more work is needed to
further characterise these less-studied functions proposed for PAI-2.

1.5.5

Evidence for possible function as an extracellular chaperone

Interest in the chaperone activities of serpins such as PAI-2 was sparked following studies of
SerpinH1 (also known as HSP47), which is proposed to be an important human chaperone for
collagen (Tasab et al. 2000). It has since been shown that PAI-2 inhibits the stress-induced
amorphous aggregation of bovine serum albumin (BSA) in vitro (Lee et al. 2015). Additionally,
PAI-2 has been shown to inhibit the stress-induced fibrillar aggregation of huntingtin and Aβ1-42
in vitro, although this effect was only modest when compared with the effects of other chaperones
including clusterin and αB-crystallin in the same assay (Lee et al. 2015). Combined with previous
observations that PAI-2 can bind to the proteasome, the results of these studies suggest that the
interactions of PAI-2 with misfolded proteins may underlie a relevant part of the intracellular
proteostasis network (Fan et al. 2004). Taken together, these initial findings are supportive of the
role of PAI-2 as a holdase-type chaperone. However, further investigations are needed to
characterise this putative function. Notably, the study by Lee et al. (2015) only utilised the
predominantly intracellular (47 kDa) non-glycosylated form and therefore it is completely
unknown whether the extracellular (60 kDa) glycosylated form can function as a chaperone. The
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latter is important to examine, given that other glycosylated proteins have markedly improved
chaperone activity compared to their non-glycosylated counterparts (Rohne et al. 2014; Singh et
al. 2019). Additionally, assessing the chaperone activity of PAI-2 following hypochloriteoxidation is of interest, as oxidised PAI-2 is structurally distinct from the native form (as discussed
in Section 1.5.1) and PAI-2 is likely to come into contact with high concentrations of biological
oxidants due to its upregulation in a large number of inflammatory conditions (as discussed in
Section 1.5.3).
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1.6 Rationale and project aims
Pregnancy is a unique life stage in which stresses that promote protein misfolding are markedly
elevated. However, virtually nothing is known regarding how the maternal body maintains
proteostasis during pregnancy. Characterisation of the pregnancy-associated proteostasis network
is important, because it has been shown that aberrant protein misfolding occurs in pre-eclampsia
(as discussed in Section 1.2.5). Consistent with what is thought to occur in other PDDs, the
accumulation of misfolded protein aggregates in maternal extracellular fluids is potentially a factor
that contributes to organ dysfunction in pregnancy. As such, the identification of novel pregnancyassociated extracellular chaperones that protect the maternal body from the accumulation of
misfolded protein aggregates is of high interest. More broadly, the identification of novel
extracellular chaperones will also further our understanding of the extracellular proteostasis
network, which remains relatively limited compared to our knowledge of the intracellular
proteostasis network. Importantly, characterisation of pregnancy-associated proteostasis
mechanisms could provide the framework for the development of novel diagnostic or therapeutic
strategies for pre-eclampsia, and potentially other disorders involving protein misfolding
independent of pregnancy.
PZP and PAI-2 are two enigmatic proteins of undefined biological importance that are markedly
upregulated during pregnancy and during non-pregnancy associated inflammatory states (as
discussed in Sections 1.4.3 and 1.5.3). To date, only a handful of in vitro studies of PZP function
have been undertaken. In part, this may be explained by the fact that no recombinant systems for
the production of PZP have been published, necessitating the purification of PZP from human
pregnancy plasma using challenging methods. Similarly, only a handful of in vitro studies using
extracellular glycosylated PAI-2 have been performed, with the majority of studies using
intracellular non-glycosylated PAI-2. Although both PZP and PAI-2 were originally characterised
as protease inhibitors, there is evidence that they have diverse biological functions. For example,
PZP may interact with a broad spectrum of cytokines as an immunomodulatory molecule, while
oxidation with hypochlorite may be important for regulating the activities of PAI-2. Importantly,
the available evidence supports the idea that PZP and PAI-2 could potentially contribute to
extracellular proteostasis during pregnancy and non-pregnancy associated inflammatory states via
holdase-type chaperone activity, but the latter activity has not yet been characterised for these
extracellular proteins.
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The overarching goal of this project is thus to provide the first evidence of a pregnancy-associated
extracellular chaperone network by characterising the holdase-type chaperone activity of PZP and
extracellular glycosylated PAI-2 in vitro. More broadly, the work described in this thesis attempts
to shed light on the likely biological importance of these multi-functional proteins.

The specific aims of this project are:
1) To optimise the protocol for the purification of PZP from human pregnancy plasma.
2) To develop an expression system using human cells for the production of recombinant
PZP.
3) To characterise the extracellular chaperone activity of PZP and compare it to that of A2M
in vitro.
4) To measure the blood plasma level of PZP in pre-eclampsia patients and verify exclusion
of A2M cross-reactivity.
5) To conduct a preliminary investigation into PZP-TNFα interactions.
6) To characterise the extracellular chaperone activity of PAI-2G and compare it to that of
PAI-2NG in vitro.
7) To evaluate the structural properties of PAI-2G and PAI-2NG under native and hypochloritemodified conditions.
8) To investigate the effect of hypochlorite-induced modifications on the protease inhibitory
and chaperone activities of PAI-2G and PAI-2NG.
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2 General materials and methods

34

2.1 Materials
Acrylamide:Bisacrylamide (37.5:1) 40% (w/v) solution was from Astral Scientific (Sydney,
Australia). Human synthetic amyloid beta 1–42 peptide (Aβ1-42) was from Anaspec (Fremont,
USA). Fetal calf serum (FCS) was from Bovogen Biologicals (Melbourne, Australia) and was
heat-inactivated by incubation at 56°C for 30 min prior to use in experiments. Skim milk powder
was from Coles Supermarket (Melbourne, Australia). Linear, transfection grade 25 kDa
polyethylenimine (PEI) was from Polysciences (Taipei, Taiwan) and was prepared at 1 mg/mL by
dissolving in MilliQ H2O overnight with stirring, adjusting the pH to 7.0 and sterile-filtering
through a 0.22 µm membrane. B-27 supplement, DH5α Escherichia coli (E. coli), DMEM/F-12,
Expi293-F cells, Expi293 medium, GlutaMAX, Lipofectamine 2000, Bacto-Tryptone and 0.05 %
(w/v) trypsin-ethylenediaminetetraacetic acid (EDTA) were from Thermo Fisher Scientific
(Melbourne, Australia). Human recombinant PAI-1 (43 kDa; stable mutant produced in E. coli)
was from Molecular Innovations (HPAI-R76E-I91L, Novi, USA). Human recombinant wild-type
PAI-2G (Isoform 1, 60 kDa; produced in CHO cells) and PAI-2NG (Isoform 1, 47 kDa; produced
in E. coli) were from Biotech Australia (Roseville, Australia). Polyethylene glycol (PEG) 6000
was from VWR Chemicals (Radnor, USA). HEK293 (CRL-1573), HEK293-T (CRL-3216),
HEPG2 (HB-8065), HKB-11 (CRL-12568), L929 (CRL-6364) and SH-SY5Y (CRL-2266) cell
lines were from the American Type Culture Collection (ATCC; Gaithersburg, USA). Unless stated
otherwise, all other reagents were from Sigma-Aldrich (Sydney, Australia).

2.2 SDS-PAGE
For sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), proteins were
diluted in 4 × denaturing loading buffer (200 mM Tris, 40% (v/v) glycerol, 2% (w/v) SDS, 0.4%
(w/v) bromophenol blue, pH 6.8) and electrophoresed using 1.5 mm-thick NuPAGE Bis-Tris 4–
12% gels (Thermo Fisher Scientific) in 2-(N-morpholino)ethanesulfonic acid (MES)-SDS running
buffer (50 mM MES, 50 mM Tris, 0.1% (w/v) SDS, 1 mM EDTA, pH 7.3) at 200 V for 35 min in
an Invitrogen Mini Gel Tank electrophoresis system (Thermo Fisher Scientific). Alternatively,
proteins were electrophoresed using hand-cast 8% Tris-glycine gels (Laemmli 1970), prepared
according to a modified method (Harlow & Lane 1988; Sambrook 1989). Briefly, 10 mL of 8%
resolving polyacrylamide gel solution was prepared (4.6 mL MilliQ H2O, 2.7 mL 30% (w/v)
Acrylamide:Bisacrylamide (37.5:1), 2.5 mL Tris (1.5 M, pH 8.8), 0.1 mL 10% (w/v) SDS, 0.1 mL
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10% (w/v) ammonium persulfate, with 0.006 mL tetramethylethylenediamine (TEMED) added
directly prior to gel casting) and 7.2 mL of this solution was pipetted into 1.5 mm-spaced glass
plates in a Mini-PROTEAN Tetra Cell casting system (Bio-RAD, Gladesville, Australia).
Absolute ethanol (1 mL) was immediately added to the top of the resolving gel and subsequently
removed by thoroughly washing with MilliQ H2O once the gel had set. The resolving gel was then
overlayed with 3 mL of 5% stacking polyacrylamide gel solution (2.1 mL MilliQ H2O, 0.5 mL
30% (w/v) Bis-acrylamide, 0.38 mL Tris (1.0 M, pH 6.8), 0.03 mL 10% (w/v) SDS, 0.03 mL 10%
(w/v) ammonium persulfate, with 0.003 mL TEMED added directly prior to gel casting) and a 10well comb was inserted. Following complete polymerisation of hand-cast gels, electrophoresis of
proteins was conducted at 100 V for 1.5 h in denaturing Tris-glycine running buffer (0.1% (v/v)
SDS, 25 mM Tris, 192 mM glycine, pH 8.3) using a Mini-PROTEAN electrophoresis system (BioRAD). Unless otherwise specified, samples were not heated before SDS-PAGE given that alphamacroglobulins are susceptible to heat-induced fragmentation (Harpel et al. 1979). In some
experiments, proteins in denaturing loading buffer were reduced by incubation with 5% (v/v) 2mercaptoethanol at room temperature (RT) for 5 min. Protein size was estimated using Precision
Plus Dual Colour Protein Standards (Bio-RAD). All gels were stained overnight with Instant Blue
(Expedeon, Cambridge, UK) and subsequently destained in MilliQ H2O overnight. Stained gels
were imaged using an Amersham 600RGB Imager (GE Healthcare, Silverwater, Australia) and
where necessary, analysed by densitometry using ImageJ software (Schneider et al. 2012). All
electrophoresis procedures were carried out at RT using a PowerPac 300 electrophoresis power
supply (Bio-RAD).

2.3 Native PAGE
Proteins > 250 kDa (typically PZP and A2M) were diluted in 4 × native loading buffer (200 mM
Tris, 40% (v/v) glycerol, 0.01% (w/v) bromophenol blue, pH 8.6) and subjected to electrophoresis
using NuPAGE 3–8% Tris-acetate pre-cast gels (Thermo Fisher Scientific) and native Tris-glycine
running buffer (25 mM Tris, 192 mM glycine, pH 8.3) at 150 V for 1.5 h in an XCell SureLock
Mini-Cell system (Thermo Fisher Scientific). Alternatively, proteins < 250 kDa (typically PAI-2
and other serpins) were electrophoresed using hand-cast 8% Tris-glycine gels (prepared exactly as
described in Section 2.2, except with an equivalent volume of MilliQ H2O added instead of SDS
in the recipe) at 100 V for 1.5 h in native Tris-glycine running buffer using a Mini-Protean
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electrophoresis system. Protein size was estimated using NativeMark Unstained Protein Standards
(Thermo Fisher Scientific). All native gels were stained and analysed as described in Section 2.2.

2.4 Western blot
Following separation by native or SDS-PAGE, proteins were transferred to a 0.45 µm
nitrocellulose membrane (Pall Corporation, Somersby, Australia) via electrophoresis at 100V for
90 min using a Mini Trans-Blot electrophoresis system (Bio-RAD) containing Western transfer
buffer (192 mM glycine, 25 mM Tris, 20% (v/v) methanol, pH 8.3). Membranes were then blocked
overnight at 4°C in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, 8 mM Na2HPO4, pH 7.4) containing 10% (w/v) skim milk powder. Proteins of interest
were subsequently probed using the primary antibodies in Table 2.1. Typically, membranes were
incubated with the primary antibody for 1 h at RT with gentle shaking, and then washed for 10
min with PBS containing 0.01% (v/v) Triton X-100 and then twice for 10 min with PBS only. The
binding of the primary antibodies was detected by subsequent incubation of the membrane with a
highly cross-adsorbed horseradish peroxidase (HRP)-conjugated secondary antibody (see Table
2.1 for details) for 30 min at RT with gentle shaking. Finally, the membranes were washed as
described above and bands were visualised by enhanced chemiluminescence using Clarity
substrate (Bio-RAD) and an Amersham 600RGB Imager. All antibodies were typically diluted at
concentrations of 1:1,000–5,000 in PBS containing 10% (w/v) skim milk powder, according to the
specific manufacturer instructions.
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Table 2.1. Summary of antibody specifications and experimental use.

Antibody

Species

Clonality

Company/ref.

Usage and description

------ Primary antibodies -----Anti-6His

Mouse

Monoclonal
(IgG1 33D10.D2)

Abcam
ab106261

Used in immunoblots.

Anti-A2M

Mouse

Monoclonal
(IgG2aκ , # M03 2B5)

Abnova
H00000002-M03

Used in immunoblots.
Some cross-reactivity with
PZP.

Anti-Aβ1-42

Mouse

Monoclonal
(IgG2aκ, # WO2)

Millipore
MABN10

Used in immunoblots.

Anti-PAI-2

Rabbit

Polyclonal
(IgG)

Abcam
ab137588

Used in immunoblots.

Anti-PZP

Rabbit

Polyclonal
(IgG)

GeneTex
GTX102547

Used in immunoblots.
Highly specific for PZP, no
cross-reactivity for A2M.

Anti-TNFα

Rabbit

Polyclonal
(IgG)

Thermo Fisher
Scientific (P300A)

Used in immunoblots.

Anti-twST

Mouse

Monoclonal
(IgG1)

IBA
(2-1507-001)

Used in immunoblots.
Some cross-reactivity with
conditioned human cell
medium.

---- Secondary antibodies ---Anti-mouse-HRP

Sheep

Polyclonal
(IgG)

GE Healthcare
NXA931

Used in immunoblots.
Secondary antibody; highly
cross adsorbed.

Anti-rabbit-HRP

Goat

Polyclonal
(IgG)

Invitrogen
A16104

Used in immunoblots.
Secondary antibody; highly
cross adsorbed.

2.5 Preparation of chemically competent DH5α E. coli
DH5α E. coli were grown at 37°C with shaking at 200 rpm in 500 mL of Luria-Bertani (LB)
medium (1% (w/v) tryptone, 1% (w/v) NaCl, and 0.5% (w/v) yeast extract) until an optical density
(OD) of 0.4 was reached. The media was harvested and E. coli were pelleted by centrifugation
(4°C, 3,000 × g, 10 min) in a Sorvall RC6 Plus centrifuge (Thermo Fisher Scientific). After
disposal of the supernatant, pelleted DH5-a E. coli were resuspended on ice with 30 mL of 0.1 M
chilled CaCl2 and incubated for 30 min at 4°C. At the conclusion of the incubation period, E. coli
were centrifuged in a Heraeus Multifuge X3R centrifuge (Thermo Fisher Scientific) and again the
supernatant was disposed. Pelleted E. coli were subsequently resuspended gently on ice in 8 mL
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of 0.1 M chilled CaCl2 supplemented with 15% (w/v) glycerol. These chemically competent DH5α
E. coli were immediately aliquoted (0.1 mL), snap-frozen in liquid N2 and stored at −80°C until
use.

2.6 Transformation of chemically competent DH5α E. coli
Thawed chemically competent DH5-a E. coli (prepared as described in Section 2.5) were
incubated on ice for 30 min with plasmid DNA (~ 100 ng) and subsequently heat-shocked at 42°C
for 30 sec. Following this, the heat-shocked cells were resuspended in 0.7 mL of LB medium and
then grown for 1 h at 37°C with shaking at 200 rpm. After this resuscitation period, 0.15 mL of
the transformation mixture was plated on a selective LB-agar plate containing 100 µg/mL
ampicillin (prepared using standard methods) and incubated at 37°C overnight to obtain single
colonies for further culturing.

2.7 Mammalian cell culture
Unless otherwise specified, all mammalian cell lines were grown in Heracell 150i humidified
incubators (Thermo Fisher Scientific) at 37°C in 5% (v/v) atmospheric CO2 under aseptic
conditions in growth medium comprised of Dulbecco’s modified eagle medium (DMEM)/F-12
supplemented with 10% (v/v) FCS and 1 × GlutaMAX. Cell counts were determined using a light
microscope and hemocytometer, with exclusion of non-viable cells by trypan blue staining.
Adherent cells were routinely passaged twice per week when 50–100% confluent by aspiration of
growth media and treatment with 0.05 % (w/v) trypsin-EDTA, followed by centrifugation of a
portion (10–25%) of the detached cells (300 × g, 5 min, RT) and resuspending the cell pellet in
growth medium. Cell lines were not used past a passage-number of 20. For cryopreservation, low
passage-number cell lines were suspended in freezing medium (50% (v/v) FCS, 40% (v/v)
DMEM/F-12, 10% (v/v) dimethyl sulfoxide) at a final concentration of 0.25 × 106 cells/mL and
aliquoted into sterile cryogenic vials, which were immediately transferred to a Mr. Frosty freezing
container (Thermo Fisher Scientific) in a −80°C freezer for attenuated cooling at approximately
−1°C/min. The next day frozen cells were transferred to liquid N2 for long term storage.
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2.8 NaOCl quantification
The concentration of sodium hypochlorite (NaOCl) in stock solutions (available chlorine 4.00–
4.99%; Sigma-Aldrich) was quantified by spectrophotometry as previously described (Hussain et
al. 1970; Morris 1966). Briefly, MilliQ H2O was brought to pH 11.5 by titration with 1 M NaOH.
This alkaline solution was used to dilute the concentrated NaOCl stock solution at ratios of 1:50,
1:100 and 1:200. The absorbance at 292 nm of each diluted sample was measured using a
Nanodrop 2000C (Thermo Fisher Scientific) using an appropriate blank solution. The
concentration of the NaOCl stock solution was subsequently calculated using the Beer-Lambert
law with molar absorptivity = 350 M-1.cm-1, accounting for each dilution.

2.9 Protein quantification
Protein concentration was estimated by measuring the absorbance at 280 nm (A280) of protein
solutions using a Nanodrop 2000C. Protein solutions were prepared at several different dilutions
and measured in triplicate. All measurements were adjusted using an appropriate blank solution.
The concentration of purified protein solutions was subsequently calculated using the values
provided (Table 2.2). The total protein concentration of complex protein solutions, such as human
plasma, were estimated as above assuming a 0.1% (1 mg/mL) absorbance = 1 or using a
bicinchoninic acid kit (Sigma-Aldrich) as per the manufacturer’s instructions.

Table 2.2. Reference values for quantification of proteins used in this project.Extinction co-efficients were
estimated using amino acid sequences (UniProtKB: A2M, P01023; PZP, P20742; PAI-2, P05120) and the ExPASy
web server ProtParam tool (Gasteiger et al. 2005).

Protein

0.1% Absorbance (1

Molecular weight (g/mol)

mg/mL)
A2M

0.89

720,000

A2M dimer

0.89

360,000

PZP

0.81

360,000

PAI-2G

0.92

60,000

PAI-2NG

0.92

47,000
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2.10 Purification of A2M
Blood (~ 100 mL) was collected from healthy consenting donors by venepuncture using
Vacutainer lithium heparin blood collection tubes (Becton Dickinson, Sydney, Australia) at the
Illawarra Health and Medical Research Institute by qualified professionals (in accordance with
Human Research Ethics Application HE02/080; approved by the University of Wollongong and
the Illawarra Shoalhaven Health District Human Research Ethics Committee). Immediately after
blood was taken, the tubes were centrifuged (1,300 × g, 10 min, 4°C) and plasma was collected
and pooled. Following centrifugation, pooled plasma was supplemented using concentrated stock
solutions of 5 M NaCl and 1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; pH
7.4) to achieve final concentrations of 1 M NaCl and 20 mM HEPES (pH 7.4). In addition, EDTAfree Complete Protease Inhibitor Cocktail (Roche Diagnostics, Sydney, Australia) was added to
the pooled plasma to inhibit endogenous protease activity. The plasma was then clarified by
centrifugation (24,000 × g, 20 min, 4°C) and then syringe-filtered through 0.45 µm and 0.22 µm
filters sequentially. The processed plasma (~ 50 mL) was then loaded onto 3 × 5 mL HiTrap
chelating HP columns connected in tandem (GE Healthcare; 15 mL total bed volume) which had
previously been washed (MilliQ H2O), stripped (50 mM EDTA, 0.5 M NaCl, 20 mM HEPES, pH
7.4), washed (MilliQ H2O), recharged (0.1 M ZnSO4) and finally equilibrated (equilibration buffer;
1 M NaCl, 20 mM HEPES, pH 7.4). After loading the plasma, the column was washed using
equilibration buffer until the A280 of the eluate had reduced to a low and stable level (typically <
0.3). The column was then washed to remove loosely bound proteins (15 mM imidazole, 0.5 M
NaCl, 20 mM HEPES, pH 7.4) and finally strongly bound proteins including A2M were eluted
using a buffer containing a high-concentration of imidazole (500 mM imidazole, 0.5 M NaCl, 20
mM HEPES, pH 7.4). Protein fractions containing A2M that were eluted using the high imidazole
buffer were concentrated to 5–15 mg/mL using an Amicon Ultra-15 centrifugal filter unit (30 kDa
MWCO; Millipore, Sydney, Australia), according to the manufacturer’s instructions. These
concentrated protein fractions were then immediately subjected to size exclusion chromatography
(SEC) at 1 mL/min (3 mL load loop) using a HiPrep 26/60 Sephacryl S-300 HR column (GE
Healthcare, 320 mL bed volume) equilibrated in 20 mM NaPO4, pH 7.4. Following SEC, protein
fractions containing highly purified A2M, as assessed by 8% reducing SDS-PAGE, native PAGE
and Western blot analyses (as described in Sections 2.2, 2.3 and 2.4), were supplemented with 100
mM sucrose and frozen at −20°C for long term storage. For short-term use, A2M was thawed,
dialysed extensively against PBS/0.01% (w/v) sodium azide (pH 7.4) and stored at 4°C. For cell
culture experiments, A2M was dialysed against PBS (pH 7.4) without sodium azide, followed by
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sterile-filtration using a 0.22 µm filter. Purified A2M concentration was quantified as described in
Section 2.9 and subjected to quality control analyses as described in Section 3.2.2.

2.11 Preparation of Aβ1–42
Human synthetic Aβ1-42 (1 mg) was reconstituted in 50 μL of 10 mM NaOH with gentle mixing to
dissolve the peptide. Following complete dissolution of the peptide, the solution was diluted to 1
mL with PBS (final concentration of 1 mg/mL). Aβ1-42 was then aliquoted into polypropylene tubes
and immediately snap-frozen in liquid N2. Snap-frozen Aβ1-42 aliquots were stored at –80°C and
slowly thawed on ice prior to use.
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3 Optimisation of methods for the purification of
endogenous PZP from pregnancy plasma and
development of a novel recombinant PZP
production system
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3.1 Introduction
Human blood plasma is a complex biological fluid, consisting of hundreds of normally secreted
extracellular proteins and also trace amounts of “leaked” intracellular proteins (Anderson &
Anderson 2002). Notably, there are a handful of constitutively abundant (> 0.1 mg/mL), major
blood plasma proteins. This includes human serum albumin (accounting for around 55% of all
plasma protein), as well as immunoglobulins (G, A and M), transferrin, fibrinogen, A2M, alpha-1
antitrypsin, complement C3, haptoglobin, apolipoproteins (A1 and A2), ceruloplasmin and alpha1-acid glycoprotein (Anderson & Anderson 2002; Hortin et al. 2008). During pregnancy, the
maternal plasma proteome undergoes numerous adaptations, including changes to the expression
levels of around 10% of plasma proteins (Romero et al. 2017; Scholl et al. 2012). It is during this
time that PZP remarkably increases from 0.01–0.03 mg/mL in non-pregnant individuals to 0.25–
3 mg/mL in mid-to-late pregnancy (Ekelund & Laurell 1994; Folkersen et al. 1981; Petersen et al.
1990). As a result of this markedly increased expression, all previously published protocols use
pregnancy plasma from mid-to-late pregnancy for the purification of PZP. The isolation of PZP
from other biological sources has not yet been reported and due to the complexity of the native
PZP molecule, a system has not yet been published which can successfully produce recombinant
PZP.
Although PZP becomes a major blood plasma protein during pregnancy, the presence of other
abundant proteins with similar biophysical properties make it extremely challenging to purify PZP
from blood plasma. For example, A2M which shares 82% amino acid sequence similarity with
PZP, is often reported as a major contaminant throughout PZP purification (Arbelaéz & Stigbrand
1997; Bohn & Winckler 1976; Chiabrando et al. 1997; Sand et al. 1985; Stigbrand & Damber
1978; Stimson & Eubank-Scott 1972; Von Schoultz & Stigbrand 1973, 1974). The intrinsic
difficulty of separating PZP from A2M has raised questions over the purity of PZP standards used
in previous studies (Petersen et al. 1990) and the specificity of antibodies raised against the two
highly similar proteins (Carlsson et al. 1985). Additionally, the tendency for PZP preparations to
be contaminated with A2M, as well as the propensity for the PZP dimer to self-associate into
tetramers during improper storage and handling (e.g. following exposure to denaturing conditions
during purification), has led to erroneous reports that native PZP is predominantly a tetramer like
A2M (720 kDa) (Bonacci et al. 2000; Christensen et al. 1989; Sottrup-Jensen et al. 1984). Another
example of a protein that commonly co-purifies with PZP using standard methods is haptoglobin.
In particular, some of the earliest published PZP purification protocols conducted by Von Schoultz
and Stigbrand (1973, 1974) were only successful when using pregnancy plasma from individuals
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with the haptoglobin 1–1 genotype (< 15% of the population) (Koch et al. 2002). This was because
haptoglobin 1–2 and 2–2 genotypes produce high molecular weight polymers that co-purify with
PZP, even using more recently developed methods (Chiabrando et al. 1997). These contaminating
proteins inherently complicate in vitro studies requiring purified PZP and necessitate the use of
complex multi-step purification procedures.
Early strategies for the purification of PZP utilised various combinations of protein precipitation,
immuno-adsorption

chromatography,

ion-exchange

chromatography,

size

exclusion

chromatography, isoelectric focusing and preparative PAGE (Bohn & Winckler 1976; Stigbrand
& Damber 1978; Von Schoultz & Stigbrand 1973, 1974). These methods generally produced low
yields of PZP, required difficult to acquire starting materials (e.g. haptoglobin type 1–1 plasma or
non-commercially available antibodies) and resulted in the denaturation of native PZP.
Furthermore, it is not clear that adequate quality control measures were included in the protocols
to determine (i) PZP purity, (ii) PZP native structure and (iii) the amount of A2M contamination.
Some of the early problems associated with the purification of PZP from pregnancy plasma were
overcome through an improved strategy devised by Sand et al. (1985) that was further refined in
later years by other researchers (Arbelaéz & Stigbrand 1997; Chiabrando et al. 1997). The
optimised approach consists of PEG 6000 precipitation, followed by diethylaminoethyl (DEAE)
anion-exchange

chromatography,

hydrophobic interaction

chromatography (useful

for

haptoglobin separation), zinc affinity chromatography (useful for A2M separation) and size
exclusion chromatography, generally in that order (Arbelaéz & Stigbrand 1997; Chiabrando et al.
1997; Sand et al. 1985). Using this strategy, small amount amounts of PZP adequate for use in
functional studies in vitro can be obtained, however, further optimisation is highly desirable for a
number of reasons. Firstly, PZP is typically separated from A2M in these strategies by zinc affinity
chromatography using a pH gradient elution (pH ~ 8–5). At the acidic end of this pH gradient the
structure and function of both PZP and A2M are likely compromised (Jones et al. 1972; SottrupJensen et al. 1984; Sottrup-Jensen et al. 1980). It has also been shown that elution at pH ~ 5 during
immuno-adsorption chromatography induced 30% of the recovered PZP to denature into nonfunctional 90 kDa fragments (Sottrup-Jensen et al. 1984). Despite the documented sensitivity of
alpha-macroglobulins to acidic conditions, the use of pH gradients to purify PZP has remained in
place in the zinc affinity chromatography step, as a portion of native PZP with intact thioesters can
still be recovered (Arbelaéz & Stigbrand 1997; Chiabrando et al. 1997; Sand et al. 1985).
However, exposure to denaturing pH gradients may be responsible for the relatively poor yield of
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PZP recovered from this step (Arbelaéz & Stigbrand 1997; Chiabrando et al. 1997; Sand et al.
1985).
Apart from the fact that previously reported methods for the purification of PZP are likely to
partially induce its denaturation, other limitations of the procedures include (i) the use of gradient
elutions during chromatography procedures instead of simpler isocratic elutions (gradient elutions
typically result in eluate dilution and necessitate the use of protein concentration steps) and (ii) a
lack of quality control procedures to track PZP purity at each step of the procedure (vital for
validating that tasks have been performed correctly). Furthermore, previously reported methods
for the purification of PZP are lengthy, which is unfavourable particularly since PZP is acutely
sensitive to forming non-native complexes (e.g. tetramers) when stored at 4°C for extended periods
of time (Bonacci et al. 2000). The challenge of purifying PZP from pregnancy plasma may indeed
be one of the major reasons that despite its discovery many decades ago, few in vitro studies of
PZP function have been performed. As such, an improved protocol that shortens the time required
to purify the protein and increases the yield of native PZP would be greatly beneficial. Importantly,
it will also make in vitro studies of native PZP more feasible for researchers.
In addition to the technical challenges associated with purifying PZP, a major limitation is the
requirement of large amounts of pregnancy plasma (e.g. > 100 mL) for PZP purification. Firstly,
there are important ethical considerations around the collection of human blood for use in research.
The need for venepuncture, potentially resulting in pain, fainting and other adverse complications
is undesirable. There are also privacy concerns regarding the use of blood products, as well as the
risk of transmission of blood-borne infections. Correspondingly, preparing detailed human
research ethics applications and the necessity for their thorough review constitutes a considerable
time investment for researchers. In particular, blood donation from pregnant women has its own
unique set of considerations. For example, pregnant women are prone to suffering from iron
deficiency anaemia (Bencaiova et al. 2012; De Benoist et al. 2008; Stevens et al. 2013) and are
not permitted to donate blood through regular blood collection services such as the Australian Red
Cross. This means that blood samples collected from an individual pregnant woman can only be
of a small volume, and thus many volunteers are needed to obtain the relatively large volumes of
blood plasma required for the purification of PZP. As a result, the restricted availability of
pregnancy plasma is an additional obstacle in the already challenging protocol for the purification
of PZP.
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An alternative approach to purifying endogenous PZP from human pregnancy plasma is the
development of a recombinant expression system. The latter is attractive for several reasons. For
example, the inclusion of an affinity-tag could simplify the process required to purify recombinant
PZP and would eliminate the need for large amounts of pregnancy plasma. However, the large
size, extensive disulfide bonding and complex post-translational modifications of PZP, including
glycosylation and an internal thioester bond, entail that a eukaryotic expression system must be
utilised for this intrinsically difficult endeavour. Previous attempts at producing human
recombinant PZP in a recombinant baculovirus-insect cell system were unsuccessful, yielding nonfunctional, structurally-truncated forms of PZP (Rompaey & Marynen 1994). Similar problems
have been observed after attempts to produce human A2M in insect and human cells, as
recombinant A2M lacks proper structural and functional features which mimic authentic A2M
(Galliano et al. 2006; Marino-Puertas et al. 2019). Although there are a handful of companies
which reportedly sell recombinant PZP, these products have considerable purity issues or appear
to be smaller fragments of the full length form of PZP, rendering them unsuitable for most
functional studies (e.g. MyBioSource, Cat# MBS948491; OriGene, Cat# TP315526; Abcam, Cat#
ab224853; Aviva, Cat# OPCA02774). Additionally, there are currently no published studies which
have used commercially available recombinant PZP.

Promisingly, recombinant alpha-2-

macroglobulin like-1 (A2ML1; a 180 kDa monomer), which shares 63% amino acid sequence
similarity with PZP, has reportedly been produced in very small amounts in HEK293 EBNA cells
(Galliano et al. 2006), although full details of the quality of the A2ML1 obtained was not described
(e.g. gels depicting protein quality were not provided). Taken together, it might be possible to
produce recombinant PZP in the native conformation, using a mammalian expression system.
Considering the limitations of purifying PZP from plasma using existing methods, the
development of a recombinant system for the production of PZP could be a valuable research tool.
Thus, the aims of the work in this chapter are:
1) To optimise the protocol for the purification of PZP from human pregnancy plasma.
2) To develop an expression system using human cells for the production of recombinant
PZP.
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3.2 Methods
3.2.1

Purification of PZP (and A2M) from human pregnancy plasma

A summary of the PZP (and A2M) purification procedure is provided (Table 3.1). Throughout the
procedure, the presence of PZP and other proteins was monitored by analysing protein fractions
by SDS-PAGE, native PAGE and Western blotting (as described in Sections 2.2, 2.3 and 2.4). All
chromatography procedures were carried out using a Next Generation Chromatography (NGC)
medium-pressure liquid chromatography system (Bio-RAD). Protein fractions were visualised
during chromatography procedures via measurement of A280 with the NGC ultraviolet-visible
detector module. Mass spectrometry of excised gel bands was performed using the Australian
Proteome Analysis Facility (APAF) standard protein identification service. Purified PZP yield was
estimated using a combination of A280 quantification (as described in Section 2.9) and sandwich
enzyme-linked immunosorbent assay (ELISA) measurement of PZP in pregnancy plasma (as
described in Section 4.2.10).

3.2.1.1 Plasma collection and preparation
Blood (~ 20 mL) was collected from pregnant women at ~ 28 weeks gestation by venepuncture
using Vacutainer lithium heparin blood collection tubes (Becton Dickinson) at St George Hospital,
Kogarah, in accordance with National Ethics Application HREC/16/WGONG/256 approved by
the Joint University of Wollongong and Illawarra Shoalhaven Local Health District Human
Research Ethics Committee. Immediately upon collection, blood was centrifuged (1,300 × g, 10
min) and plasma was isolated for storage at −20°C. For the purposes of PZP purification,
pregnancy plasma was thawed, pooled (~ 60 mL total) and clarified by centrifugation (24,000 × g,
20 min, 4°C). Clarified pregnancy plasma was placed on ice and supplemented with Complete
Protease Inhibitor Cocktail (Roche Diagnostics), 5 mM EDTA and 100 mM NaCl in preparation
for PEG 6000 precipitation.

3.2.1.2 PEG 6000 precipitation
PEG 6000 precipitation was performed by adding a stock solution containing 50% (w/v) PEG
6000 (prepared in MilliQ H2O) to the plasma (slowly with continuous stirring at 4°C) until a final
concentration of 6% (w/v) PEG 6000 was reached. The plasma was centrifuged (24,000 × g, 20
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min, 4°C) to remove precipitated material (“fraction P1”) and the supernatant further
supplemented with PEG 6000 to achieve a final PEG 6000 concentration of 16% (w/v). The
solution was once again clarified by centrifugation (24,000 × g, 20 min, 4°C) and the supernatant
(“fraction P3”) was removed. The pellet containing proteins precipitated by 6–16% (w/v) PEG
6000 (“fraction P2”; containing PZP and other macroglobulins) was solubilised using ice cold
buffer (20 mM NaPO4, 20 mM NaCl, pH 7), and gentle rocking at 4°C overnight in preparation for
the next step.

3.2.1.3 DEAE anion-exchange chromatography
For DEAE anion-exchange chromatography (AEC), fraction P2 from PEG 6000 precipitation was
extensively dialysed against AEC equilibration buffer (20 mM NaPO4, 20 mM NaCl, pH 7),
syringe-filtered (0.22 µm membrane) and loaded onto a HiPrep DEAE FF 16/10 AEC column (GE
Healthcare; 20 mL bed volume) at 3 mL/min. Once the protein from fraction P2 was loaded onto
the column, the column was extensively washed with equilibration buffer to remove unbound
protein. The column was then washed with 20 mM NaPO4, 60 mM NaCl, pH 7, at a flow rate of 4
mL/min. PZP and other macroglobulins (such as A2M) were obtained by elution with 20 mM
NaPO4, 140 mM NaCl, pH 7. Finally, the column was regenerated by washing with 20 mM NaPO4,
1 M NaCl, pH 7.

3.2.1.4 Hydrophobic interaction chromatography
Hydrophobic interaction chromatography (HIC) was performed essentially as previously
described (Chiabrando et al. 1997). Briefly, protein recovered following AEC elution in buffer
containing 140 mM NaCl was supplemented with Na2SO4 (slowly with stirring at RT) until a final
concentration of 1 M Na2SO4 was reached. This solution was centrifuged (24,000 × g, 20 min,
4°C), syringe-filtered (0.45 µm membrane), and then loaded at a flow rate of 3 mL/min onto a
Phenyl Sepharose CL-4B column (Sigma-Aldrich; 25 mL bed volume) which had been
equilibrated in HIC buffer A (1 M Na2SO4, 20 mM NaPO4, pH 7.0). The column was then washed
with HIC Buffer A until the A280 of the eluate had returned to the baseline level. Next the column
was washed sequentially with buffers of decreasing ionic strength including HIC buffer B (0.4 M
Na2SO4, 20 mM NaPO4, pH 7.0), HIC buffer C (0.2 M Na2SO4, 20 mM NaPO4, pH 7.0), HIC
Buffer D, (20 mM NaPO4, pH 7.0) and finally MilliQ H2O. A2M- and PZP-enriched fractions
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eluted from the column by HIC buffer D and E, respectively, were immediately supplemented with
20 mM HEPES, pH 7.4 and 0.5 M NaCl in preparation for the next step.

3.2.1.5 Zinc affinity chromatography
For zinc affinity chromatography (ZAC), 2 × 5 mL HiTrap chelating HP column (GE Healthcare;
10 mL total bed volume) connected in series were washed, (MilliQ H2O), stripped (50 mM EDTA,
0.5 M NaCl, 20 mM HEPES, pH 7.4), washed (MilliQ H2O), recharged (0.1 M ZnSO4) and finally
equilibrated with ZAC equilibration buffer (0.5 M NaCl, 20 mM HEPES, pH 7.4). The PZP- or
A2M-enriched fractions from HIC were processed in separate chromatography runs by loading the
protein onto the equilibrated zinc column at a flow rate of 2 mL/min and washing with ZAC
equilibration buffer to remove any unbound proteins. Using a flow rate of 4 mL/min, loosely bound
proteins (inducing PZP) were eluted using 15 mM imidazole, 0.5 M NaCl, 20 mM HEPES, pH 7.4
and more strongly bound proteins (including A2M) were eluted using 500 mM imidazole, 0.5 M
NaCl, 20 mM HEPES, pH 7.4. Fractions of either PZP or A2M were subsequently concentrated
using an Amicon Ultra-15 centrifugal filter unit (according to the manufacturer’s instructions), in
preparation for size exclusion chromatography.

3.2.1.6 Size exclusion chromatography
As a final clean up step, size exclusion chromatography (SEC) was performed on PZP-enriched
fractions from ZAC using a HiPrep 26/60 Sephacryl S-200 HR column (GE Healthcare; 120 mL
bed volume) equilibrated with 20 mM NaPO4, pH 7.4, at a flow rate of 0.5 mL/min. The load
volume was typically 2.5 mL (< 3 mg/mL PZP) which was injected via a 3 mL sample loop. SEC
was performed on A2M fractions using a Superose 6 10/300 GL column (GE Healthcare; 24 mL
bed volume) equilibrated with 20 mM NaPO4, pH 7.4, at a flow rate of 0.5 mL/min. The load
volume was typically 0.75 mL (< 5 mg/mL A2M) which was injected via a 1 mL sample loop.
SEC-purified PZP or A2M were supplemented with 100 mM sucrose for long-term storage at
−20°C, or dialysed into PBS/0.01% (w/v) sodium azide for short-term storage at 4°C.
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Table 3.1 Summary of PZP (and A2M) purification procedures from human pregnancy plasma.
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3.2.2

Generation of modified A2M and PZP

Purified A2M or PZP were typically prepared at 0.1–0.5 mg/mL in PBS (pH 7.4) for reaction with
either: (i) 400 mM NH4Cl overnight at RT, which results in cleavage of alpha-macroglobulin
thioester bonds, (ii) 25–200 µM NaOCl at 37°C for 30 min, which generates hypochloritemodified alpha-macroglobulins (including dissociated A2M dimers) or (iii) chymotrypsin for 0.5–
2 h at 37°C, which generates protease-alpha-macroglobulin complexes. For the latter, the molar
ratio of alpha-macroglobulin-to-protease was 1:0.5, 1:1 or 1:2, depending on the experiment.
Modified alpha-macroglobulins were analysed by native PAGE (as described in Section 2.3) and
dialysed extensively in PBS to remove unreacted reagents before being used in experiments.

3.2.3

Preparation of PZP plasmids for expression in mammalian cells

Full-length human PZP cDNA (4,446 bp) encoding the 1,482 amino acid PZP monomer including
the endogenous signal sequence (UniProtKB - P20742-1) was cloned into the pcDNA3.1 (+)
vector backbone by Genscript (Piscataway, USA), flanked by either C-terminal FLAG, 6His or
twin-Strep-tag (twST) tags (pPZP-FLAG, pPZP-6His and pPZP-twST, respectively). Each
plasmid was sequenced at Genscript and verified to contain the full-length PZP cDNA insert,
cloned without error and in-frame to destination vector elements. Other important features and
full length sequences for each of the PZP plasmids is provided (Appendix 8.1). Each PZP plasmid
was transformed into chemically competent E.coli for amplification (as described in Section 2.6)
and purified to transfection-grade quality using HiSpeed Plasmid Maxi Kits (QIAGEN,
Melbourne, Australia), according to the manufacturer’s instructions.

3.2.4

Transfection of mammalian cells

The optimum conditions for transfection were determined following numerous screening
experiments and are described here. Cells were typically seeded in 12-well plates in 1 mL of
growth medium at a density that resulted in 70–90% confluency after 18–24 hr (see Section 2.7
for further details of mammalian cell culture methods). When the desired confluency was reached
18–24 h post-seeding, 0.1 mL of cell media was removed and 0.1 mL of DMEM/F-12 containing
plasmid DNA (2 µg) and PEI (4 µg) (pre-incubated for 15 min at RT to facilitate DNA-PEI
complex formation) was added. Alternatively, 0.1 mL of DMEM/F-12 containing 2 µg of plasmid
DNA and 3 µL of Lipofectamine 2000 (pre-incubated for 5 min at RT to facilitate DNA52

Lipofectamine 2000 complex formation), was added. The amount of DNA and transfection reagent
was scaled up or down as required, ensuring that the ratio of DNA:transfection reagent was
maintained and the volume of transfection mixture added was < 10% of the total culture volume
(proportional to the experimental design, the amount of growth area and the number of cells
present). Cells were typically grown for 72 h post-transfection, at which point the conditioned
growth medium was harvested and stored at −20°C. Conditioned growth medium was
subsequently thawed, clarified by centrifugation (16,000 × g, 5 min, RT) and subjected to native
Western blot analysis with the relevant antibodies (as described in Section 2.4) to monitor
recombinant PZP production.

3.2.5

Comparison of transient PZP-6His expression in HKB-11 and HEK293 cells

HEK293 and HKB-11 cells were transfected under identical conditions in a side-by-side format
with 1:2 or 2:4 µg of pPZP-6His:PEI, and recombinant PZP production was subsequently analysed
after 72 h (as described in Section 3.2.4).

3.2.6

Production of HEK293 and HEPG2 stable cell lines stably secreting PZP-6His

HEK293 or HEPG2 cells were transfected (as described in Section 3.2.4) in T-25 cm2 flasks using
10 µg of pPZP-6His DNA and 20 µg of PEI. Control flasks of HEK293 and HEPG2 cells were
subjected to the same transfection procedures without the addition of pPZP-6His DNA (“mocktransfected”). To select for stable polyclonal transformants, the media of all transfected and mocktransfected flasks was refreshed every 2 days post-transfection with fresh growth medium
containing either 0.5 mg/mL or 0.75 mg/mL Geneticin for HEK293 and HEPG2 cells, respectively
(p-PZP-6His contains the neo gene which confers Geneticin resistance; Appendix 8.1). Antibiotic
selection of polyclonal transformants took approximately 1 week as evidenced by complete loss
in viability of mock-transfected HEK293 and HEPG2 cultures receiving Geneticin. Stable
polyclonal cultures of PZP-6His-expressing HEK293 or HEPG2 cells (HEK293-PZP-6His or
HEPG2-PZP-6His, respectively) were maintained and passaged in growth medium containing the
relevant amount of Geneticin for a further two weeks. At this time, stable polyclonal cultures of
HEK293-PZP-6His and HEPG2-PZP-6His were subjected to standard limiting dilution procedures
in 96-well plates using a plating density of 0.5 cell/well. Clones arising from a single cell were
identified by light microscopy and expanded into 12 well-plates. Growth medium from polyclonal
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and monoclonal cultures was harvested 72 h after the cells reached 100% confluency, clarified by
centrifugation (16,000 × g, 5 min, RT) and analysed by anti-PZP native Western blotting (as
described in Section 2.4). For large-scale production of PZP-6His, a monoclonal HEK293-PZP6His cell line was seeded at low confluency (< 30%) into T-175 flasks (20 mL growth medium
each) and cultured for seven days.

3.2.7

Transient transfection and production of PZP-6His in HEK293-T cells

HEK293-T cells were seeded in T-175 cm2 flasks at 70% confluency in 20 mL growth medium
and transfected with 40 µg of pPZP-6His and 80 µg PEI (as described in Section 3.2.4). The media
was harvested after 72 h, centrifuged (2,000 × g, 15 min, 4°C) and stored at −20°C for 2 weeks
before being subjected to purification procedures (as described in Section 3.2.9).

3.2.8

Transient transfection and production of PZP-6His in Expi293-F cells

Expi293-F cells, an engineered HEK293-derivative that grows in suspension culture to high
densities (< 15 × 106 cells/mL) in proprietary serum-free Expi293 medium, were cultured as per
the manufacturer’s instructions with some exceptions. During the transfection step for a 30 mL
production format, Expi293-F cells (2.5 ×106 cells/mL) were transfected using 30 µg pPZP-6His
DNA and 60 µg PEI (using the process described in Section 3.2.4), the latter being an efficient
and affordable substitute for the recommended Expifectamine transfection reagent in a recently
published protocol (Fang et al. 2017). Additionally, 20 h post-transfection, cultures were
supplemented with 3.5 mM valproic acid and 7 mM sodium propionate (from 0.22 µm sterilefiltered stocks of 0.5 M and 1 M, respectively), which are purported to boost recombinant protein
production (Chun et al. 2003; Fan et al. 2005), as an economical substitute for the recommended
Transfection Enhancer 1 and 2. All cultures were grown at 37°C, 8% (v/v) atmospheric CO2 within
a New Brunswick S41i humidified shaking incubator (Eppendorf, Sydney, Australia) at 120 rpm
in sterile non-baffled 0.2 µm vent-capped polycarbonate Corning Erlenmeyer flasks. Cultures were
typically between 30–100 mL in volume and allowed to grow for 3−4 days post-transfection, or
until the cellular viability reached approximately 50%. After the active growth period of 3−4 days
the media supernatant was harvested, centrifuged (2,000 × g, 15 min, 4°C) and stored at −20°C
for 2 weeks before being subjected to purification procedures (as described in Section 3.2.9).
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3.2.9

Purification of recombinant PZP-6His by cobalt affinity chromatography

Cell culture media containing PZP-6His produced by transfected cells was thawed, clarified by
centrifugation (24,000 × g, 20 min, 4°C) and filtered under vacuum through a 0.45 µm filter. When
working with large volumes (> 150 mL), media was concentrated at 4°C using a 200 mL Amicon
pressurised stirred-cell ultrafiltration unit (Millipore). Clarified media was extensively dialysed
against equilibration buffer (50 mM Tris, 500 mM NaCl, 5 mM imidazole, pH 7.4). The dialysed
media was syringe-filtered (0.45 µm) and loaded at 2 mL/min onto a HisPur cobalt
chromatography cartridge (1 mL bed volume; Thermo Fisher Scientific) and the column was
washed using equilibration buffer until the A280 of the eluate reduced to a baseline level. The
column was subsequently washed with wash buffer (50 mM Tris, 500 mM NaCl, 15 mM
imidazole, pH 7.4) and finally bound 6His-tagged protein was eluted with elution buffer (50 mM
Tris, 500 mM NaCl, 500 mM imidazole, pH 7.4). Chromatography fractions were analysed by
denaturing or non-denaturing PAGE (as described in Sections 2.2 and 2.3). Where applicable,
fractions containing PZP-6His were further purified by SEC on a Superose 6 10/300 GL column
(as described in Section 3.2.1). Untreated purified PZP-6His, or following treatment at 37°C for
30 min with chymotrypsin at a 1:0.5 molar ratio of PZP-6His:chymotrypsin, was analysed by
native PAGE (as described in Sections 2.3 and 3.2.2).
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3.3 Results
3.3.1

PEG 6000 precipitation of human pregnancy plasma

Analysis of the protein composition of human pregnancy plasma by SDS-PAGE (Figure 3.1A)
produced an electrophoretic protein pattern consistent with that of previous studies (Marshall
1984; Thieme et al. 2015), with human serum albumin comprising 52.0 ± 1.3% of the total protein
present as determined by densitometry (mean ± standard error of the mean (SEM), n = 3 is reported
for all densitometry analysis in this chapter). A strong band between the 250 kDa and 150 kDa
molecular weight markers was also observed (Figure 3.1A), which accounted for 4.6 ± 0.2% of
the total protein as determined by densitometry. The latter band was estimated to be approximately
180 kDa in size using a standard curve of the protein size standards (data not shown), which
corresponds to the expected size of A2M and PZP that both migrate as a monomer of 180 kDa
under reducing conditions (Sand et al. 1985). PEG 6000 precipitation was employed as an initial
step to remove albumin whilst enriching PZP and A2M, in line with previously published protocols
(Arbelaéz & Stigbrand 1997; Atha & Ingham 1981; Chiabrando et al. 1997; Liu et al. 2016; Sand
et al. 1985). Following PEG 6000 precipitation, reducing SDS-PAGE analysis indicated that
fractionation of plasma using 6–16% (w/v) PEG 6000 (P2) markedly reduced the abundance of
albumin (26.1 ± 1% by densitometry) and concomitantly increased the abundance of the putative
alpha-macroglobulin ~ 180 kDa band (Figure 3.1B), which comprised 14.1 ± 0.8% of the total
protein as determined by densitometry. Given that both PZP and A2M migrate as a 180 kDa band
under reducing conditions, Western blot analysis was performed to determine the location of PZP
using a highly specific, commercially available antibody for PZP (Appendix 8.2). Using this
approach it was confirmed that PZP was contained within the 6–16% PEG 6000 fraction (P2) of
pregnancy plasma (Figure 3.1C). Negligible immunoreactivity for PZP was observed in the other
PEG fractions (Figure 3.1C). Taken together, the data demonstrate the usefulness of the PEG
precipitation as an initial step for generating an albumin-depleted, PZP-enriched protein fraction
from human pregnancy plasma and provides an example of a strategy which can be used to
successfully monitor the efficacy of this procedure.
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Figure 3.1. Reducing SDS-PAGE and matched Western blot analyses of unfractionated or PEG 6000fractionated pregnancy plasma. (A) The equivalent of 1 µL of unfractionated pregnancy plasma (PP) diluted in PBS
(60 µg total protein) was separated by SDS-PAGE using a NuPAGE 4–12% Bis-Tris gel under reducing conditions.
Bands corresponding to the expected size of monomeric alpha-macroglobulin belonging to A2M or PZP (αM; both
180 kDa), as well as the position of albumin (alb; 67 kDa), are indicated. Protein molecular weight standards (lane M)
are shown in kDa. (B) Pregnancy plasma was fractionated using PEG 6000 and the resultant fractions were analysed
by reducing SDS-PAGE using an 8% Tris-glycine gel. Protein fractions produced by precipitation with < 6% (P1), 6–
16% (P2) and > 16% (P3) PEG 6000 (8, 10 and 4 µg of total protein, respectively) are shown. (C) A matched Western
blot of (B) probed with an anti-PZP antibody.
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3.3.2

DEAE AEC of pregnancy plasma protein fraction precipitated by 6–16% PEG 6000

Similar to previously published protocols for the purification of PZP (Arbelaéz & Stigbrand 1997;
Chiabrando et al. 1997; Sand et al. 1985), the fraction (P2) containing the majority of PZP obtained
by precipitation of plasma proteins using 6–16% (w/v) PEG 6000 was next subjected to DEAE
AEC. This was performed using an optimised NaCl step-elution strategy developed through pilot
studies (Figure 3.2). Following application of the P2 protein fraction obtained by PEG 6000
precipitation to the DEAE AEC column, loosely bound proteins were removed by sequentially
washing with buffer containing 20 mM NaCl and 60 mM NaCl (Figure 3.2A and B, lanes 1–4).
Loosely bound protein fractions contained negligible amounts of PZP as indicated by anti-PZP
native Western blot analysis (Figure 3.2C, lanes 1–4). PZP and presumably A2M (given that A2M
and PZP both appear as a 180 kDa band in reducing SDS-PAGE) were subsequently obtained in a
sharp peak upon elution with buffer containing 140 mM NaCl as identified using a combination
of A280, reducing SDS-PAGE and anti-PZP native Western blot analyses (Figure 3.2A, B and C,
lanes 5–7). The latter also indicated that the majority of PZP migrated at a size assumed as the ~
360 kDa dimeric form, although a small amount of high molecular weight PZP species were also
observed. This step-elution strategy was highly reproducible and resulted in the elution of protein
fractions at 140 mM NaCl which were almost completely depleted of human serum albumin but
enriched for both PZP and A2M (Figure 3.2B), with the ~ 180 kDa PZP/A2M band accounting for
31.7 ± 1.9% of total protein as determined by densitometry. Proteins that remained strongly bound
to the column were removed by washing with 1 M NaCl and only trace amounts of PZP were
detected in the eluate from this column regeneration procedure (Figure 3.2A, B and C, lane 9).
Together, these data demonstrate the usefulness of the optimised DEAE AEC step-elutions for
further depleting albumin while enriching PZP and A2M from 6–16% PEG 6000-precipitated
pregnancy plasma.
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Figure 3.2. Elution profile, reducing SDS-PAGE and native Western blot analyses of protein fractions obtained
by DEAE AEC following 6–16% PEG 6000-fractionation of pregnancy plasma. (A) The PZP-enriched fraction
obtained following 6–16% PEG 6000 precipitation (see Section 3.3.1) was loaded onto a DEAE AEC column. Proteins
were eluted using applications of 20 mM NaPO4, pH 7 buffer containing either 20 mM NaCl (arrowhead w), 60 mM
NaCl (arrowhead x), 140 mM NaCl (arrowhead y) or finally 1 M NaCl (arrowhead z). The absorbance at 280 nm
(black line) and conductivity (mS/cm; red line) were continuously monitored. Fractions taken for analysis are labelled
using numbers and matched to the lanes in panels B and C (1–9). (B) Reducing SDS-PAGE of corresponding fractions
from DEAE AEC performed using an 8% Tris-glycine gel. Protein standards (lane M: sizes in kDa) are shown. Bands
corresponding to albumin (alb) and PZP or A2M alpha-macroglobulin monomers (αM) are indicated. (C)
Corresponding fractions from DEAE AEC were separated by native PAGE using a NuPAGE 3–8% Tris-acetate gel
and then transferred to a nitrocellulose membrane for detection of PZP using an anti-PZP antibody. The expected
position of the native 360 kDa PZP dimer is indicated.
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3.3.3

HIC of PZP-enriched fractions from DEAE AEC

After obtaining a PZP-enriched protein fraction from DEAE AEC, ZAC using a pH 8–5 gradient
and SEC in line with previous strategies (Arbelaéz & Stigbrand 1997; Sand et al. 1985) were next
employed with limited success and only small amounts of purified PZP could be recovered (yields
of 1–5%). Contamination with haptoglobin was one of the primary issues that hindered this
approach as identified by PAGE analyses and the reddish-brown hue (positive colour identification
for haptoglobin) of PZP fractions obtained (data not shown). The PZP-enriched fraction obtained
from DEAE AEC was instead subjected to HIC as previously described in another strategy
(Chiabrando et al. 1997), which is reportedly effective for removing haptoglobin and haptoglobin
polymers from PZP. Using an elution strategy involving decreasing concentrations of Na2SO4,
reddish-brown fractions, with a protein band corresponding to the expected mass of haptoglobin
by reducing SDS-PAGE, were eluted by sequential washings of 20 mM NaPO4 buffer containing
0.4 and 0.2 M Na2SO4 (Figure 3.3A and B, lanes 1–2). PZP eluted in the subsequent elution steps
in which Na2SO4 was absent as assessed by reducing SDS-PAGE and anti-PZP native Western
blot (Figure 3.3A, B and Ci, lanes 3–4). The results of Western blot analysis indicated that the PZP
eluted by 20 mM NaPO4 buffer included non-native species (e.g. putative PZP tetramers), but the
PZP eluted in MilliQ H2O migrated as a single band corresponding to the expected position of the
PZP dimer (Figure 3.3i.). In comparison, the majority of A2M eluted in 20 mM NaPO4 buffer
containing 0.4, 0.2 and 0 M Na2SO4 as determined by reducing SDS-PAGE and anti-A2M native
Western blot analysis (Figure 3.3A, B and Cii, lanes 1–3), using a commercially available antibody
for A2M that displays some cross-reactivity to PZP (Appendix 8.2). Notably, only a relatively
small amount of A2M was observed in the protein fractions eluted in MilliQ H2O that contained
the majority of dimeric PZP (Figure 3.3Cii., lane 4). Consistent with the results of previous work
(Chiabrando et al. 1997), the results shown here demonstrate that HIC is a useful approach for
separating haptoglobin and A2M from PZP. For the first time, this work also demonstrates that
HIC can be used to separate dimeric PZP from aberrant PZP species including putative PZP
tetramers.
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Figure 3.3. Elution profile, reducing SDS-PAGE and native Western blot analyses of protein fractions obtained
by Phenyl Sepharose CL-4B HIC of the PZP-enriched protein fraction from DEAE AEC. (A) The PZP-enriched
fraction obtained following DEAE AEC (see Section 3.3.2) was loaded onto a Phenyl Sepharose CL-4B
chromatography column. Proteins were eluted using applications of 20 mM NaPO4, pH 7.0 buffer containing 1 M
Na2SO4 (arrowhead v), 0.4 M Na2SO4 (arrowhead w), 0.2 M Na2SO4 (arrowhead x) or 0 M Na2SO4 (arrowhead y).
Finally, MilliQ H2O alone was applied to the column (arrowhead z). The absorbance at 280 nm (black line) and
conductivity (mS/cm; red line) were continuously monitored. Fractions taken for analysis are labelled and matched to
the lanes in panels B and C (1–4). (B) Reducing SDS-PAGE of corresponding fractions from HIC performed using an
8% Tris-glycine gel. Protein standards (lane M: sizes in kDa) are shown. Bands corresponding to haptoglobin (Hp)
and PZP or A2M alpha-macroglobulin monomers (αM) are indicated. (C) Corresponding fractions from HIC were
separated by native PAGE using a NuPAGE 3–8% Tris-acetate gel in duplicate and then transferred to a nitrocellulose
membrane for detection of (i) PZP using an anti-PZP antibody or (ii) A2M using an anti-A2M antibody. The expected
position of PZP 720 kDa tetramers (PZP T) and 360 kDa dimers (PZP D) are marked. Putative PZP which has been
detected due to cross-reactivity of the anti-A2M antibody is indicated (PZP x).
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3.3.4

ZAC of PZP-enriched HIC fractions

Considering that complete separation of PZP from A2M was not possible by HIC, ZAC was next
employed to separate the two highly similar proteins. Rather than utilise a pH gradient (Arbelaéz
& Stigbrand 1997; Chiabrando et al. 1997; Sand et al. 1985), a novel non-denaturing strategy was
developed that used increasing concentrations of imidazole to separate PZP from A2M. The results
show that the majority of the PZP was eluted from the column in buffer containing 15 mM
imidazole along with smaller (< 150 kDa) contaminant proteins (Figure 3.4A, B and Ci, lane 1).
This protein fraction had no observable band corresponding to the A2M tetramer by native PAGE
(Figure 3.4B, lane 1). Moreover, the 15 mM imidazole-PZP fraction held no detectable
immunoreactivity for A2M as determined by the results of anti-A2M native Western blot (Figure
3.4Cii). When buffer containing 500 mM imidazole was applied to the ZAC column to elute
strongly bound proteins a small amount of PZP was recovered along with the majority of A2M
(Figure 3.4A, B and C, lane 2). The A2M recovered appeared to be heterogeneous, containing high
molecular weight species, A2M tetramer and putative A2M or PZP dimer (Figure 3.4B and Cii,
lane 2). Ultimately, the data indicates that PZP can be separated from A2M using imidazole when
eluting the proteins from a zinc stationary phase.
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Figure 3.4. Elution profile, native PAGE and native Western blot analyses of fractions obtained by ZAC. (A)
The PZP-enriched fraction obtained following HIC (see Section 3.3.3), was next applied to a HiTrap column that had
been charged with zinc. The column was washed with 20 mM HEPES, 0.5 M NaCl, pH 7.4 buffer containing 0 mM
imidazole (arrowhead x), 15 mM imidazole (arrowhead y) or 500 mM imidazole (arrowhead z). Fractions taken for
analysis are labelled and matched to the lanes in panels B and C (1–2). The absorbance at 280 nm was continuously
monitored. (B) Native PAGE of corresponding fractions from ZAC performed using a NuPAGE 3–8% Tris-acetate
gel. (C) Matched native Western blots in which protein from (B) was transferred to a nitrocellulose membrane for
detection of (i) PZP using an anti-PZP antibody or (ii) A2M using an anti-A2M antibody. Protein molecular weight
standards (lane M) are included for comparison, with sizes as shown in kDa. High molecular weight species (HMW),
A2M tetramers (A2M), putative A2M dimer (A2M D), PZP dimer (PZP D) and smaller contaminating proteins (Ctm)
are labelled. A2M D may also represent PZP D due to cross-reactivity of the anti-A2M antibody.
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3.3.5

SEC of PZP-enriched ZAC fractions

As a final clean up step, the protein fraction containing PZP obtained following ZAC was subjected
to SEC using a Sephacryl S-200 column to remove smaller contaminating proteins. Two major
protein peaks eluted from the column as assessed by monitoring the A280 (Figure 3.5A).
Considering the separation range of this column (250–5 kDa), the first peak eluting in the void
volume with size exclusion limit > 250 kDa (36–40 mL) was consistent with the expected size of
PZP (360 kDa) (Figure 3.5A). Native PAGE analysis indicated that fractions obtained from the
void volume following filtration on Sephacryl S-200 contained highly purified PZP, with
negligible amounts of smaller contaminating proteins (Figure 3.5B). Lower amounts of PZP eluted
in fractions after the void volume (> 40 mL) as visualised by native PAGE analysis (Figure 3.5B).
Re-processing of fractions eluted at 40–44 mL by SEC allowed for increased recovery of purified
PZP. The smaller contaminating protein of unknown identity, which accounted for the majority of
the other resolved peak eluting > 40 mL, migrated at ~25 kDa by reducing SDS-PAGE (Figure
3.5C). The ~ 25 kDa gel band was excised and identified as apolipoprotein A1 with 75.7% peptide
coverage using the APAF protein identification service (Figure 3.5D). At the conclusion of SEC,
the total amount of purified PZP was quantified by spectrophotometry A280 and indicated that an
approximate yield of 9 ± 0.35 mg PZP had been obtained from 100 mL of pooled pregnancy
plasma, which had originally contained 0.26 ± 0.02 mg/mL PZP (data are means ± SD, n = 2
separate purifications), as measured by sandwich ELISA. This is consistent with an approximate
yield of 35% of the total PZP in pregnancy plasma. Purified PZP further matched the size of
endogenous PZP detected in human pregnancy plasma by native Western blot analysis (Figure
3.5E).
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Figure 3.5. Analyses of fractions obtained by SEC of the PZP-enriched protein fraction from ZAC. (A) The
PZP-enriched protein fraction obtained following ZAC (see Section 3.3.4) was next processed by SEC using a
Sephacryl S-200 column equilibrated with 20 mM NaPO4, pH 7.4. Fractions of 2 mL were collected and the
absorbance at 280 nm was continuously monitored. The two main peaks are labelled and matched to panel B (1–2).
(B) Each of the 2 mL fractions collected in SEC were analysed by native PAGE using a NuPAGE 3–8% Tris-acetate
gel. The positions of native dimeric PZP (PZP D) and smaller contaminating proteins (Ctm) are marked. (C) Protein
corresponding to peak 2 obtained by SEC was analysed by non-reducing SDS-PAGE using a NuPAGE 4–12% BisTris gel. Protein molecular weight standards (lane M) are shown in kDa. (D) The single gel band identified in panel
C was excised and analysed through the APAF protein identification service. (E) The equivalent of 1 µL of
unfractionated pregnancy plasma (PP) diluted in PBS (60 µg total protein) and purified PZP (100 ng) were separated
by native PAGE using a NuPAGE 3–8% Tris-acetate gel and then transferred to a nitrocellulose membrane for
detection of PZP using an anti-PZP antibody.
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3.3.6

Co-purification of batch-matched A2M from pregnancy plasma

Previous protocols have purified batch-matched A2M and PZP from pregnancy plasma (Arbelaéz
& Stigbrand 1997; Bonacci et al. 2000; Sand et al. 1985). However, these methods involve
exposing the proteins to acidic pH 6–5 during the ZAC step. Exposure of A2M to pH 6–5 results
in (i) insoluble aggregation of A2M and (ii) structural perturbation of the purified product as
observed by native PAGE, which included conversion of A2M into the compact,
electrophoretically fast tetrameric conformation (Figure 3.6A). As such, batch-matched A2M was
purified by collecting fractions which eluted in 20 mM NaPO4, 0 M Na2SO4, pH 7.0 from HIC
(see Section 3.3.3, Figure 3.3A–C, fraction/lane 3) and subjecting these fractions to the nondenaturing ZAC strategy outlined earlier in this chapter (Section 3.3.4). Analysis by native PAGE
showed that the majority of PZP and other contaminating proteins were eluted in the flow through
as the sample was loaded or in buffer containing 15 mM imidazole, whereas A2M was eluted in
buffer containing 500 mM imidazole (Figure 3.6B and C). The fraction containing A2M was next
subjected to SEC using a Superose 6 column, which was largely a clean-up step to remove a small
amount of contaminating proteins. The purity of A2M was confirmed by the SEC elution profile
and native PAGE (Figure 3.6D and E). A280 quantification indicated that this purification strategy
recovered approximately 30 ± 1.4 mg of purified A2M/100 mL of pregnancy plasma (n = 2
separate purifications), corresponding to an approximate yield of 10% based on previous
estimations of the amount of A2M in human plasma (Tunstall et al. 1975). For experiments where
it was critical that purified A2M was free from potential contamination with PZP, A2M was
purified from normal human plasma using well-established methods (as described in Section 2.10).
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Figure 3.6 Elution profile and native PAGE analyses of A2M co-purified from pregnancy plasma. (A) Native
PAGE analysis using a NuPAGE 3–8% Tris-acetate gel of A2M purified using a non-denaturing strategy or by the
protocol involving exposure to pH 6–5 during gradient elution. Native A2M (0.5 mg/mL in PBS) was incubated in
the presence of 400 mM NH4Cl (overnight at RT) as a control to depict the migratory position of the A2M fast tetramer
(as labelled). (B) The A2M-enriched fraction eluted in 20 mM NaPO4, 0 M Na2SO4, pH 7.0 by HIC (see Section
3.3.3), was next applied to a ZAC column. The column was washed with 20 mM HEPES, 0.5 M NaCl, pH 7.4 buffer
containing 0 mM imidazole (arrowhead x), 15 mM imidazole (arrowhead y) or 500 mM imidazole (arrowhead z).
Fractions taken for analysis are labelled and matched to the lanes in panel C (1–2). (C) Native PAGE of corresponding
fractions from ZAC performed using a NuPAGE 3–8% Tris-acetate gel. (D) The A2M-enriched protein fraction
obtained following ZAC as described in (B) was next processed by SEC using a Superose 6 column equilibrated with
20 mM NaPO4, pH 7.4. Fractions of 1 mL were collected and the absorbance at 280 nm was continuously monitored.
(E) Each of the 1 mL fractions collected as described in SEC (D) were pooled and analysed by native PAGE using a
NuPAGE 3–8% Tris-acetate gel.
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3.3.7

Quality control analysis of A2M and PZP purified from pregnancy plasma

A2M and PZP are relatively unstable proteins that can adopt non-native structures as a result of
improper handling or storage (as discussed in Section 3.1). Standard quality control analyses to
confirm the activity and correct quaternary structure of native A2M and PZP involves treatment
of the proteins with proteases, small nucleophiles or other agents which produces characteristic
alterations in the electrophoretic mobility of the proteins by native PAGE (Christensen et al. 1989;
Jensen & Stigbrand 1992; Reddy et al. 1994; Sand et al. 1985). Native PAGE analysis indicated
that purified A2M migrated as a single band with less electrophoretic mobility compared to
NH4Cl-treated A2M (e.g. transformed, electrophoretically fast A2M which is relatively more
compact compared to native A2M) and A2M dimers that were formed by reaction with NaOCl
(Figure 3.7A). The latter is consistent with the purified preparation of A2M being in the native
tetrameric conformation. Concomitantly, by native PAGE analysis purified PZP migrated as a
single band with similar electrophoretic mobility to dissociated A2M dimers (Figure 3.7A). This
was indicative that the purified preparation of PZP was in the native dimeric conformation. By
native PAGE, upon reaction with NH4Cl the migration of PZP appeared mostly unchanged, which
was in accordance with previous observations showing that PZP does not readily adopt a fast
conformation (e.g. like A2M) upon reaction with monoamines (Christensen et al. 1989; Jensen &
Stigbrand 1992; Sand et al. 1985). Reaction of PZP with NaOCl has not been previously described,
and upon reaction with NaOCl the migration of PZP increased, with two bands of
electrophoretically fast PZP visible by native PAGE analysis (Figure 3.7A). Following reaction of
PZP with chymotrypsin, PZP migrated as three distinct bands consistent with the presence of
dimeric, fast dimeric and tetrameric PZP (Figure 3.7B). The presence of the latter two bands is
indicative that native PZP with protease inhibitory activity had been purified (Christensen et al.
1989; Jensen & Stigbrand 1992).
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Figure 3.7. Native PAGE analyses showing the migration of A2M and PZP following chemical treatment or
reaction with proteases to generate forms with altered electrophoretic mobility. (A) A2M and PZP (0.34 mg/mL
in PBS) were incubated in the presence of 400 mM NH4Cl (overnight at RT), or 100 µM NaOCl (for 30 min at 37°C).
Batch-matched, untreated native A2M and PZP were kept at 4°C for comparison. The samples were separated using
a NuPAGE 3–8% Tris-acetate gel. The positions of the various forms of A2M and PZP are indicated. (B) Native
PAGE analysis using a NuPAGE 3–8% Tris-acetate gel showing the migration of native dimeric PZP or PZP following
reaction with chymotrypsin (chym) to generate fast dimeric PZP and tetrameric PZP-protease complexes. PZP (0.25
mg/mL in PBS) was reacted with chymotrypsin (8.75 µg/mL) for 30 min at 37°C.
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3.3.8

Production of affinity-tagged recombinant PZP in HEK293 cells

HEK293 cells were transiently transfected with pcDNA 3.1 (+) plasmid constructs encoding PZP
cDNA conjugated to either C-terminal FLAG, 6His or twST affinity tags (p-PZP-FLAG, p-PZP6His and p-PZP-twST, respectively) (Appendix 8.1). As the PZP cDNA sequence contains an
endogenous N-terminal signal sequence that directs PZP to the secretory pathway, the conditioned
media of untransfected and transfected HEK293 cells was analysed by anti-PZP native Western
blot. The results showed that a band corresponding to the size of native dimeric PZP purified from
pregnancy plasma was absent in untransfected media but present in small amounts in the
conditioned media of HEK293 cells transfected with p-PZP-FLAG (Figure 3.8A). Further
optimisation experiments using HEK293 cells and p-PZP-FLAG identified that expression of
recombinant PZP using lipofectamine for transfection was comparable to p-PZP-FLAG:PEI at
mass ratios of 1:1, 1:1.5 or 1:2 (but not 1:3), with the ratio of 1:2 appearing to give the best
expression (Figure 3.8B). The latter ratio was identified as suitable for large-scale transient
transfections involving production of recombinant PZP. Additional analysis by native Western
blot showed that conditioned media of HEK293 cells transfected with p-PZP-FLAG, p-PZP-6His
or p-PZP-twST produced a single band consistent with the size of dimeric PZP (Figure 3.8C).
Slight differences in the expression level and migration of recombinant PZP-FLAG, PZP-6His and
PZP-twST were observed, which was attributed to the different affinity tags of each PZP construct
(Figure 3.8C). Given that stationary phases with affinity for 6His and twST are relatively
economical, these tags were chosen for downstream attempts at purification of recombinant PZP
from the conditioned media. Correspondingly, it was important to determine if the epitopes of the
6His and twST affinity tags were accessible under native conditions in order to facilitate
purification of recombinant PZP. The results of native Western blot analysis showed that
recombinant PZP-6His produced by HEK293 cells was reactive with an anti-6His antibody (Figure
3.8D). The 6His-immunoreactive band was not detected in the conditioned media of HEK293 cells
transfected with p-PZP-twST (Figure 3.8D). Similarly, conditioned media of HEK293 cells
transfected with p-PZP-twST was reactive with an anti-twST antibody at a position corresponding
to recombinant PZP-twST, while p-PZP-6His transfection media did not harbour any twST
epitopes at the position of PZP (Figure 3.8E). Taken together, the results indicated that HEK293
cells can be used to produce recombinant PZP (i) at a size consistent with the size of native PZP
and (ii) with accessible 6His or twST tags that could facilitate downstream attempts at purification.
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Figure 3.8 Images of native Western blots showing recombinant PZP production in HEK293 conditioned media
following transfection with PZP cDNA plasmid constructs encoding different C-terminal affinity tags. Unless
otherwise specified, in all experiments HEK293 cells were transfected at approximately 70% confluency in 12-well
plates using 2 µg PZP plasmid DNA:3 µL Lipofectamine 2000. After 72 h, untransfected control samples and
conditioned medium of cells transfected with PZP plasmid DNA was collected. Samples were separated on a NuPAGE
3–8% Tris-acetate gel, transferred by Western blotting to a nitrocellulose membrane and probed using the relevant
antibodies as indicated below. Unless otherwise stated, all results are representative of three independent experiments.
(A) Untransfected and conditioned medium of cells transfected with p-PZP-FLAG was collected from two
independent experiments (n = 1 and 2) and analysed by native Western blot using an anti-PZP antibody. A pregnancy
plasma-purified PZP standard (1 µg) was included which shows the migratory position of the native 360 kDa PZP
dimer (PZP) and small amounts of the non-native 720 kDa PZP tetramer (PZP T). (B) Standard transfection using 2
µg p-PZP-FLAG:3 µL Lipofectamine 2000 was compared to transfection using 2 µg p-PZP-FLAG:2, 3, 4 or 6 µg PEI
(plasmid DNA:PEI ratios of 1:1, 1:1.5, 1:2, or 1:3, respectively) and analysed by native Western blot using an antiPZP antibody. (C) Untransfected and conditioned medium of cells transfected with p-PZP-FLAG, p-PZP-6His or pPZP-twST, analysed by native Western blot using an anti-PZP antibody. (D) Conditioned medium of cells transfected
with p-PZP-6His or p-PZP-twST was analysed by native Western blot using either (i) anti-6His or (ii) anti-twST
antibodies.
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3.3.9

Comparison of HKB-11 with HEK293 for production of recombinant PZP-6His

Given the simplicity of purifying 6His-tagged proteins, p-PZP-6His was chosen as the lead
plasmid for further development of the recombinant PZP system. The HKB-11 cell line (an
engineered HEK293/B-cell hybrid) is reportedly more effective than HEK293 cells at producing
higher yields of recombinant coagulation factor VIII, a complex protein exhibiting extensive posttranslational modifications similar to those found in PZP (Cho et al. 2002). Anti-PZP native
Western blot and densitometry analysis showed that under identical transfection conditions,
HEK293 produced approximately 2-fold more PZP-6His than HKB-11 (n = 2) (Figure 3.9). As
such, the HKB-11 cell line was identified to be a less suitable system for the production of
recombinant PZP in comparison to HEK293. Given the poor expression level observed, production
and purification of PZP-6His from the HKB-11 cell line was not attempted further in the current
project.

Figure 3.9. Native Western blot analysis of PZP-6His production in HEK293 and HKB-11 cells. HEK293 and
HKB-11 cells were transfected in 12-well plates under identical conditions with p-PZP-6His (1 µg plasmid DNA:2
µg PEI or 2 µg plasmid DNA:4 µg PEI; labelled 1:2 and 2:4 respectively in the figure above). After 72 h, the
conditioned medium from each treatment was collected, separated using a NuPAGE 3–8% Tris-acetate gel and
transferred by Western blot to a nitrocellulose membrane for detection of recombinant PZP with an anti-PZP antibody.
Results are representative of two independent experiments.
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3.3.10 Production of a stably transfected monoclonal HEK293-PZP-6His cell line
HEK293 and HEPG2 were chosen as candidate cell lines for stable cell line development, given
the promising recombinant PZP expression observed with the former and the hepatic origin of the
latter (the liver is a major site for PZP synthesis in vivo). Initially, expression of recombinant PZP6His could not be detected in the conditioned medium of stably transfected HEK293-PZP-6His or
HEPG2-PZP-6His polyclonal cultures by anti-PZP native Western blot (Figure 3.10A). Limiting
dilution of the polyclonal parent lines was therefore performed in an attempt to obtain highexpressing monoclonal cell lines. Unfortunately, HEPG2-PZP-6His monoclonal cell lines could
not be established due to an inability to grow single cell cultures. Conversely, HEK293-PZP-6His
monoclonal cell lines were successfully produced and subsequently screened for recombinant
PZP-6His production by anti-PZP native Western blot analysis. The results showed that the
majority of HEK293-PZP-6His monoclonal cell lines had very low or undetectable levels of PZP6His expression as assessed by native Western blot analysis (Figure 3.10A). In the screening
process a single, higher-expressing HEK293-PZP-6His clone was identified (Figure 3.10A; lane
6). Using native Western blot analysis and densitometry with purified PZP standards (data not
shown), this higher-expressing clone was estimated to express PZP-6His at approximately 50
ng/cm2 of growth area. Conditioned medium from large-scale static cultures of the high-expressing
monoclonal HEK293-PZP-6His cell line (7 days, 1,050 cm2, 120 mL growth medium) was
subjected to cobalt affinity chromatography. Protein estimation using A280 and native PAGE
analysis indicated that only a very small amount of PZP-6His (< 40 µg) was recovered (Figure
3.10B and C; E1). Furthermore, the recovered protein migrated as a smear rather than a distinct
band at the expected position of PZP by native PAGE analysis (Figure 3.10C; lane 5).
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Figure 3.10 Screening of PZP-6His stable cell lines and analysis of purified PZP-6His from a monoclonal cell
line. The conditioned medium from polyclonal HEK293 (HEK293P), HEPG2 (HEPG2P) or monoclonal HEK293
(HEK293M; each clone in lane 1–7 obtained by limiting dilution of HEK293P), produced using Geneticin selection for
p-PZP-6His, was separated on a NuPAGE 3–8% Tris-acetate gel and transferred by Western blotting to a
nitrocellulose membrane for PZP detection using an anti-PZP antibody. (B) The single high expressing clone identified
(A; lane 6) was grown on a large-scale for 7 days in 6 × T-175 flasks (120 mL total growth medium). This conditioned
medium was subsequently loaded onto a cobalt affinity column and washed with 50 mM Tris, 500 mM NaCl, pH 7.4
buffer containing 5 mM imidazole (arrowhead x), 15 mM imidazole (arrowhead y) or 500 mM imidazole (arrowhead
z). Fractions taken for analysis are labelled and matched to the lanes in panel C (1–5). The absorbance at 280 nm was
continuously monitored. (C) Corresponding fractions obtained by cobalt affinity chromatography were analysed by
native PAGE using a NuPAGE 3–8% Tris-acetate gel.
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3.3.11 Purification of recombinant PZP-6His from transiently transfected HEK293-T cells
grown in static culture
Given that large amounts of recombinant PZP-6His could not be generated for purification using
HEK293 cells, the HEK293-T cell line was next investigated for its ability to produce recombinant
PZP. HEK293-T was chosen due to its expression of the SV40 large-T antigen, which allows for
episomal amplification of SV40 ori-containing plasmids such as the PZP plasmids used in this
study (Appendix 8.1), leading to a potential boost in recombinant protein production (Van
Craenenbroeck et al. 2000). Initial analyses by anti-PZP native Western blot and densitometry
indicated that, under identical conditions, HEK293-T had approximately 2.5-fold higher
production of PZP-6His in comparison to HEK293 (n = 3) (Figure 3.11A). Conditioned medium
from large-scale static cultures of HEK293-T cells transiently transfected with p-PZP-6His (3
days, 700 cm2, 80 mL growth medium) was subjected to purification procedures using cobalt
affinity chromatography. Protein quantification and reducing SDS-PAGE analysis showed that a
small amount of purified protein was obtained (< 80 µg), which migrated at ~180 kDa under
reducing conditions, corresponding to the size of the reduced PZP monomer (Figure 3.11B and
C). However, by native PAGE analysis the majority of the protein migrated as a smear and a
discrete band corresponding to the PZP dimer was not evident (Figure 3.11D). The data suggest
that although increased expression of PZP-6His could be obtained by transient transfection in
HEK293-T cells compared to regular HEK293 cells, in the current study, it was not possible to
purify meaningful quantities of dimeric PZP-6His using this system.
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Figure 3.11. Analyses of PZP-6His expression and purification following production in HEK293-T cells.
(A) HEK293-T and HEK293 cells were transfected under identical conditions in a 12-well plate with 2 µg p-PZP6His:3 µL Lipofectamine 2000. After 72 h, the conditioned medium from each transfected cell line was collected,
separated using a NuPAGE 3–8% Tris-acetate gel and transferred by Western blot to a nitrocellulose membrane for
detection of recombinant PZP-6His with an anti-PZP antibody. Results shown are representative of three independent
experiments (B) HEK293-T cells were seeded in 4 × T-125 flasks in 20 mL growth medium and each transfected with
40 µg p-PZP-6His:80 µg PEI. After 72 h, this conditioned medium was subsequently loaded onto a cobalt affinity
column and washed with 50 mM Tris, 500 mM NaCl, pH 7.4 buffer containing 5 mM imidazole (arrowhead x), 15
mM imidazole (arrowhead y) or 500 mM imidazole (arrowhead z). Fractions taken for analysis are labelled and
matched to the lanes in panels C and D (1–3). The absorbance at 280 nm was continuously monitored. (C)
Corresponding fractions obtained by cobalt affinity chromatography were analysed by reducing SDS-PAGE using a
NuPAGE 4–12% Bis-Tris gel. Protein molecular weight standards (lane M) are shown in kDa. The expected migratory
position of recombinant PZP-6His monomers under reducing conditions is marked. (D) PZP-6His obtained by cobalt
affinity chromatography (fraction/lane 3; panels B and C) was further purified by SEC using a Superose 6 column
equilibrated in PBS. The major peak collected was analysed by native PAGE using a NuPAGE 3–8% Tris-acetate gel.
The expected position of PZP-6His is marked.
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3.3.12 Purification of PZP-6His from transiently transfected Expi293-F cells grown in
suspension culture
According to the manufacturer (Thermo Fisher Scientific), Expi293-F cells are reportedly a highly
transfectable derivative of the HEK293 cell line, which readily grows to high densities in serumfree suspension culture and generates superior yields of recombinant protein in comparison to
other HEK293 cell lines. Initial assessment by anti-PZP native Western blot analysis and
densitometry revealed that the suspension Expi293-F system had approximately 5-fold greater
production of secreted PZP-6His following transient transfection in comparison to the adherent
HEK293-T system (n = 3) (Figure 3.12A). Conditioned medium from large-scale cultures of
Expi293-F cells (120 mL) transfected with p-PZP-6His was subjected to cobalt affinity
chromatography. Protein quantification using A280 and reducing SDS-PAGE analysis showed that
a modest amount of purified protein was obtained (< 0.25 mg) following elution with 500 mM
imidazole (Figure 3.12B and C, fraction/lane 4). The most abundant protein in this fraction
migrated at the expected size of the ~ 180 kDa PZP monomer under reducing conditions, although
small amounts of other contaminating proteins were also present (Figure 3.12C, lane 4).
Comparative analysis by SDS-PAGE under non-reducing conditions indicated that the majority of
protein obtained following elution in 500 mM imidazole by cobalt affinity chromatography was
present as SDS-stable, high molecular weight aggregates (including aggregates that were retained
in the wells of the gel), that were removed upon treatment with reducing agent (Figure 3.12C, lane
4). The latter comparison suggests that recombinant PZP-6His was possibly incorrectly disulfide
bonded with itself or other proteins (such as constitutively expressed proteins secreted by Expi293F cells during normal growth) and/or contaminated with misfolded protein aggregates which may
exhibit disulfide linkages. Further purification by SEC led to marginal improvements in the quality
of PZP-6His, but some high molecular weight assemblies persisted as visualised by smearing in
native PAGE (Figure 3.12D). Bands corresponding to the PZP tetramer and dimer could also be
seen by native PAGE migration (Figure 3.12D). Interestingly, the smearing associated with PZP6His by native PAGE was removed following treatment with chymotrypsin, which corresponded
with a faster electrophoretic mobility of the PZP dimer and tetramer by native PAGE (Figure
3.12D). Ultimately, the results show that purified recombinant PZP-6His can be obtained from
Expi293-F cells at approximate yields of 2 mg/L, but some PZP-6His is present as tetramers or in
high molecular weight disulfide-bonded assemblies, with only a portion of PZP-6His consistent
with the size of native dimeric PZP.
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Figure 3.12. Analyses of PZP-6His expression and purification following production in Expi293-F cells.
(A) Expi293-F or HEK293-T cells were each transfected with p-PZP-6His using their respective optimised conditions.
After 72 h, the conditioned medium from each transfected cell line was collected, separated using a NuPAGE 3–8%
Tris-acetate gel and transferred by Western blot to a nitrocellulose membrane for detection of recombinant PZP-6His
with an anti-PZP antibody. The results shown are representative of three independent experiments. (B) Expi293-F
suspension cells (2.5 ×106 cells/mL) were transfected with 120 µg p-PZP-6His:240 µg PEI in 120 mL growth medium.
After 96 h, this conditioned medium was subsequently loaded onto a cobalt affinity column and washed with 50 mM
Tris, 500 mM NaCl, pH 7.4 buffer containing 5 mM imidazole (arrowhead x), 15 mM imidazole (arrowhead y) or
500 mM imidazole (arrowhead z). Fractions taken for analysis are labelled and matched to the lanes in panels C and
D (1–4). The absorbance at 280 nm was continuously monitored. (C) Corresponding fractions obtained by cobalt
affinity chromatography were analysed by SDS-PAGE under non-reducing or reducing conditions (as marked), using
an 8% Tris-glycine gel. Positions corresponding to reduced PZP-6His monomers and non-reduced high molecular
weight aggregates (HMWA) are labelled. (D) PZP-6His obtained by cobalt affinity chromatography from Expi293-F
cells (fraction/lane 4; panels B and C) was further purified by SEC using a Superose 6 column equilibrated in PBS
and analysed by native PAGE using a NuPAGE 3–8% Tris-acetate gel. A sample was included of PZP-6His (0.25
mg/mL in PBS) which had been reacted with chymotrypsin (8.75 µg/mL) for 30 min at 37°C. PZP-6His tetramers (T)
and dimers (D) are marked.
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3.4 Discussion
A fundamental challenge for biochemical studies of PZP in vitro is the difficulty in obtaining
adequate amounts of purified PZP in its native dimeric form. By building upon previous protocols
(Arbelaéz & Stigbrand 1997; Chiabrando et al. 1997; Sand et al. 1985), in the present study an
improved strategy for the purification of native PZP from human pregnancy blood plasma was
developed. The procedure consists of PEG 6000 fractionation (Figure 3.1), followed by DEAE
AEC (Figure 3.2), HIC (Figure 3.3), ZAC (Figure 3.4) and SEC (Figure 3.5). Importantly the
purified dimeric PZP contains intact thioesters as determined by the formation of tetrameric PZPprotease complexes in native PAGE analysis (Figure 3.7). Previous PZP purifications protocols
that use an acidic pH gradient may result in partial denaturation of PZP and also generate varying
amounts of PZP tetramer as seen by native PAGE analysis (Arbelaéz & Stigbrand 1997;
Chiabrando et al. 1997; Sand et al. 1985). The use of heterogeneous purified PZP consisting of
tetramer and dimer in biochemical studies is undesirable, given that preformed tetrameric PZP
displays functional differences to the PZP dimer including loss of protease binding (Bonacci et al.
2000). Replacing the denaturing pH gradient elution in the ZAC step of previous protocols with
elution in non-denaturing imidazole at defined concentrations appears to greatly improve the
fraction of endogenous PZP purified in a dimeric conformation, consistent with the native form
present in pregnancy plasma.
An additional advantage of the optimised purification procedure described in this chapter is that
all gradient elutions have been replaced with isocratic step-elutions. This means that; (i) the
procedure can now be performed with very simple chromatography systems not fitted with
gradient capabilities and (ii) proteins elute in smaller volumes compared to gradient elution,
meaning time-consuming protein concentration steps that decrease protein yield are no longer
necessary (although protein concentration is still recommended prior to SEC to maximise
separation). The elimination of almost all of the protein concentration steps, and aforementioned
improvements in the ZAC step, are likely to be major contributing factors to the increased yield of
PZP obtained in this study (~ 35% of the total in pregnancy plasma) compared to earlier studies
(~ 20–25% of the total in pregnancy plasma) (Chiabrando et al. 1997; Sand et al. 1985). The
markedly higher yield of ~ 55% reported by Arbelaéz and Stigbrand (1997), was not able to be
reproduced in the current study and this method for PZP purification does not appear to have been
reproduced by many other research groups. This discrepancy may be because this method lacks a
HIC step, which was observed to be critical for obtaining PZP free of haptoglobin contamination
in the present study and by others (Chiabrando et al. 1997).
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Given the close relationship of the two proteins, studies of PZP often involve A2M for comparative
analysis or as a control in biochemical assays. Another benefit of the current procedure is that it
includes steps for purifying batch-matched A2M under native conditions from the same pregnancy
plasma used for PZP purification. Given that A2M is acutely sensitive to denaturation at acidic pH
gradient elution (pH 6–5) as shown by native PAGE analysis (Figure 3.6A) and by others (Pochon
et al. 1989; Sottrup-Jensen et al. 1980), replacing the pH gradient previously used in ZAC with
elution in imidazole allows for the best chance of purifying native, non-denatured A2M . In
agreement, A2M purified under these conditions migrates by native PAGE as a band
corresponding to the native tetramer and contains intact thioester bonds as assessed by conversion
of A2M tetramer to fast A2M upon methylamine treatment (Figure 3.7A). The ability to purify
batch-matched A2M and PZP under native conditions removes potential bias associated with
studies where A2M and PZP are purified from different sources.
A ~ 25 kDa protein band identified as apolipoprotein A1 was observed to co-purify with PZP until
the final SEC step (Figure 3.1–3.5). A protein band consistent with the size of apolipoprotein A1
(< 32 kDa) also co-purified with PZP up until the final SEC step in the procedure of Chiabrando
et al. (1997), although the identity of this band was not provided. Apolipoprotein A1 is a major
component of high-density lipoprotein (HDL) particles that is highly abundant in human plasma
(1.4–1.6 mg/mL) (Leino et al. 1995), where it plays an important role in lipid transport and
metabolism. No information could be found in the literature regarding physical interactions of PZP
with apolipoprotein A1 or HDL particles. However, there is evidence that A2M plays a role in
lipid metabolism through its interactions with various lipoproteins, lipid particles and common
lipoprotein receptors. It has been shown that A2M is non-covalently bound to apolipoprotein E in
human plasma in particles of sizes corresponding to HDL or low-density lipoprotein (LDL)
particles (Krimbou et al. 1998). Furthermore, A2M and apolipoprotein E-enriched β-migrating
very-low-density lipoprotein (VLDL) share a common receptor, LRP1, which is proposed to
mediate clearance of plasma proteases and cholesteryl ester-rich remnant lipoproteins (Kowal et
al. 1989; Kristensen et al. 1990; Strickland et al. 1990). In addition, it has been demonstrated that
A2M non-covalently binds to lecithin: cholesterol acyltransferase (LCAT), and this binding can
be competitively reduced by co-incubation of A2M:LCAT mixtures with either reconstituted
apolipoprotein A1 or native HDL particles (Krimbou et al. 2001). It is therefore tempting to
speculate that co-purification of apolipoprotein A1 and PZP as observed in this study is not coincidental and PZP may physically interact with lipoproteins and lipid particles similar to A2M.
The latter would account for why PZP does not completely elute in the void volume during SEC
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considering the size exclusion limit is > 250 kDa, with some PZP being retained in fractions < 250
kDa containing apolipoprotein A1 (Figure 3.5A and B).
Currently A2M can be easily purified from non-pregnant human plasma in 1–2 steps (Kurecki et
al. 1979; Wyatt et al. 2015), whereas PZP purification specifically requires pregnancy plasma
taken from mid-to-late gestation and consists of at least 5–7 steps. Although significant progress
has been made in this project towards improving the purification of PZP from human pregnancy
plasma, there are still numerous limitations of the present purification strategy. First and foremost,
the procedure still requires large volumes of pregnancy plasma which can be both logistically and
ethically challenging to obtain. Furthermore, highly specific antibodies are required for monitoring
PZP contamination with A2M (and vice versa), which can be difficult to acquire given even
monoclonal antibodies for PZP or A2M may be cross-reactive as shown previously (Carlsson et
al. 1985). Additionally, the purification consists of numerous steps and is consequentially
laborious. Further simplification of the protocol is desirable, but was outside the scope of the
current project. One potential area for future investigation involves purification of PZP by
immunoaffinity techniques under non-denaturing conditions, by purpose-engineering a highly
specific monoclonal PZP antibody which displays sensitivity to polyol and NaCl for disruption of
antigen-antibody interactions (Burgess & Thompson 2002; Thompson & Burgess 2001).
In an attempt to circumvent the laborious multi-step purification of PZP and avoid the requirement
for human pregnancy plasma, in this study, recombinant affinity-tagged PZP was generated using
human cells in vitro. While considerable ground has been made in this project towards production
of recombinant human PZP, additional work will be required in order to develop a system in which
large quantities of native dimeric PZP can be purified. The yield of recombinant PZP obtained in
the best performing recombinant system was low (2 mg/L PZP-6His in Expi293-F) and the quality
of the recombinant PZP-6His obtained is a major issue. Specifically, purified recombinant PZP6His appears heterogeneous with respect to the presence of PZP dimers and PZP tetramers, whilst
also exhibiting characteristics of protein aggregation and incorrect disulfide bond formation
(speculated to be erroneous disulfide bond formation within PZP or with other proteins which are
constitutively secreted through the endoplasmic reticulum-Golgi network of the production cell)
(Figure 3.12). The latter accounts for why recombinant PZP migrates as a smear in native PAGE
but not in Western blots (Figures 3.8–3.12), as erroneously bound proteins or non-native PZP
structures corresponding to smears are unlikely to be recognised by the anti-PZP antibody used in
this study (Appendix 8.2). These findings are analogous with that of a recent report, which found
that A2M produced in Expi293-F cells had similar problems with yield (~ 0.4 mg/L) and the final
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protein quality, with the recombinant A2M migrating predominantly as a high molecular weight
smear by native PAGE (Marino-Puertas et al. 2019). It is perhaps unsurprising that production of
recombinant PZP and A2M is challenging given the structural complexity of these molecules. For
example, both PZP and A2M (i) are made up of large multi-domain 180 kDa sub-units, (ii) exhibit
glycosylation accounting for 10% of the entire protein mass, (iii) involve assembly of 13 intrachain disulfide bonds within each 180 kDa sub-unit, and 2 inter-chain disulfide bonds per dimer
(equivalent to 28 and 56 total disulfide bonds for PZP and A2M, respectively) and (iv) require the
formation of an internal thioester bond (Jensen & Sottrup-Jensen 1986; Sottrup-Jensen 1989) —
all of these factors represent challenges for high fidelity recombinant protein synthesis. As a
workaround, some researchers have successfully produced, refolded and purified truncated
recombinant A2M fragments in E. coli for piecemeal study (Holtet et al. 1994), which is a strategy
that could also be applied for the production and study of recombinant PZP. However, studying
protein fragments is not always ideal for interrogating authentic functions of full-length native
proteins. In any case, although a great deal of time and effort was invested in the development of
recombinant systems to purify PZP, ultimately, endogenous PZP purified from pregnancy plasma
remained the best source of protein for the functional in vitro studies described in this thesis.
There are a large number of variables that can be adjusted to improve the yield and quality of
recombinant proteins produced from mammalian expression systems. For example, (i) host cell
lines, (ii) vector elements, (iii) gene codon usage, (iv) modes of transfection, (v) clonal selection,
(vi) culture methods, (vii) growth media components and (viii) post-translational modifications,
are just some of the most common areas targeted for parameter optimisation to improve
recombinant protein production in mammalian expression systems (Butler 2006; Hunter et al.
2019; Jenkins et al. 2008; Kim et al. 1997; Nishimiya 2014). The major variable which was
targeted for optimisation in the current study was the use of different cell lines for recombinant
PZP production. HEK293 and its derivative cell lines, which are considered a gold standard for
human-like recombinant protein production due to their high transfectability and yields, gave the
highest expression, while expression of recombinant PZP from liver-derived HEPG2 cells could
not be achieved in the present study. Further work to establish a recombinant protein production
platform using liver cells is of interest given the role of the liver in the synthesis of human blood
plasma proteins such as PZP (Charlton 1996). Additionally, the recent CAP/CAP-T human
amniocyte (Fischer et al. 2012) and PER.C6 human retina (Jones et al. 2003) cell lines have shown
promise for production of complex recombinant human proteins with correct post-translational
modifications. Synthesis of recombinant PZP could also be attempted in the ubiquitous CHO cell
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line given its well-known prowess for recombinant protein production, but caution must be taken
as this approach could result in the production of a recombinant PZP molecule bearing non-human
glycosylation profiles with potentially detrimental effects for downstream in vivo applications
(Goh & Ng 2018). Given that incorrect disulfide bonding was identified to be a problem in the
current study, it may also be beneficial to optimise the post-translational modification capacity of
cellular production systems in future work. For example, co-expression of endoplasmic reticulumresident chaperones that assist in post-translational protein folding and/or disulfide bonding (such
as protein disulfide isomerase) could potentially improve recombinant PZP quality and yield,
although this is not a panacea for all recombinant proteins exhibiting this problem (Nishimiya
2014). Alternatively, rather than targeting one parameter for optimisation at a time, it may be more
prudent to employ systematic omics-style testing as previously described (Dietmair et al. 2012;
Kildegaard et al. 2013), which could help identify the specific pitfall area(s) in the current
recombinant PZP production protocol and thus guide future optimisation strategies. Unfortunately,
all of these approaches involve a significant resource and time investment, with no guarantee of
yielding significant improvements to the system.
An alternative strategy for the production of PZP in vitro could potentially be devised by
considering the physiological conditions that normally drive PZP synthesis in vivo. Gestational
estrogens are thought to be one of the main drivers of increased PZP expression during pregnancy
(Damber et al. 1976; Ekelund & Laurell 1994; Petersen et al. 1990). However, other promoters
are thought to exist, given that PZP is also upregulated in a variety of inflammatory disorders
(Horne et al. 1979; IJsselstijn et al. 2011; Nijholt et al. 2015; Sarcione & Biddle 2001; Scott et al.
1985; Smith et al. 2017; Thomson et al. 1981; Zarzur et al. 1986; Zarzur et al. 1989). Inclusion
into the synthetic protocol of these currently undefined gestational estrogens or inflammationbased drivers of PZP expression in vivo could also perhaps improve the cellular capacity for
recombinant PZP synthesis in vitro. Although the specific factors which induce synthesis are
unknown, inclusion of a combined estrogen and progesterone hormone supplement could be a
reasonable starting point, considering the results of in vivo studies and the physiological conditions
of PZP synthesis during pregnancy (Damber et al. 1976; Ekelund & Laurell 1994; Ottosson et al.
1981). Conversely, a previous report suggested that the addition of estrogen- and progesteronebased hormones had no effect on PZP expression in human cell lines (Lundgren et al. 1979), but
it is unclear if this study administered the hormones individually or in combination, which is an
important consideration. Overall, implementation of recombinant protein technology for the
production of complex human proteins such as PZP is an exciting and emerging frontier, which is
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being increasingly applied in numerous fields such as protein therapeutics and basic research.
Further improvements to the recombinant PZP system as outlined in this chapter could greatly
empower future studies of PZP.
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4 Characterisation of novel functions of PZP
including extracellular chaperone activity
Part of this chapter includes data that has been published by the candidate and will be
acknowledged accordingly.
Reference
Cater, JH, Kumita, JR, Abdallah, RZ, Zhao, G, Bernardo-Gancedo, A, Henry, A, Winata, W, Chi,
M, Grenyer, BSF, Townsend, ML, Ranson, M, Buhimschi, CS, Stephen Charnock-Jones, D,
Dobson, CM, Wilson, MR, Buhimschi, IA & Wyatt, AR 2019, ‘Human pregnancy zone protein
stabilizes misfolded proteins including preeclampsia- and Alzheimer's associated amyloid beta
peptide’, Proceedings of the National Academy of Sciences of the United States of America, vol.
116, no. 13, pp. 6101-10.

All work appearing in this chapter is the sole product of the candidate and does not feature
contribution from any other person unless otherwise indicated.
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4.1 Introduction
Despite its discovery over 60 years ago, the physiological function(s) of PZP remain a mystery. It
has been suggested that PZP may have some biological importance as a protease inhibitor, but
there are numerous problems with this proposal (as discussed in Section 1.4.4). Briefly, this
includes a lack of suitable biological targets of PZP inhibition, as well as the presence of other
more abundant and/or efficient protease inhibitors. In particular, the presence of A2M, a more
efficient and abundant inhibitor of all targets of PZP protease inhibition, severely weakens the
theory that PZP is an important protease inhibitor. It is reasonable to expect that PZP may be able
to provide some supplementary protease inhibitory activity in vivo against chymotrypsin-like
serine proteases. However, the majority of studies have assessed the protease inhibitory activities
of PZP and A2M using purified proteins under isolated conditions, and therefore the contribution
of PZP to protease inhibition in a competitive environment, such as in pregnancy plasma in situ,
is unknown.
The high sequence similarity between PZP and the known extracellular chaperone A2M suggests
that PZP potentially has holdase-type chaperone activity (as discussed in Sections 1.4.1 and 1.4.5).
Notably, the holdase-type chaperone activity of native A2M is enhanced by its conversion into a
360 kDa dimer upon treatment with NaOCl (Wyatt et al. 2014), which is analogous to the 360 kDa
dimeric structure of native PZP. In addition, co-localisation of PZP with Aβ aggregates has been
observed in immunohistochemical studies of Alzheimer’s disease brain and it has been speculated
that PZP may be involved in clearing toxic Aβ from the circulation via LRP1-mediated endocytosis
(Nijholt et al. 2015). PZP is also one of a small number of proteins proposed as a plasma biomarker
for pre-symptomatic Alzheimer’s disease (IJsselstijn et al. 2011) and reduced blood plasma levels
of PZP have been reported in pre-eclampsia (Auer et al. 2010; Griffin 1983; Horne et al. 1972;
Nguyen et al. 2019; Rasanen et al. 2010), both of which are PDDs exhibiting protein misfolding
as part of the pathophysiology. However, conflicting results exist regarding the level of maternal
blood plasma PZP in pre-eclampsia (Armstrong et al. 1986; Blumenstein et al. 2009), which is
potentially the result of problems due to cross-reactivty with constitutively abundant A2M (as
discussed in Section 1.4.3). Studies which rule out A2M cross-reactivity will thus be informative
in establishing a paradigm for the association of low maternal plasma PZP with pre-eclampsia.
Furthermore, a large number of studies have reported that the exogenous addition of Aβ1-42 to
cultures of neuronal SH-SY5Y cells induces a cytotoxic phenotype in vitro (Datki et al. 2003;
Krishtal et al. 2017; Oguchi et al. 2017; Omar et al. 2019; Sakagami et al. 2018; Wyatt et al. 2014),
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and that A2M is protective against Aβ1-42-induced cytotoxicity in vitro (using neuronal cell lines
including SH-SY5Y) and in vivo (Cascella et al. 2013; Fabrizi et al. 2001; Wyatt et al. 2014;
Yerbury et al. 2010). However, nothing is known about the corresponding ability of PZP to protect
against Aβ1-42-induced cytotoxicity. Overall, given the circumstantial nature of all current evidence
and lack of direct data, there exists a need to conduct an investigation into the chaperone activity
of PZP in vitro. Experiments which compare the holdase-type chaperone activity of native A2M
and native PZP are of particular interest. This work would provide the first functional evidence for
PZP as an inflammation- and pregnancy-upregulated extracellular chaperone, which could hold
diagnostic and/or therapetuic significance for disorders like Alzheimer’s disease and preeclampsia.
A different theory suggests that PZP instead functions as an immunosuppressive molecule during
pregnancy, which protects the allogenic foetus from destruction by the maternal immune system
(Skornicka et al. 2004; Stimson 1976; Von Schoultz et al. 1973). The mechanism by which PZP
achieves its proposed immunosuppressive activity during pregnancy is unknown, but it has been
shown that PZP binds PP14 and together they synergistically inhibit Th1 cell activation in vitro
(Skornicka et al. 2004). PZP is also upregulated during a number of inflammatory disorders and
has been shown to bind a small number of growth factors and cytokines, which is expected to have
varying immunomodulatory consequences in vivo (as discussed in Section 1.4.4). Taken together,
these observations indicate that the proposed immunomodulatory activity of PZP relates to its
ability to interact with cytokines and other signalling molecules as part of the immune system.
However, the full gamut of signalling molecules that PZP may bind (which is expected to be large
given A2M interacts with a huge number of cytokines) has not been investigated. In this regard, it
is of particular interest to ascertain whether PZP has any ability to bind TNFα, a central proinflammatory cytokine. TNFα is secreted primarily as part of the acute phase reaction by the same
leukocyte cell types as PZP, and is an important regulator of numerous processes in inflammation
and pregnancy, including apoptosis, necrosis, pro-inflammatory cytokine production, fever,
embryogenesis and placentation (Alijotas-Reig et al. 2017; Chu 2013). Considering that A2M is
reported to bind TNFα (Crookston et al. 1994; Wollenberg et al. 1991), with increased affinity
upon conversion of A2M into 360 kDa dimers (Wu et al. 1998), this is suggestive that dimeric
macroglobulins like PZP may have an enhanced propensity for binding TNFα. Investigating
whether PZP binds TNFα is an important first step in defining immunomodulatory function(s) of
PZP in inflammation and pregnancy.
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Thus, the aims of this chapter are:
1) To characterise the extracellular chaperone activity of PZP and compare it to that of A2M
in vitro.
2) To measure the blood plasma level of PZP in pre-eclampsia patients and verify exclusion
of A2M cross-reactivity.
3) To conduct a preliminary investigation into PZP-TNFα interactions.
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4.2 Methods
4.2.1

Purification of PZP and A2M

PZP and A2M were purified, quantified and stored frozen as described in Sections 2.9, 2.10 and
3.2.1. Once thawed, proteins were kept no longer than two weeks at 4°C in PBS/0.01% (w/v)
sodium azide, except for protein used in cellular assays where sodium azide was omitted from the
formulation.

4.2.2

PZP and A2M protease inhibition assays

To examine the protease inhibitory activity of PZP and A2M in vitro, purified PZP or A2M were
incubated at a 2:1 molar ratio with chymotrypsin (PZP or A2M:chymotrypsin) for 30 min at 37°C
and analysed by native PAGE (as described in Section 2.3). To examine the corresponding
endogenous protease inhibitory activity of PZP or A2M in heparinised pregnancy plasma in situ,
the equivalent of 1 µL of pregnancy plasma was incubated with 1 µM chymotrypsin for 45 min at
37°C. The plasma was then subjected to native PAGE and Western blot analyses, with anti-PZP
or anti-A2M detection (as described in Sections 2.3 and 2.4). Following Western blotting,
densitometry was used to quantify the proportion of native PZP dimers, chymotrypsin-inhibitory
PZP tetramers, native A2M tetramers and chymotrypsin-inhibitory A2M fast tetramers.

4.2.3

Production of A2M dimers

A2M dimers were generated by incubating 0.4 mg/mL A2M with 120 µM NaOCl in PBS overnight
at RT, followed by extensive dialysis against PBS to remove unreacted NaOCl. NaOCl-modified
A2M dimers were purified from residual A2M tetramer via SEC using a Superose 6 10/300 GL
column equilibrated in PBS (as described in Section 3.2.1.6). Production of A2M dimers was
confirmed by native PAGE analysis (as described in Section 2.3) and A2M dimers were quantified
as described in Section 2.9.

4.2.4

ThT assays of Aβ1-42 aggregation

Aβ1-42 (5 μM in PBS), containing 25 μM Thioflavin T (ThT), was added to a clear 384-well plate
(n = 4, 80 µL/well) in the absence or presence of A2M, PZP or SEC-purified A2M dimer at molar
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ratios of 1:20, 1:40 or 1:80 (A2M or PZP:Aβ1-42). The plate was then incubated at 32°C with
periodic shaking and ThT fluorescence (excitation = 440 nm, emission = 480 nm) was measured
at 5 min intervals using a FLUOstar OMEGA plate reader (BMG Labtech, Melbourne, Australia).

4.2.5

Transmission electron microscopy

Aβ1–42 (5 µM) was incubated at 32°C for ~ 15 h with periodic shaking in the absence or presence
of native A2M, PZP or oxidised A2M dimer at a 1:20 molar ratio (A2M or PZP:Aβ1-42) and
immediately snap frozen in liquid N2. Prior to analysis, samples were thawed, applied to 400-mesh
carbon film copper grids (Agar Scientific, Stansted, UK), stained with 1% (w/v) phosphotungstic
acid and imaged on an FEI Tecnai G2 transmission electron microscope (Cambridge Advanced
Imaging Center, University of Cambridge, UK). Images were analysed using the SIS Megaview
II Image Capture System (Olympus, Hamburg, Germany). Imaging was performed by Dr Janet
Kumita (Center for Misfolding Diseases, Department of Chemistry, University of Cambridge,
UK). All other work was performed by the candidate.

4.2.6

Bis-ANS assays

A2M, PZP or SEC-purified A2M dimer (170 nM) were incubated at RT for 5 min with 10 µM
4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid (bis-ANS). The protein solutions were
dispensed into the wells of a clear 384-well plate (n = 3, 50 µL/well) and the bis-ANS fluorescence
(excitation = 355 nm, emission = 480 nm) indicative of surface-exposed hydrophobicity was
measured using a FLUOstar OMEGA plate reader. Fluorescence values were corrected against a
PBS/10 µM bis-ANS blank (n = 3, 50 µL/well).

4.2.7

Aβ1-42 cytotoxicity assays

Before commencement of cytotoxicity assays, all protein solutions were prepared in PBS (pH 7.4)
and 0.22 µm sterile-filtered. SH-SY5Y cells were initially seeded at 40% confluency in a 96-well
plate with DMEM/F-12 media supplemented with 10% (v/v) FCS. The next day, the media was
aspirated and refreshed with treatments consisting of Aβ1-42 (10 µM) prepared in neurobasal
medium/1 × B-27/1 × GlutaMAX ± PZP or A2M at molar ratios between 1:20–80 PZP or
A2M:Aβ1-42 (n = 3 technical replicates/100 µL/well). Vehicle control cells were also prepared that
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received equivalent volumes of PBS instead of protein solution (“medium alone”). All protein
solutions were incubated for 5 h at 37°C prior to being added to SH-SY5Y cells, to generate toxic
soluble oligomers of Aβ1-42 (Appendix 8.3). Upon addition of the protein solutions, all wells were
immediately supplemented with 250 nM Cytotox Green dead cell stain (Essen Bioscience,
Melbourne, Australia; according to the manufacturer’s instructions) and further incubated under
standard cell culture conditions for 24–72 h. Cells were visualised using an IncuCyte ZOOM
(2016A) live cell imager (Essen Bioscience) on the phase and green fluorescence (excitation = 490
nm, emission = 524 nm; acquisition time = 400 ms) channels fitted with a 10 × objective.
Fluorescent object count (FOC; indicative of cell death) was calculated using an IncuCyte green
object analysis mask under a fixed threshold with a green calibration unit (GCU) of 100 and edge
split turned on (set to 0).

4.2.8

CPK aggregation assays

Creatine phosphokinase (CPK; 6.5 µM in PBS) was added to a clear 384-well plate (n = 3, 80
µL/well) in the absence or presence of A2M or PZP at a molar ratio of 1:5 (A2M or PZP:CPK).
The plate was then incubated at 43°C with shaking and the turbidity of the solution was monitored
at 5 min intervals by recording the absorbance at 360 nm using a FLUOstar OMEGA plate reader.
Absorbance values were corrected against a PBS blank (n = 3, 80 µL/well).

4.2.9

Plasma protein aggregation assays

The aggregation of protein in human pregnancy plasma in situ was assessed using previously
described strategies (Wyatt & Wilson 2010, 2013). Briefly, heparinised blood plasma samples
from individuals exhibiting uncomplicated pregnancy (n = 6) or pre-eclampsia (n = 9) were pooled.
Total protein was estimated as described in Section 2.9, and the plasma was supplemented with
0.01% (w/v) sodium azide to prevent microbial growth during the course of the assay. The plasma
level of PZP was quantified as described in Section 4.2.10. Four 70 µL aliquots of pooled plasma
from each cohort were dispensed into a 384-well plate and incubated at 38°C for 600 h with
periodic shaking in a FLUOstar OMEGA plate reader. The absorbance at 595 nm was measured
as an indicator of plasma turbidity. Samples of pooled plasma from each cohort at the 0 h and 600
h time-points were probed by native Western blot analysis using the relevant antibodies for the
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detection of PZP (as described in Sections 2.3 and 2.4). Plasma samples were clarified by
centrifugation (24,000 × g, 20 min) prior to analysis by native Western blot.

4.2.10 Measurement of PZP levels in pre-eclampsia plasma by sandwich ELISA
All study participants were recruited at St George Hospital (Kogarah) and provided informed
consent,

in

line

with

the

conditions

described

in

National

Ethics

Application

HREC/16/WGONG/256 approved by the Joint University of Wollongong and Illawarra
Shoalhaven Local Health District Human Research Ethics Committee. Pre-eclampsia was
diagnosed using the International Society for the Study of Hypertension in Pregnancy guidelines
(Brown et al. 2018), by systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90 mmHg
accompanied by proteinuria, maternal organ dysfunction (including liver involvement,
neurological complications and/or haematological complications) and/or uteroplacental
dysfunction (such as fetal/intrauterine growth restriction). Study group 1 included women with
pre-eclampsia (n = 32) and study group 2 included normotensive women with no major pregnancy
or health complications (n = 32) who were each matched for gestational age (± 7 days) and
maternal age (± 5 years) to individuals in the PE group. Blood (~ 10 mL) was collected by
venepuncture from individuals in each study group using Vacutainer lithium heparin blood
collection tubes (Becton Dickinson) and centrifuged (1,300 × g, 10 min). Plasma was immediately
isolated and stored at −20°C. Prior to analysis, plasma was thawed and clarified by centrifugation
(24,000 × g, 20 min, 4°C). PZP levels for individual pregnancy plasma samples (n = 64) were
quantified in triplicate using a purified PZP standard curve (10,000–156 pg/mL; n = 3) using a
solid phase sandwich ELISA kit and ancillary reagents (R&D Systems, Melbourne, Australia; cat
# DY8280-05 and DY008). Plasma samples were subjected to 3 × 70-fold dilutions (total 343,000fold dilution factor) using PBS as diluent, to ensure measurements of PZP would fall within the
range of the purified PZP standard curve. Dr Amanda Henry, Wendy Winata and Avindri
Abeygunasekara (School of Medicine, University of New South Wales, Australia) recruited
patients, collected blood samples and recorded clinical database information. All other work was
performed by the candidate.
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4.2.11 Statistical analyses of PZP levels in pre-eclampsia and matched control cohorts
All data were tested using D’Agnostino & Pearson omnibus normality tests. Parametric data which
passed normality testing (displaying a Gaussian distribution) are reported as mean ± SD and were
analysed using a two-tailed Student’s t-test. Non-parametric data which failed normality tests
(displaying a non-Gaussian distribution) are reported as median (interquartile range) and were
analysed by a two-tailed Mann-Whitney U significance test. Categorical data are reported as
frequency (%) and were analysed for significance using Fisher’s exact test (for ≤ 2 categorical
groups) or a chi-squared test (for ≥ 3 categorical groups). Level of PZP (mg/mL) and measured
clinical variables for each individual were plotted and analysed using Pearson’s and Spearman’s
correlation tests. For correlation tests, each the Pearson’s and Spearman’s correlation coefficient
is reported alongside the respective P value. Diagnostic performance of PZP levels were further
assessed using receiver operator characteristic (ROC) curve analysis. All statistical analyses were
performed using GraphPad Prism 5 with a significance cut-off of α = 0.05.

4.2.12 Production of radiolabelled [125I]-TNFα
Radiolabelled [125I]-TNFα was produced in line with previously described strategies (Bailey 1996;
Wu et al. 1998) with the assistance of Dr Ivan Greguric and Amanda McDonald at the Australian
Nuclear Science and Technology Organisation. Briefly, iodogen was prepared at 1 mg/mL in
dichloromethane and evaporated to dryness in a glass vial using a stream of N2 gas, forming a
reactive a coating. Subsequently, 75 µL human TNFα (Sigma-Aldrich; code: H8916) prepared at
0.1 mg/mL in PBS (pH 7.4), 100 µL of 50 mM borate buffer (pH 8.5) and 3 µL (~ 6 MBq) of
Na[125I] (Perkin Elmer, Waltham, USA; specific activity 17 Ci/mg in 100 mM NaOH pH 12–14)
were combined. The reaction vial was then incubated at RT for 30 min with gentle shaking.
Radiolabelled [125I]-TNFα was purified from the reaction mixture by passing through three Zeba
Spin Desalting Columns, 7K MWCO (Sigma-Aldrich; according to the manufacturer’s
instructions), using PBS/0.01% (w/v) sodium azide as the elution buffer. The specific activity of
[125I]-TNFα was 550–270 Ci/mmol. Radiolabelling was confirmed by high-performance liquid
chromatography (HPLC) SEC analysis using a BioSep-5µm-SEC-S2000 column (Phenomenex,
Sydney, Australia) connected to a Waters HPLC system fitted with gamma radioactivity and
ultraviolet-visible A280 detector modules (Waters Corporation, Sydney, Australia). Radiolabelled
[125I]-TNFα was injected at 1 µg and separated using a flow rate of 0.35 mL/min. For comparison,
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unlabelled TNFα was analysed by HPLC SEC using the same conditions. Radiolabelled [125I]TNFα was kept at 4°C and not used after 30 days of storage

4.2.13 Native PAGE autoradiography analysis of A2M and PZP binding to [125I]-TNFα
Radiolabelled [125I]-TNFα (40 ng) was incubated at 37°C for 30 min in the absence or presence of
A2M, fast A2M (produced as described in Section 3.2.2) A2M dimer (produced as described in
Section 3.2.2) or PZP, at a 1:20 molar ratio (A2M or PZP:[125I]-TNFα) and separated by native
PAGE using a NuPAGE 3–8% Tris-acetate gel (as described in Section 2.3). The gel was then
exposed to a BAS-IP storage phosphor screen (GE Healthcare) for 2 h in the absence of ambient
light and imaged on a Typhoon FLA 7000 (GE Healthcare) using the phosphorimaging setting.
Radiograph images were processed in Fiji (Schindelin et al. 2012) using average binning (X = 2,
Y = 2), filter (mean = 2), brightness/contrast (auto) and lookup table (mpl-viridis).

4.2.14 PZP-TNFα native Western blot binding assays
TNFα (0.2–0.32 µM, 200–320 ng total) was incubated for 30 min at 37°C in the absence or
presence of 0.1–2 µM PZP and subjected to native Western blotting for detection of TNFα or PZP
using the relevant antibodies (as described in Sections 2.3 and 2.4). To derive a dissociation
constant (Kd), densitometry quantification of TNFα immunoreactivity at positions corresponding
to PZP in native Western blots was performed and fitted with a one site specific binding model
with hill slope using GraphPad Prism 5.

4.2.15 TNFα cytotoxicity assays
Before commencement of cytotoxicity assays, all protein solutions were prepared in PBS (pH 7.4)
and 0.22 µm sterile-filtered. L929, a murine fibroblast cell line, was seeded into 96-well plates at
15% confluence in DMEM/F-12 media supplemented with 10% (v/v) FCS. The next day, cell
media was aspirated and refreshed with treatments (n = 3 technical replicates/100 µL/well)
consisting of TNFα (2.3 nM) prepared in DMEM/F-12 ± PZP or A2M at molar ratios of 1:65–130
(PZP or A2M:TNFα). Control cells receiving DMEM/F-12 (which contained equivalent volumes
of PBS instead of protein as a vehicle control) ± 300 nM PZP or A2M were also prepared. All
treatments were pre-incubated for 30 min at 37°C prior to addition to L929 cell monolayers.
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Immediately following the addition of media, Cytotox Green fluorescent dye (excitation = 490
nm, emission = 524 nm) was added for identification of dead cells. Treated cells were subsequently
incubated under standard cell culture conditions for a further 48 h. Cells were periodically
visualised over 48 h using an IncuCyte ZOOM (2016A) live cell imager on the phase and green
fluorescence (excitation = 490 nm, emission = 524 nm; acquisition time = 400 ms) channels fitted
with a 10 × objective. FOC was quantified using an IncuCyte green object analysis mask using
top-hat background subtraction with a GCU of 2 and edge split turned on (set to 0).
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4.3 Results
4.3.1

PZP is not a major protease inhibitor in pregnancy plasma in situ compared to A2M

In the present study, the protease trapping ability of PZP and A2M was examined using
chymotrypsin, a substrate for both alpha-macroglobulins. When purified PZP was co-incubated
with chymotrypsin, a small amount of PZP formed high molecular weight species by native PAGE
analysis (Figure 4.1Ai). This result supports the proposed model for protease trapping in which
two PZP molecules form a tetrameric complex around the covalently bound protease to complete
the inhibitory cage (Christensen et al. 1989; Jensen & Stigbrand 1992). Comparatively, upon
reaction with chymotrypsin under the same conditions, a marked amount of A2M migrated faster
by native PAGE (Figure 4.1Bi). The latter is consistent with the model for protease trapping by
A2M, in which cleavage of the bait region triggers the A2M tetramer to collapse around the
protease for steric inhibition (Sottrup-Jensen 1989). Interestingly, when human pregnancy plasma
was supplemented with 1 µM chymotrypsin at 37°C for 45 min and analysed by anti-PZP or antiA2M native Western blotting, formation of PZP tetramer-chymotrypsin was minimal, whereas
formation of fast A2M tetramer-chymotrypsin was much more substantial (Figure 4.1Aii and Bii).
Native Western blot densitometry analysis indicated that incubation of pregnancy plasma with
chymotrypsin induced formation of 23 ± 5% (mean ± SD, n = 3) PZP tetramer versus 61 ± 8% fast
A2M (Figure 4.1C).
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Figure 4.1 Formation of protease complexes with PZP or A2M in vitro and in pregnancy plasma in situ. (Ai)
Purified PZP or (Bi) purified A2M (each 3 µg) were analysed by native PAGE ± treatment for 30 min at 37°C with
chymotrypsin (chym), at a 2:1 molar ratio of PZP or A2M:chymotrypsin using a NuPAGE 3–8% Tris-acetate gel
(labelled as “gel”). A similar experiment involved (Aii) detection of PZP or (Bii) A2M in pregnancy plasma (PP; 1
µL) following incubation at 37°C for 45 min ± chymotrypsin (1 µM). Plasma was separated using a NuPAGE 3–8%
Tris-acetate gel and then transferred to a nitrocellulose membrane for detection of PZP or A2M using the relevant
antibodies (labelled as “blot”). (C) Densitometry analysis of (Aii) and (Bii) displaying the proportion of native PZP
dimers and chym-inhibitory PZP tetramer, versus the proportion of native A2M and chym-inhibitory fast A2M
tetramers (data are means ± SD, taken from n = 3 independent experiments).
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4.3.2

PZP inhibits formation of Aβ1-42 amyloid fibrils more efficiently than A2M

In the present study, the ability of purified PZP to inhibit the fibrillar aggregation of Aβ1-42 was
assessed using a ThT assay, whereupon ThT binds to fibrillar Aβ aggregates and displays an
increased fluorescence (Biancalana & Koide 2010). Under the conditions used, Aβ1-42 aggregated
over a period of ~ 10 h following a short lag phase of ~ 1 h (Figure 4.2A). Co-incubation of Aβ142

with PZP both extended the lag phase and reduced the rate of fibril formation in a dose-

dependent manner (Figure 4.2Ai, ii and iii). Compared with the native A2M tetramer, PZP more
efficiently inhibited the ThT fluorescence associated with the formation of Aβ1-42 fibrils (Figure
4.2Ai and ii), except at the lowest ratio of alpha-macroglobulin:Aβ1-42 tested (e.g. 1 molecule of
A2M or PZP to 80 molecules of Aβ1-42) (Figure 4.2Aiii). In the latter case, both native A2M and
PZP reduced the initial rate of fibril formation but did not significantly reduce the overall ThT
fluorescence at the conclusion of the assay. Consistent with a previous report (Wyatt et al. 2014),
A2M dimers (generated by pre-treatment with NaOCl and purified by SEC) inhibited Aβ1-42–
associated ThT fluorescence far more efficiently than the native A2M tetramer in all experiments
(Figure 4.2A). Comparatively, the effect of PZP was less than that of the NaOCl-modified A2M
dimer preparation, except at the highest ratio of alpha-macroglobulin:Aβ1-42 tested (e.g. 1 molecule
of PZP or A2M dimer to 20 molecules of Aβ1-42), when the two dimeric proteins had similar effects
(Figure 4.2A). Analysis using bis-ANS, a dye which becomes fluorescent upon binding to areas
of surface-exposed hydrophobicity on proteins (Hawe et al. 2008), showed differences in the
surface-exposed hydrophobicity of A2M, PZP and A2M dimer (Figure 4.2B). Consistent with the
results of prior studies (Birkenmeier et al. 1989; Chiabrando et al. 2002; Jensen et al. 1993), bisANS assay showed that native PZP was significantly more hydrophobic than native A2M. In the
case of the NaOCl-modified A2M dimer, a dramatically elevated surface-exposed hydrophobicity
was observed compared to native A2M and PZP , which was likely to be a result of (i) the
dissociation of the normally buried hydrophobic interface of non-covalently associated A2M
dimers and (ii) non-native NaOCl-induced perturbations to the secondary structure of A2M (Wyatt
et al. 2014).
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Figure 4.2 Effects of the A2M tetramer, A2M dimer and PZP on the aggregation of Aβ1-42 as assessed by ThT
assay. (A) Aβ1-42 (5 µM) was incubated with 25 µM ThT in PBS at 32°C with periodic shaking ± native A2M, PZP or
SEC-purified A2M dimer at molar ratios of (i) 1:20, (ii) 1:40 or (iii) 1:80 (native A2M, native PZP or A2M dimer:Aβ142. Data are mean ThT fluorescence (AFU; excitation = 440 nm, emission = 480 nm) SD (n = 4) and are representative
of three independent experiments. One-way ANOVA with post-hoc Tukey’s HSD was conducted on the assay
endpoints to identify non-significant (ns) and significant differences (*** = P < 0.001; ** = P < 0.01; * = P < 0.05)
with respect to the control containing Aβ1–42 alone. (B) Corresponding bis-ANS analysis of native A2M, PZP and
A2M dimer preparations as described in (A). Proteins were incubated at 37°C for 30 min with 20 µg/mL bis-ANS.
Data are mean bis-ANS fluorescence (AFU; excitation= 355 nm, emission = 480 nm) ± SD (n = 3) and are
representative of three independent experiments. Statistical analysis was conducted as described in (A).
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Qualitative analysis by transmission electron microscopy indicated that aggregation of Aβ1–42
alone resulted in assemblies with morphologies consistent with amyloid fibrils (Figure 4.3). The
relative abundance of fibrillar material observed correlated closely with the results of the ThT
assays, whereby co-incubation with the native A2M tetramer appeared less efficient at inhibiting
fibril formation compared with PZP and the NaOCl-modified A2M dimer, respectively (Figure
4.3). In samples containing Aβ1–42 co-incubated with PZP, small non-fibrillar aggregates that were
relatively uniform in size and morphology were present (Figure 4.3).

Figure 4.3 Transmission electron microscopy images of Aβ1–42 ± co-incubation with native A2M, A2M dimer
or PZP. (A) Aβ1–42 (5 µM) was incubated ± native A2M, PZP, or SEC-purified A2M dimer at a molar ratio of 1:20
(A2M or PZP:Aβ1–42) at 32 °C with periodic shaking for ~ 15 h. Samples of the protein solutions were snap-frozen in
liquid N2 before analysis by transmission electron microscopy. Scale bars = 100 nm.
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4.3.3

PZP protects the SH-SY5Y cell line against Aβ1-42-induced cytotoxicity

Exogenous addition of Aβ1-42 to cultures of SH-SY5Y neuronal cells induces a cytotoxicity in vitro
(as discussed in Section 4.1). This was confirmed in the present study using SH-SY5Y cells treated
with 10 µM Aβ1-42 that had been pre-incubated at 37°C for 5 h (determined as optimal for inducing
cytotoxicity; Appendix 8.3), as a sharp increase in Cytotox Green FOC indicative of cell death
was observed after 20 h of incubation, reaching maximal FOC after 40 h (Figure 4.4C).
Synonymous with previous findings (Fabrizi et al. 2001; Wyatt et al. 2014; Yerbury & Wilson
2010), A2M significantly reduced Aβ1-42-induced cytotoxicity of SH-SY5Y cells when Aβ1-42 was
pre-incubated with A2M at a molar ratio of 1:20 A2M:Aβ1-42 (Figure 4.4A). This protective effect
was dose-dependent, as molar ratios of 1:40 or 1:80 A2M:Aβ1-42 were decreasingly effective and
did not offer significant protection against Aβ1-42-induced cytotoxicity (Figure 4.4A). In contrast,
PZP provided significant protection against Aβ1-42-induced cytotoxicity when Aβ1-42 was preincubated with PZP at molar ratios of 1:40, 1:60 or 1:80 PZP:Aβ1-42, while A2M did not provide
significant protection at a molar ratio of 1:40 A2M:Aβ1-42 in the same assay (Figure 4.4B and C).
Notably, within the PZP and A2M:Aβ1-42 molar ratios tested in both of the assays, it was observed
that either increasing amounts of A2M (Figure 4.4A), or decreasing amounts of PZP (Figure 4.4B
and C), were most effective at inhibiting Aβ1-42-induced cytotoxicity. Altogether, the data
indicated that both PZP and A2M were able to offer protection against Aβ1-42-induced cytotoxicity,
however PZP was more effective than A2M at maintaining the protective effect at the lowest doses
of PZP and A2M tested. This was consistent with the finding that PZP was more effective than
A2M at inhibiting Aβ1-42 aggregation in ThT assays shown earlier in this chapter.
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Figure 4.4 The effect of PZP and A2M on Aβ1–42-induced cytotoxicity on SH-SY5Y cells as assessed by Cytotox
Green fluorescence assays. SH-SY5Y cells were seeded into 96-well plates at 40% confluence in DMEM/F-12 media
supplemented with 10% FCS. The next day, cell media was aspirated and refreshed with treatments (n = 3 technical
replicates/100 µL/well) consisting of Aβ1-42 (10 µM) prepared in neurobasal medium ± PZP or A2M at molar ratios
of 1:20–80 PZP or A2M:Aβ1-42 as indicated in (A) or (B). A treatment of neurobasal medium was also prepared
(medium alone) which received equivalent volumes of PBS instead of protein as a vehicle control. All treatments were
pre-incubated for 5 h at 37°C prior to addition to SH-SY5Y cell monolayers. Immediately following addition of
treatments, Cytotox Green fluorescent dye (excitation = 490 nm, emission = 524 nm) was added for identification of
dead cells and cells were subsequently incubated under standard cell culture conditions for a further 48 h with each of
the treatments. Microscope images were collected over the course of the experiment using an IncuCyte ZOOM
(2016A) live cell imager using the phase and green collection channels (excitation = 490 nm, emission = 524 nm;
acquisition time = 400 ms) fitted with a 10 × objective. FOC indicative of cell death was calculated using an analysis
mask under a fixed threshold with a GCU of 100 and edge split turned on (set to 0). Data shown are means ± SD (n =
3) and are representative of two independent experiments. One-way ANOVA with post-hoc Tukey’s HSD was
conducted on the 48 h endpoints to identify non-significant (ns) and significant differences (*** = P < 0.001; ** = P
< 0.01; * = P < 0.05). Significant and non-significant differences are shown for comparisons made to the control
containing Aβ1–42 alone. (C) Time-course graph for (B).
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Representative microscope images of SH-SY5Y cells used to produce the data in Figure 4.4 are
shown (Figure 4.5). After 48 h of incubation in medium alone, the majority of SH-SY5Y cells
displayed a generally healthy morphology with numerous processes extending outwards from cell
bodies (Figure 4.5A), which is consistent with previously reported phenotypic characteristics of
SH-SY5Y cells (Kovalevich & Langford 2013). A small number of dead cells were observed in
SH-SY5Y cells treated with medium alone, which adopted a small rounded morphology that
stained with punctate green fluorescence, with no visible processes extending from the body
(Figure 4.5A). After 48 h of incubation with Aβ1-42, SH-SY5Y cells appeared to be almost
completely non-viable, with only dead cells visible by green fluorescence (Figure 4.5B).
Treatment with PZP reduced the amount of non-viable cells induced by Aβ1-42 cytotoxicity, as a
mixed population of dead and healthy cells were observed in SH-SY5Y cells treated with a molar
ratio of 1:40 PZP:Aβ1-42 (Figure 4.5C). Comparatively, treatment with A2M was less effective than
treatment with PZP, as a larger amount of non-viable cells were observed in SH-SY5Y cells treated
with a molar ratio of 1:40 A2M:Aβ1-42 (Figure 4.5D).
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Figure 4.5 Representative microscope images showing the effect of PZP and A2M on Aβ1–42-induced cytotoxicity
and cellular morphology of SH-SY5Y cells. Images for the 48 h endpoint from the experiment described in Figure
4.4B and C are shown for (A) medium alone, (B) Aβ1-42 alone, (C) PZP:Aβ1-42 (1:40 molar ratio) and (D) A2M:Aβ1-42
(1:40 molar ratio).
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4.3.4

PZP inhibits heat-induced protein aggregation in vitro and in pregnancy plasma in
situ

Considering that the accumulation of misfolded proteins in pre-eclampsia is not limited to the Aβ
peptide (as discussed in Section 1.2.5), the effect of PZP on CPK, a model protein used to form
amorphous protein aggregates, was examined. Heating of CPK at 43°C induced its aggregation
over a period of ~ 12 h as measured by the absorbance of the solution at 360 nm (e.g. turbidity of
the solution), and co-incubation of CPK with PZP significantly reduced the level of CPK
aggregation over the course of the assay (Figure 4.6A). When present at an equivalent molar
concentration to that examined for PZP, A2M provided some inhibition of CPK aggregation but
did not significantly reduce the level of CPK aggregation by the conclusion of the assay (Figure
4.6A). The latter supports that PZP more potently inhibits heat-induced CPK precipitation
compared to A2M.
Using conditions that are known to induce plasma protein precipitation (Wyatt & Wilson 2010,
2013), the aggregation propensities of plasma protein from pre-eclamptic women or women
experiencing uncomplicated pregnancy (control) were examined. The pooled plasma samples used
were similar in terms of the average maternal age of the donors and their total protein levels, but
the pooled pre-eclampsia plasma sample contained ~ 50% less PZP than the control (Table 4.1).
The data show that after 600 h of incubation, the turbidity of the PZP-deficient pooled plasma
sample from pre-eclamptic women had increased significantly, while the corresponding increase
in turbidity for the control pool was smaller and non-significant (Figure 4.6B). Native Western
blotting showed that after 600 h of incubation, PZP migrated as a high molecular weight smear in
the plasma of women with uncomplicated pregnancy or pre-eclampsia, suggesting possible
formation of PZP-misfolded plasma protein complexes (Figure 4.6C). Combined, these results
support the conclusion that similar to other extracellular chaperones (Wyatt et al. 2013c), PZP may
stabilise a range of misfolded protein clients, including aggregation prone peptides and denatured
proteins.
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Table 4.1. Characteristics of plasma samples that were pooled from individuals exhibiting pre-eclampsia or
uncomplicated pregnancy for heat-induced aggregation analyses.

Preeclampsia

Control

Total protein (mg/mL)

59 ± 1

60 ± 1

PZP* (mg/mL)

0.22 ± 0.004

0.46 ± 0.011

Maternal age (years)

33 ± 6.0

34 ± 3.9

Gestational age (weeks)

33 ± 2.7

28 ± 1.5

Individual samples pooled (n)

9

6

Data are mean ± SD.

Figure 4.6 Effects of PZP on heat-induced aggregation protein aggregation in vitro and in situ. CPK (6.5 µM in
PBS) was incubated at 43°C with shaking ± PZP or A2M at a molar ratio of 1:5 (A2M:CPK or PZP:CPK). Turbidity
indicative of CPK aggregation was monitored by measuring absorbance at 360 nm of the solution. Data are means ±
SD (n = 3) and are representative of three independent experiments. One-way ANOVA with post-hoc Tukey’s HSD
was conducted on the assay endpoints to identify non-significant (ns) and significant differences (*** = P < 0.001; **
= P < 0.01; * = P < 0.05), with respect to the sample containing CPK alone. (B) Pooled plasma from individuals
exhibiting normal uncomplicated pregnancy (control) or pre-eclampsia (Table 4.1) was incubated at 38°C for 600 h
and routinely agitated. Turbidity was assessed by absorbance at 595 nm for the 0 and 600 h time-points. Data are
means ± SD (n = 4) and are representative of two independent experiments. Statistical analysis was conducted as
described in (A), with comparisons shown between 0 and 600 h time-points. (C) Samples of pooled plasma from (B)
were separated by native PAGE using a NuPAGE 3–8% Tris-acetate gel and subjected to native Western blotting with
detection for PZP using the relevant antibodies. Positions of the native PZP dimer (at 0 h) and high molecular weight
aggregates associated with PZP immunoreactivity (at 600 h; HMWA) are marked.
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4.3.5

Pregnancy plasma levels of PZP are significantly reduced in pre-eclampsia patients
in comparison to matched controls

Given previously reported discrepancies regarding the maternal blood plasma level of PZP (as
discussed in Section 4.1), in the present study the concentration of PZP in blood plasma from 64
women at 28–40 weeks gestation (n = 32 with pre-eclampsia, n = 32 matched controls) was
analysed. The demographic and pregnancy outcomes for each cohort are shown (Table 4.2). The
maternal and gestational ages of women with pre-eclampsia (32.3 ± 5.4 years, 35.1 ± 2.9 weeks)
was not significantly different to that of matched controls with uncomplicated pregnancy (32.0 ±
4.4 years, 35.6 ± 2.7 weeks). In line with diagnostic expectations, women with pre-eclampsia
showed significantly increased (P < 0.0001) diastolic and systolic blood pressure (BP) in
comparison to matched controls. Furthermore, there was a significantly higher incidence of preeclampsia in women with a past history of either pre-eclampsia (P = 0.036), gestational
hypertension (P < 0.035), or nulliparity (P = 0.019). There was also a significantly higher incidence
of co-morbidities including gestational diabetes (P = 0.027), threatened pre-term labour (P =
0.0048), intrauterine growth restriction (IUGR) (P = 0.0003) or low birthweight (P < 0.0001) in
women with pre-eclampsia compared to matched controls.
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Table 4.2 Demographics and pregnancy outcomes of pre-eclampsia and matched control cohorts.

Pre-eclampsia

Matched control

P value

Maternal age (years)

32.3 ± 5.4

32.0 ± 4.4

0.82

Gestational age (weeks)

35.1 ± 2.9

35.6 ± 2.7

0.68

Body mass index (kg/m2)

25.9 ± 5.7

24.5 ± 3.5

0.24

Systolic BP (mmHg)

145 (140–153.5)

109 (98.5–112)

< 0.0001

Diastolic BP (mmHg)

93 (90–100)

70 (60–70)

< 0.0001
0.45

Country of birth
•

Australia

15 (47%)

11 (34%)

•

Other

17 (53%)

21 (66%)

Smoking statusa

0.19

•

Smoker at recruitment

3 (10%)

0 (0%)

•

Past history

5 (16%)

5 (16%)

•

Never smoked

23 (74%)

27 (84%)

Primigravida

10 (31%)

5 (16%)

0.24

Nulliparous

17 (53%)

7 (22%)

0.019

History of pre-eclampsiab

6 (27%)

1 (4%)

0.036

History of gestational hypertensionb

4 (18%)

0 (0%)

0.035

History of gestational diabetesb

2 (9%)

1 (4%)

0.58

Gestational diabetesc

8 (25%)

1 (3%)

0.027

Threatened pre-term labour

8 (25%)

0 (0%)

0.0048

Small for gestational age/IUGR

11 (34%)

0 (0%)

0.0003

15 (47%)

0 (0%)

< 0.0001

3 (9%)

0 (0%)

0.24

(< 10th centile)
Low birthweight (< 2500 g)d
Apgar score at birth (< 7)

Data are mean ± SD, median (interquartile range) or n (%).
a
missing smoking status for n = 1 pre-eclampsia participant.
b
n = 22 multigravidas for pre-eclampsia and n = 27 multigravidas for matched control cohorts.
c
n = 1 pre-eclampsia participant with pre-existing diabetes (included in the analysis).
d
missing birthweights for n = 1 pre-eclampsia and n = 2 matched control participants.

108

The plasma level of PZP was measured in women with pre-eclampsia and matched controls using
a sandwich ELISA. Purified A2M (0.1 mg/mL) was undetectable in the assay confirming that there
was no antibody cross-reactivity. Levels of PZP widely varied across both cohorts with a range of
approximately 0–0.83 mg/mL (Figure 4.7A). Women with pre-eclampsia had a significantly lower
(P = 0.012) plasma level of PZP (0.16 ± 0.14 mg/mL) in comparison to matched controls with
uncomplicated pregnancy (0.28 ± 0.20 mg/mL) (Figure 4.7A). A receiver operator characteristic
(ROC) curve revealed an area under the curve (AUC) of 0.69, indicating only marginal diagnostic
utility for the level of PZP in pre-eclampsia (Figure 4.7B).

Figure 4.7 Analysis of pregnancy plasma levels of PZP in pre-eclampsia patients and matched controls. (A) The
level of PZP in pregnancy plasma was measured by sandwich ELISA in pre-eclampsia patients (maternal age = 32.3
± 5.4 years, gestational age = 35.1 ± 2.9 weeks; n = 32) and matched controls (maternal age = 32.0 ± 4.4 years,
gestational age = 35.6 ± 2.7 weeks; n = 32). Mean (middle horizontal bar) and SD (error bars) are shown. Student’s ttest was used for identification of significant difference (* = P < 0.05). (B) ROC curve of pre-eclampsia patients and
matched controls with AUC displayed.
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The level of PZP in pre-eclampsia patients did not correlate strongly with any of the measured
clinical parameters including protein/creatinine ratio, platelet count, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), systolic BP, diastolic BP, body mass index, gestational
age or birthweight (Table 4.3). Further stratification showed that there were no marked or
significant differences in plasma PZP levels between pre-eclampsia patients in which neurological
symptoms, elevated liver enzymes (AST and/or ALT), haemolysis/elevated liver enzymes/low
platelet count (HELLP) syndrome, gestational diabetes or normal platelet counts were present or
absent (Table 4.4), although the ability to test the level of PZP in HELLP syndrome was limited
in the present study due to a low incidence number (n = 2). A markedly lower level of PZP in preeclampsia patients with IUGR (0.064 (0.023–0.216) mg/mL) compared to those without IUGR
(0.15 (0.047–0.291) mg/mL) was observed, but the difference was not significant (P = 0.23).
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Table 4.3 Correlations of pre-eclampsia patient clinical variables with PZP levels.

Participants

Pearson

Spearman

analysed

correlation

correlation

(n)

r (P value)

r (P value)

Protein/creatinine ratio (mg/mmol)

31

0.0074 (0.97)

0.022 (0.91)

Platelet count (×109/L)

32

0.0023 (0.99)

-0.12 (0.53)

ALT (U/L)

10

-0.20 (0.59)

0.52 (0.13)

AST (U/L)

11

-0.33 (0.39)

0.060 (0.86)

Systolic BP (mmHg)

32

0.11 (0.54)

0.050 (0.79)

Diastolic BP (mmHg)

32

0.20 (0.27)

0.079 (0.67)

Body mass index (kg/m2)

32

0.080 (0.67)

-0.039 (0.83)

Gestational age (weeks)

32

0.024 (0.89)

0.047 (0.80)

Birthweight (g)

31

0.052 (0.78)

0.056 (0.76)

Table 4.4. Comparison of PZP levels in the absence or presence of co-morbid conditions of pre-eclampsia.

Level of PZP (mg/mL)
Neurological symptoms
HELLP syndrome
Gestational diabetesa
Elevated liver enzymes
(AST and/or ALT)
Small for gestational age/
IUGR (< 10th centile)

Condition absent

Condition present

P value

0.19 ± 0.16

0.14 ± 0.12

0.42

(n = 17)

(n = 15)

0.16 ± 0.15

0.14 ± 0.17

(n = 30)

(n = 2)

0.16 ± 0.15

0.17 ± 0.13

(n = 24)

(n = 8)

0.17 ± 0.15

0.15 ± 0.13

(n = 19)

(n = 13)

0.15 (0.047–0.291)

0.064 (0.023–0.216)

(n = 21)

(n = 11)

Data are mean ± SD or median (interquartile range).
a

n = 1 pre-eclampsia participant with pre-existing diabetes (included in condition present).
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0.82
0.93
0.73
0.23

The observation that pre-eclampsia patients exhibiting IUGR had a lower level of PZP than preeclampsia patients without IUGR prompted further analyses of this sub-group with comparison to
the matched control cohort. Pre-eclampsia patients exhibiting IUGR had a significantly lower (P
= 0.030) level of PZP (0.064 (0.023–0.216) mg/mL) when compared to matched controls with
normal pregnancy (0.250 (0.087–0.310) mg/mL) (Figure 4.8A). A ROC curve revealed an AUC
of 0.78 (Figure 4.8B), indicating a slightly improved diagnostic utility for the level of PZP in preeclampsia accompanied by IUGR compared to the AUC of 0.69 observed earlier for non-stratified
pre-eclampsia (Figure 4.8B).

Figure 4.8 Analysis of pregnancy plasma levels of PZP in pre-eclampsia patients with IUGR and matched
controls. (A) The level of PZP in pregnancy plasma compared in pre-eclampsia patients exhibiting IUGR (n = 11)
and matched controls (n = 11). Median (middle horizontal bar) and interquartile range (error bars) are shown. MannWhitney U test was used for identification of significant differences (* = P < 0.05). (B) ROC curve of pre-eclampsia
patients exhibiting IUGR and matched controls with AUC displayed.
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4.3.6

Preliminary evidence of PZP-TNFα binding interactions in vitro

Considering that A2M is reported to bind TNFα (Crookston et al. 1994; Wollenberg et al. 1991),
which is increased when A2M is induced to form dimers (Wu et al. 1998), it was resolved to test
if PZP could also bind TNFα. Similar to these studies, the methodological approach of the present
study involved radiolabelling of TNFα and analysis of its migration with PZP by native PAGE
autoradiography. Initial assessment by SEC indicated that unlabelled TNFα eluted at 8–9 mL,
which was similar to the elution of ovalbumin (~ 45 kDa) and consistent with the expected size of
TNFα (~ 50 kDa) (Figure 4.9A). Following radiolabelling and purification of [125I]-TNFα, the
elution of [125I]-TNFα by SEC was similar to the elution of unlabelled TNFα, although some high
molecular weight protein species were observed at 5 mL elution (Figure 4.9B). Additionally, the
major peak of radioactivity was observed to correlate with the [125I]-TNFα protein peak (Figure
4.9B). Together, these results suggested that [125I]-TNFα had been successfully radiolabelled. In
line with previous experimental strategies (Wollenberg et al. 1991; Wu et al. 1998), co-incubation
of [125I]-TNFα with A2M, A2M fast or A2M dimer leads to the formation of a stable TNFα-A2M
complex which can be visualised by native PAGE autoradiography. However, co-migration
(indicative of a stable binding interaction) of [125I]-TNFα close to the expected positions of A2M,
fast A2M or A2M dimer could not be observed in the current study by native PAGE
autoradiography following co-incubation for 30 min at 37°C (Figure 4.9C and D). Binding of
[125I]-TNFα to PZP was also not observed in this experiment (Figure 4.9C and D). Instead, the
majority of radioactivity associated with [125I]-TNFα was observed in the well at the top of the gel
as a very large complex, or in varying amounts in the dye front, upon co-incubation with A2M,
fast A2M, A2M dimer or PZP (Figure 4.9C). Only a small amount of [125I]-TNFα was recovered
in the dye front when [125I]-TNFα was incubated alone (Figure 4.9C). Further attempts to optimise
the experimental strategy by reducing the specific radioactivity of [125I]-TNFα from 550 Ci/mmol
to 270 Ci/mmol, or the use of TNFα from a different supplier (Genscript), did not change the
results.
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Figure 4.9 Production of [125I]-TNFα and native PAGE autoradiography analysis of [125I]-TNFα-alphamacroglobulin binding interactions. (A) Unlabelled TNFα and (B) radiolabelled [125I]-TNFα were analysed by
HPLC SEC using a BioSep-5µm-SEC-S2000 column. Protein elution and radioactivity were monitored via A280 and
gamma counting (Gamma R), respectively. The approximate migratory position of ovalbumin is marked (downward
arrowhead). (C) [125I]-TNFα (40 ng) was co-incubated ± A2M, fast A2M, A2M dimer or PZP at a 1:20 molar ratio of
A2M or PZP:[125I]-TNFα for 30 min at 37°C and separated using a NuPAGE 3–8% Tris-acetate gel. [125I]-TNFα
radioactivity was immediately imaged (shown in fluorescent green) using a photostimulable phosphor screen. (D)
Matched native PAGE to (C) in the absence of [125I]-TNFα depicting the migration of native A2M, fast A2M
(generated by pre-treatment with NH4Cl), A2M dimer (generated by pre-treatment with NaOCl) or native PZP.
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Due to the inability to observe co-migration of [125I]-TNFα with either A2M or PZP using the
autoradiography approach, the binding of unlabelled TNFα to PZP was examined using native
Western blotting. Analysis by anti-TNFα native Western blotting showed that, when incubated
alone, unlabelled TNFα migrated near the dye front which is consistent with its relatively low
molecular weight of 17–52 kDa (Figure 4.10Ai). Upon co-incubation at a 1:1 molar of PZP with
TNFα (30 min, 37°C), TNFα immunoreactivity was detected co-migrating at a position which
corresponded to the expected position of the native PZP dimer by native Western blotting (Figure
4.10Ai and ii). Co-migration of TNFα with PZP was dose-dependent, whereby co-incubation of
TNFα with decreasing concentrations of PZP yielded less co-migration of TNFα at the position
corresponding to PZP (Figure 4.10B). Densitometry was used to quantify TNFα immunoreactivity
at positions corresponding to PZP and the data were fitted with a one site specific binding model
with hill slope (Figure 4.10C). Using this model a preliminary Kd of 0.62 ± 0.05 µM (mean ± SD,
n = 2) was derived for the putative binding interaction of PZP with TNFα (Figure 4.10C).
Comparatively, PZP-TNFα binding was approximately 2–3-fold stronger than previously reported
for native A2M-TNFα binding (Kd of 1.27–1.8), but approximately 2-fold weaker than oxidised
dimeric A2M-TNFα binding (Kd of 0.34) (Crookston et al. 1994; Wu et al. 1998).
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Figure 4.10 Native Western blot and densitometry analysis of putative PZP-TNFα binding. (A) TNFα (320 ng)
was incubated for 30 min at 37°C in the absence or presence of PZP at 1:1 molar ratio of PZP:TNFα. Matched samples
were separated by native PAGE using a NuPAGE 3–8% Tris-acetate gel and subjected to native Western blotting for
detection of (i) TNFα or (ii) PZP, using the relevant antibodies. (B) TNFα (0.2 µM, 200 ng total) was co-incubated
with 2, 1, 0.5, 0.2, 0.1 or 0 µM PZP for 30 min at 37°C and separated by native PAGE using a NuPAGE 3–8% Trisacetate gel. The gel was then subjected to native Western blotting with detection for TNFα. (C) Densitometry
quantification of TNFα immunoreactivity at positions corresponding to varying concentrations of PZP in native
Western blots performed as described in (B). Data are means ± SD (n = 2) and are fitted with a one site specific binding
model with hill slope.
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It is widely reported that TNFα induces cytotoxicity in the murine fibroblast-like L929 cell line
(Flick & Gifford 1984; Humphreys & Wilson 1999; Lévesque et al. 1995; Mishra 1995; Shiau et
al. 2001; Trost & Lemasters 1994). Within this system, it has been observed that co-incubation of
TNFα with A2M potentiates the cytotoxic effect of TNFα on L929 cells (Wollenberg et al. 1991).
In the present study, using a Cytotox Green assay it was observed that TNFα induced a significant
cytotoxic effect in L929 cells after 48 h of incubation (Figure 4.11). Incubation of L929 cells in
medium ± PZP or A2M displayed minimal levels of cytotoxicity (Figure 4.11). Similar to previous
findings (Wollenberg et al. 1991), co-incubation of TNFα with A2M significantly increased L929
cytotoxicity compared to TNFα alone (Figure 4.11). Interestingly, co-incubation of TNFα with
PZP also significantly increased cytotoxicity compared to TNFα alone, which was comparable to
the cytotoxic effect observed for TNFα co-incubated with A2M (Figure 4.11).
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Figure 4.11 The effect of A2M and PZP on TNFα-induced cytotoxicity of L929 cells. L929 cells were seeded into
96-well plates at 15% confluence in DMEM/F-12 media supplemented with 10% FCS. The next day, cell media was
aspirated and refreshed with treatments (n = 3 technical replicates/100 µL/well) consisting of TNFα (2.3 nM) prepared
in DMEM/F-12 ± PZP or A2M at molar ratios of 1:130 or 1:65 PZP or A2M:TNFα. Treatments of DMEM/F-12
(which received equivalent volumes of PBS instead of protein as a vehicle control) ± PZP or A2M (300 nM) were
also prepared. All treatments were pre-incubated for 30 min at 37°C prior to addition to L929 cell monolayers.
Immediately following addition of treatments, Cytotox Green fluorescent dye (excitation = 490 nm, emission = 524
nm) was added for identification of dead cells and cells were subsequently incubated under standard cell culture
conditions for a further 48 h with each of the treatments. Microscope images were collected over the course of the
experiment using an IncuCyte ZOOM (2016A) live cell imager using the phase and green collection channels
(excitation = 490 nm, emission = 524 nm; acquisition time = 400 ms) fitted with a 10 × objective. FOC indicative of
cell death was calculated using an IncuCyte green object analysis mask using top-hat background subtraction with a
GCU of 2 and edge split turned on (set to 0). Data shown are means ± SD (n = 3) and are representative of two
independent experiments. One-way ANOVA with post-hoc Tukey’s HSD was conducted on the 48 h endpoints to
identify significant differences (*** = P < 0.001; ** = P < 0.01; * = P < 0.05). Significant differences are shown for
comparisons made to the control containing TNFα.
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Representative microscope images of L929 cells used to produce the analysis in Figure 4.11 are
shown (Figure 4.12). After 48 h of incubation in medium ± PZP or A2M, the majority of L929
cells displayed a generally healthy morphology with few dead cells visible (Figure 4.12A). After
48 h of incubation with TNFα, a large amount of dead L929 cells were observed which stained
with punctate green fluorescence as small, rounded cell bodies (Figure 4.12B). The cellular
morphology of L929 cells co-incubated with TNFα ± PZP or A2M was similar to L929 cells coincubated with TNFα, whereby a large amount of small, rounded cell bodies were observed which
stained with punctate green fluorescence (Figure 4.12C and D). There also did not appear to be
any differences in the morphology of L929 cells co-incubated with TNFα ± PZP or A2M (Figure
4.12C and D).
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Figure 4.12 Representative microscope images showing the effect of A2M and PZP on TNFα-induced
cytotoxicity and cellular morphology of L929 cells. Representative images for the 48 h endpoint from the
experiment described in Figure 4.11 are shown for (A) medium ± PZP or A2M, (B) TNFα, (C) TNFα:A2M (1:130) or
(D) TNFα:PZP (1:130).
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4.4 Discussion
Pregnancy is a state where numerous stresses are elevated that can induce protein misfolding and
aggregation, but pregnancy-associated proteostasis mechanisms involving extracellular
chaperones have not yet been described. This study has shown for the first time that PZP stabilises
misfolded fibrillar Aβ1–42 and amorphous CPK more efficiently than the native A2M tetramer in
vitro. Building on this observation, PZP provided superior protection from Aβ1–42 induced
cytotoxicity in SH-SY5Y cells when compared with A2M, suggesting that sequestration of
misfolded proteins by PZP may also further shield tissues from toxicity. Although determination
of the full extent of misfolded proteins which bind PZP in vivo was beyond the scope of the present
study, putative PZP-misfolded protein complexation was observed in heat-stressed pregnancy
plasma, and higher pregnancy plasma levels of PZP corresponded with reduced aggregation of
plasma proteins in situ. Taken together, and given the dramatic upregulation of PZP in pregnancy
plasma to levels of 0.25–3 mg/mL in mid-to-late gestation (Ekelund & Laurell 1994; Petersen et
al. 1990), it is reasonable to surmise that PZP is a major contributor to maintenance of extracellular
proteostasis during pregnancy through stabilisation of misfolded proteins. As such, the holdasetype chaperone activity of PZP represents a plausible mechanism by which the maternal body
adapts to cope with proteostasis stress encountered during pregnancy.
There are various possible explanations for why PZP displays superior chaperone activity
compared to A2M. For instance, the native PZP dimer possesses greater surface-exposed
hydrophobicity compared to the native A2M tetramer, as observed in the present study (Figure
4.2B) and by others (Birkenmeier et al. 1989; Chiabrando et al. 2002; Jensen et al. 1993).
Considering that hydrophobic interactions are one of the main forces by which chaperones bind
and stabilise misfolded proteins, it is therefore likely that the greater hydrophobicity of PZP is
responsible for its superior chaperone activity in comparison to A2M. However, given that 3D
structures of native A2M and PZP do not yet exist, accurate modelling of possible hydrophobic
binding sites for misfolded proteins cannot be undertaken. For example, the best currently
available structure of A2M is in the fast conformation (Marrero et al. 2012), and given that A2M
displays an increase in hydrophobicity upon conversion to the fast conformation (Birkenmeier et
al. 1989; Jensen et al. 1993), fast A2M is not an accurate structure for modelling hydrophobic
interactions of misfolded proteins with native A2M (or PZP). Notably, a high affinity site for
binding monomeric Aβ is reportedly buried in the native A2M tetramer at amino acids 1314–1365,
but is exposed upon conformational change to the A2M fast form (Mettenburg et al. 2002). Based
on an EMBOSS Needle alignment, a homologous sequence occurs at amino acids 1320–1371 in
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PZP, sharing 88.5% amino acid chemical similarity to the Aβ binding site in A2M. Given the
enhanced suppression of Aβ aggregation by PZP in comparison to A2M, it is speculated that amino
acids 1320–1371 are solvent-exposed in PZP. Going forward, information regarding the native 3D
structures of A2M and PZP will be critical for understanding the biochemical characteristics which
underlie the chaperone activity of these proteins.
There is evidence that A2M and PZP interact with distinct species of Aβ1-42 formed along the
amyloidogenic aggregation pathway. For example, it has been previously reported that native A2M
stabilises larger species of oligomeric Aβ1-42 (Yerbury et al. 2009), while dimeric and fast A2M
bind monomeric and/or small oligomeric species of Aβ1-42 (Mettenburg et al. 2002; Wyatt et al.
2014). In comparison, we have shown that PZP binds monomeric and/or small oligomeric species
of Aβ1-42 (Cater et al. 2019). Binding of these species by PZP, which are required for the initiation
and elongation phases of the amyloidogenic pathway, likely accounts for why PZP is superior at
inhibiting Aβ1-42 aggregation in ThT assays compared to native A2M. Furthermore, sequestration
of smaller oligomeric species of Aβ1-42, which are believed to be the most toxic species formed
along the amyloidogenic pathway (as discussed in Section 1.2.3), may explain why PZP more
effectively reduces Aβ1-42 cytotoxicity in comparison to native A2M. Additionally, this mechanism
may further account for why larger oligomeric fibrils are observed in transmission electron
microscopy images of A2M but not PZP co-incubated with Aβ1-42 (Figure 4.3). Taken together,
the current data support a model in which native PZP binds smaller Aβ1-42 species from earlier in
the amyloidogenic pathway, whereas native A2M binds larger Aβ1-42 species formed later in the
amyloidogenic pathway.
The description of NaOCl-induced enhancement of A2M chaperone activity via its conversion into
dimers suggests that A2M could function as an important chaperone during inflammatory stress
(Wyatt et al. 2014). This is further supported by the results of this study, which showed that
NaOCl-modified A2M dimers had enhanced chaperone activity compared to native tetrameric
A2M and PZP (Figure 4.2). However, additional studies are needed to characterise the precise
conformations of hypochlorite-modified A2M that are generated during inflammation and define
their relative abundance in vivo, before the physiological relevance of dimeric A2M chaperone
activity can be assessed. The dramatic increase in chaperone activity upon the conversion of A2M
into hydrophobic PZP-like dimers is strongly suggestive that the dimeric quaternary structure of
alpha-macroglobulins is linked to improved chaperone activity. Therefore, the fact that native PZP
exists under normal conditions as a dimer in extracellular fluids suggests that PZP may be uniquely
adapted to function as an extracellular chaperone, whereas native A2M may be more uniquely
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adapted for other functions such as efficient, broad-spectrum protease trapping. Given that PZP is
also upregulated in plasma during non-pregnancy associated inflammatory disorders to levels as
high as 0.4 mg/mL (IJsselstijn et al. 2011; Nijholt et al. 2015; Sarcione & Biddle 2001; Zarzur et
al. 1986; Zarzur et al. 1989), it is feasible that PZP may also stabilise misfolded proteins alongside
NaOCl-induced A2M dimers during inflammatory stress.
The finding that blood plasma PZP was reduced in the plasma of women with pre-eclampsia
supports that a deficiency of PZP could contribute to the accumulation of misfolded proteins in
pre-eclampsia. However, the level of PZP is widely variable, and some women with normal
pregnancy have similar levels of PZP as those with pre-eclampsia. Considering that pre-eclampsia
is a complex heterogeneous syndrome (Benton et al. 2018; Ness & Roberts 1996; Phipps et al.
2016), it may thus be important to consider the level of PZP in specific subtypes of the disorder,
rather than pre-eclampsia as a whole. For example, a promising preliminary analysis conducted
herein suggests that the level of PZP in pre-eclampsia patients with IUGR may have potentially
enhanced diagnostic utility over the level of PZP in generally-diagnosed pre-eclampsia (Figure
4.8), although this cohort was of a small sample size (n = 11). In general, a small sample size
further limited this study, as there was not sufficient data to analyse the level of PZP in other
subtypes of pre-eclampsia, such as pre-eclampsia co-morbid with HELLP (n = 2). These analyses
highlight the need to examine the level of PZP in specific subtypes of pre-eclampsia using larger
sample sizes in future studies, which could have enhanced diagnostic potential. Examination of
the level of PZP in conjunction with other known extracellular chaperones such as haptoglobin,
clusterin and A2M would also be of interest, to determine if other extracellular chaperones
compensate for low levels of PZP in some women. There is already some evidence that
dysregulated plasma levels of clusterin (Kim et al. 2016), A2M (Kim et al. 2016; Liu et al. 2011;
Mary et al. 2017) and haptoglobin (Kolialexi et al. 2017; Mary et al. 2017; Wilke et al. 1992) are
associated with pre-eclampsia, but a study which simultaneously measures the regulation of all
potential members of the extracellular chaperone network in pre-eclampsia remains to be
undertaken.
Potentially numerous maternal organs are susceptible to damage from circulating cytotoxic
misfolded proteins in pre-eclampsia, which may account for the varied clinical manifestation of
dysfunction in the placenta, kidney, liver, endothelium and brain. Although in the case of the latter,
it is currently unknown whether misfolded proteins generated during pre-eclampsia can cross the
blood brain barrier. Notably, this study has shown that PZP can bind and prevent the toxicity of
misfolded Aβ, but it is currently unknown if PZP can carry out a similar activity with other proteins
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reported to misfold in pre-eclampsia, which was outside the scope of the present study. Similar to
the broad spectrum chaperone activity reported for A2M, the inhibition of rabbit CPK by PZP
(Figure 4.6) supports that PZP also has a broad spectrum chaperone activity which non-specifically
sequesters misfolded proteins through areas of surface-exposed hydrophobicity (French et al.
2008). As such, it is proposed that PZP could be important for guarding against toxic proteoforms
of multiple misfolded proteins found in pre-eclampsia plasma, rather than restricted to Aβ.
There has been decades of research regarding the role of A2M in the pathophysiology of
Alzheimer’s disease. Genomic studies have reported links between mutations in A2M and the risk
of Alzheimer’s disease (Liao et al. 1998; Mariani et al. 2006; Xu et al. 2013; Zappia et al. 2004),
although these have not been confirmed in recent genome-wide association studies (Shen & Jia
2016). Furthermore, it is widely documented that A2M can (i) inhibit the formation of Aβ amyloid
fibrils and (ii) protect against Aβ-induced cytotoxicity by binding to Aβ and facilitating its
clearance via LRP1-mediated endocytosis in vitro and in vivo (Cascella et al. 2013; Fabrizi et al.
2001; Hughes et al. 1998; Narita et al. 1997), which is believed to be an important process for
influencing Alzheimer’s disease pathophysiology. Despite the similarity of PZP to A2M, only in
the last decade has a role of PZP in Alzheimer’s disease been investigated. So far, both A2M and
PZP have been observed to co-localise with Aβ in immunohistochemical studies of Alzheimer’s
disease brain (Nijholt et al. 2015; Thal et al. 1997). Interestingly, elevated plasma levels of PZP
in women, whereas elevated plasma levels of A2M in men, have been proposed as potential
biomarkers for presymptomatic Alzheimer’s disease (IJsselstijn et al. 2011; Varma et al. 2017).
The reason for the latter difference is unknown, but it may relate to the differential expression of
A2M and PZP by men and women (e.g. estrogens influence PZP expression) (Folkersen et al.
1981; Hashimoto et al. 1991; Petersen et al. 1990). Building on this previous research, the work
presented in this thesis supports that PZP may participate in Aβ homeostasis in vivo. Specifically,
PZP may sequester Aβ aggregates and reduce their toxicity as a neuroprotective agent. Supported
by immunohistochemical studies of PZP in Alzheimer’s disease brain (Nijholt et al. 2015), and
given neurons, microglia, activated astrocytes, brain endothelial cells and pericytes express LRP1
(Andersen & Willnow 2006; Bu et al. 1994; Marzolo et al. 2000; Spuch et al. 2012), LRP1mediated endocytosis represents a possible mechanism by which PZP-Aβ complexes are cleared
from the extracellular space. As such, PZP may hold an important role for influencing the
pathophysiology of Alzheimer’s disease, but whether it is overlapping or discrete to the role of
A2M, remains to be determined.
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Previous studies have often characterised the protease inhibitory activity of PZP against target
proteases in isolation using purified proteins (Arbelaez et al. 1995; Christensen et al. 1989; Jensen
& Stigbrand 1992; Sánchez et al. 1998b; Sand et al. 1985), but it is important to consider the
extracellular environment where PZP exists, which contains a multitude of other protease
inhibitors including A2M. In the present study, the protease inhibitory activity of PZP and A2M
in pregnancy plasma was investigated in situ. This assay involved supplementing pregnancy
plasma with chymotrypsin, which PZP effectively inhibits given its bait region is more easily
cleaved by chymotrypsin compared to other proposed target proteases (Christensen et al. 1989;
Sánchez et al. 1998b; Sand et al. 1985). While this assay gives information about the amount of
PZP or A2M that participates in protease inhibition, it does not give information about the amount
of chymotrypsin activity following protease complexation. A good complement to this assay
would thus be to measure chymotrypsin activity. Aside from this, the markedly lower abundance
of protease inhibitory forms of tetrameric PZP compared to fast A2M in chymotrypsinsupplemented plasma supports that PZP is a less important protease inhibitor than A2M (Figure
4.1). Given the other issues regarding physiological inhibition of proteases by PZP (as discussed
in Section 1.4.4) it is thus difficult to surmise that the functional importance of PZP in vivo is
exclusively related to its protease inhibitory activity.
In the current study, attempts to study interactions of TNFα with A2M and PZP using radiolabelled
[125I]-TNFα were unsuccessful. According to the methodology of previous studies, co-incubation
of [125I]-TNFα with A2M leads to the formation of a stable non-covalent complex which can be
visualised by native PAGE autoradiography (Crookston et al. 1994; Wollenberg et al. 1991; Wu
et al. 1998). However, in the present study, complexes of [125I]-TNFα and A2M (or PZP) were not
observed by native PAGE autoradiography following co-incubation, despite TNFα appearing to
be successfully labelled by native PAGE and SEC (Figure 4.9). A possible explanation is that the
radiolabelled [125I]-TNFα produced in this study was biochemically different to preparations of
[125I]-TNFα used in previous studies. For example, although SEC showed that the size of [125I]TNFα was mostly unchanged following radiolabelling, this method gives no information about
subtle changes to TNFα structure or the exact types of chemical modification that have taken place
post-radiolabelling. In general, radioiodination results in non-specific and heterogeneous
modification of surface-exposed tyrosine and histidine residues (Dewanjee 1992). However, the
identity and amount of tyrosine and histidine residues that were labelled in previous studies is
unclear (Crookston et al. 1994; Wollenberg et al. 1991; Wu et al. 1998), which would be useful
for producing biochemically similar preparations of radiolabelled TNFα in the present study. In
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addition, the presence of high molecular weight species of radiolabelled TNFα in SEC and native
PAGE (Figure 4.9) is possibly suggestive of some protein denaturation and aggregation caused by
oxidative protein damage, which is a known problem of radioiodination (Parker 1990). The current
methodology could not determine whether PZP or A2M were bound to high molecular weight
species of radiolabelled TNFα, as co-radiolabelling was not feasible. Additional attempts to
radiolabel under more conservative conditions with lower oxidant and
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I did not lead to

improvements in [125I]-TNFα structural integrity or binding to A2M or PZP. It is therefore
recommended that future attempts to study the interactions of radiolabelled cytokines with A2M
or PZP should employ a milder radiolabelling strategy, such as peroxidase-facilitated
radioiodination (Marchalonis 1969) or tritium radiolabelling (Tack et al. 1980), which is generally
milder and results in good preservation of protein structure. Alternatively, studies of PZP-cytokine
interactions using techniques which do not require radiolabelling is perhaps preferable, given the
safety and technical complications associated with the use of radiolabels. In particular, PZPcytokine interactions could be characterised under label-free conditions using techniques such as
surface plasmon resonance, or under labelled conditions using a biotin-streptavidin Western blot
system, which have both previously been used for studying PZP-ligand interactions (Skornicka et
al. 2004; Skornicka et al. 2002).
Interactions of PZP with cytokines are presumably the mechanism by which PZP achieves its
proposed immunomodulatory activity, but so far PZP has only been demonstrated to bind a few
cytokines in vitro (Philip et al. 1994; Skornicka et al. 2004; Skornicka et al. 2002). Demonstration
of PZP binding to TNFα (Figure 4.10), a master regulator of inflammation, is an important first
step for defining the immunomodulatory activity of PZP. In particular, PZP binding of TNFα was
stronger than that previously reported for native A2M, yet weaker than that of dimeric A2M
(Crookston et al. 1994; Wu et al. 1998). This suggests that PZP and dimeric A2M, which are both
expected to be produced during inflammation (Petersen 1993; Reddy et al. 1994; Wyatt et al.
2014), may be relatively more important for regulating TNFα function in comparison to native
A2M. Due to fiscal and technical constraints, PZP-TNFα binding could not be investigated in
further replicates (n > 2) or using additional techniques such as surface plasmon resonance. In
addition, the wider functional implications of alpha-macroglobulin-TNFα binding are currently
unclear, but both native PZP and native A2M appear to potentiate the cytotoxic effect of TNFα in
murine L929 cells in vitro (Figure 4.11) (Wollenberg et al. 1991), which supports the idea that the
binding of TNFα by alpha-macroglobulins is biologically relevant. However, the murine L929
system is limited for studying the effects of PZP- or A2M-TNFα binding. This is because human
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TNFα as used in this study only binds murine tumor necrosis factor receptor 1 (TNFR1) and does
not bind murine tumor necrosis factor receptor 2 (TNFR2) (Ameloot et al. 2001; Lewis et al.
1991), both of which are involved in TNFα signalling in humans. Depending on the cell type,
TNFR1 and TNFR2 can have similar or opposing effects on apoptosis, cell survival, inflammation
and tissue regeneration (Dostert et al. 2019; Holbrook et al. 2019; Parameswaran & Patial 2010).
PZP and A2M, therefore, may not potentiate the cytotoxic effect of TNFα in humans in vivo and
could instead have opposing effects. As such, future assays utilising human cells containing both
TNFR1 and TNFR2 will be useful for studying the wider functional implications of PZP-TNFα
binding. Considering that TNFα has an important role in the pathogenesis of rheumatoid arthritis
(Feldmann 2002; Vasanthi et al. 2007), and remission of rheumatoid arthritis in women with
pregnancy has been correlated with the increased expression of PZP (Quinn et al. 1993; Unger et
al. 1983), it is tempting to speculate that PZP-TNFα may instead suppress the pro-inflammatory
activity of TNFα in vivo. Similarly, A2M has been reported to inhibit cartilage and bone catabolism
induced by TNFα in mice, rat and bovine models of arthritis, with A2M injections now being
employed as a human therapeutic for arthritic joints (Li et al. 2019; Wang et al. 2014; Zhang et al.
2017). Further defining the immunomodulatory effects of PZP-TNFα binding is thus of great
interest, especially given the altered expression of PZP in many other inflammatory disorders
which feature aberrant TNFα signalling, such as Alzheimer’s disease (Decourt et al. 2017;
IJsselstijn et al. 2011; Nijholt et al. 2015), bronchiectasis (Mukhopadhyay et al. 2006; Smith et al.
2017), autoimmune thyroid disease (Gianoukakis et al. 2008; Scott et al. 1985), Behcet’s
syndrome (Thomson et al. 1981; Tong et al. 2019), hepatitis (Valaydon et al. 2016; Zarzur et al.
1986; Zarzur et al. 1989) and HIV-1 (Pasquereau et al. 2017; Sarcione & Biddle 2001).
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5.1 Introduction
Despite numerous ongoing efforts, the functions of PAI-2 in vivo remain a mystery (as discussed
in Section 1.5). In brief, this may partly be attributed to the fact that PAI-2 is bi-topologically
distributed, predominantly as a non-glycosylated intracellular 47 kDa form (PAI-2NG) and also as
a secreted extracellular 60 kDa glycoprotein (PAI-2G) (Kruithof et al. 1987; Wohlwend et al.
1987). Numerous potential intracellular and extracellular functions for PAI-2 have been proposed
(Lee et al. 2011; Medcalf & Stasinopoulos 2005; Wyatt et al. 2016), including regulation of
proteolysis through inhibition of uPA and tPA in the plasminogen activation system (Lee et al.
2011), immune modulation (Schroder et al. 2010), holdase-type chaperone activity (Lee et al.
2015), protection from apoptosis (Dickinson et al. 1995) and regulation of transcription in the
nucleus (Darnell et al. 2003). Owing mainly to the ease of recombinant protein production in
prokaryotic systems, the vast majority of in vitro studies have focused on PAI-2NG, and as a result
very little is known about the functional properties of PAI-2G. In particular, nothing is known
regarding whether PAI-2G has holdase-type chaperone activity similar to that which has been
reported for PAI-2NG (Lee et al. 2015). Reduced blood serum levels of PAI-2 in pregnancy have
been linked-to pre-eclampsia (Estelles et al. 1989; Reith et al. 1993), and PAI-2 has been found to
be associated with Aβ in plaques of Alzheimer’s disease brain (Akiyama et al. 1993); both of
which are complex multi-factorial disorders that involve extracellular protein misfolding and
aggregation (Buhimschi et al. 2014; Buhimschi et al. 2008; Kalkunte et al. 2013). Therefore,
investigations of PAI-2G chaperone activity will advance our understanding of the importance of
PAI-2 in extracellular proteostasis and could possibly hold significance for elucidating the
contribution of PAI-2G in guarding against disorders involving protein misfolding.
The most widely studied of the proposed functions for PAI-2 is its protease inhibitory activity for
the plasminogen activators uPA and tPA in vitro (Al-Ejeh et al. 2004; Brown et al. 1995; Genton
et al. 1987; Kruithof et al. 1995; Lee et al. 2010; Mikus et al. 1993; Sprengers & Kluft 1987;
Thorsen et al. 1988). The current consensus is that both PAI-2G and PAI-2NG are inhibitors of
extracellular uPA and tPA, but this role of PAI-2 is often considered as insignificant in vivo due
to the overshadowing presence of PAI-1, a more efficient and abundant inhibitor of uPA and tPA
(Thorsen et al. 1988; Vaughan 2005). An interesting study has suggested that the value of PAI-2
lies specifically in its resistance to inflammatory oxidants such as hypochlorite which inactivate
PAI-1, potentially rendering PAI-2 the primary controller of uPA and tPA proteolysis under
inflammation (Baker et al. 1990). However, this study only utilised PAI-2NG and not PAI-2G, the
latter of which is more relevant to the extracellular context. Moreover, direct comparisons of PAI129

2 and PAI-1 protease inhibitory activity have not previously been conducted under in vitro
conditions which recapitulate inflammatory conditions. It is particularly important to determine
the consequences of hypochlorite-induced modification of PAI-2, given that PAI-2 is upregulated
during inflammation and pregnancy, which are both physiological states that exhibit enhanced
release of biological oxidants including hypochlorite (Fialova et al. 2006; Gandley et al. 2008;
Hammer et al. 2001; Klebanoff 2005; Weiss 1989).

Thus, the aims of this chapter are:
1) To characterise the extracellular chaperone activity of PAI-2G and compare it to that of
PAI-2NG in vitro.
2) To evaluate the structural properties of PAI-2G and PAI-2NG under native and hypochloritemodified conditions.
3) To investigate the effect of hypochlorite-induced modifications on the protease inhibitory
and chaperone activities of PAI-2G and PAI-2NG
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5.2 Methods
5.2.1

SDS-PAGE, native PAGE and Western blot

SDS-PAGE, native PAGE and Western blot procedures were performed as described in Sections
2.2, 2.3 and 2.4. Approximately 5 µg and 0.1–2 µg of protein was loaded for PAGE and Western
blot procedures, respectively.

5.2.2

Treatment of PAI-2 and PAI-1 with NaOCl

PAI-2G, PAI-2NG or PAI-1 were typically incubated for 2 h at RT at a final protein concentration
of 0.25 mg/mL in the presence of 0–200 µM reagent grade NaOCl in PBS (see Section 2.8 for
methods concerning NaOCl quantification). Unreacted NaOCl was removed by extensive dialysis
against PBS/0.01% (w/v) sodium azide or using 0.5 mL Zeba Spin Desalting Columns, 7K MWCO
(according to the manufacturer’s instructions), with PBS/0.01% (w/v) sodium azide as the elution
buffer.

5.2.3

Generation of PAI-2 monomer standards by reduction and S-carboxymethylation

PAI-2G or PAI-2NG (0.5 mg/mL in PBS) were incubated for 1 h at 37°C in the presence of 8.25
mM dithiothreitol reducing agent. Iodoacetic acid (20 mM) was then added and the reaction
allowed to proceed in the dark for 30 min at RT. To quench the reaction, the solution was further
supplemented with dithiothreitol to achieve a final concentration of 17 mM dithiothreitol. Reduced
and S-carboxymethylated PAI-2G or PAI-2NG were then buffer exchanged against PBS/0.01%
(w/v) sodium azide using a 0.5 mL Zeba Spin Desalting Column, 7K MWCO (according to the
manufacturer’s instructions).

5.2.4

Circular dichroism spectroscopy

Before commencing circular dichroism (CD) spectroscopy analyses, PAI-2G and PAI-2NG (pretreated with 0–200 µM NaOCl as described in Section 5.2.2) were dialysed extensively against 10
mM sodium phosphate buffer (pH 7.4), diluted to 0.1 mg/mL and syringe-filtered through a 0.22
µm membrane. PAI-2G and PAI-2NG were subsequently analysed using wavelengths 190–250 nm
at 24°C in a 1 mm quartz cuvette using a JASCO (Tokyo, Japan) J-810 spectropolarimeter
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connected to a JASCO CDF-426S Peltier temperature control device. The following parameters
were used for data acquisition: sensitivity = 100 mdeg, data pitch = 0.5 nm, scanning speed = 100
nm/min, response = 1 sec, bandwidth = 1 nm, accumulation = 6. High tension V was monitored
and did not range outside of 200–700 V for all measurements. Data were converted to mean residue
ellipticity (MRE) and analysed using the BeStSel online secondary structure determination tool
for CD spectra (Micsonai et al. 2018; Micsonai et al. 2015).

5.2.5

Analytical SEC

Prior to commencement of chromatography procedures, PAI-2G and PAI-2NG (pre-treated with 0–
200 µM NaOCl as described in Section 5.2.2) were syringe-filtered through a 0.22 µm membrane.
Each of the PAI-2G and PAI-2NG samples (0.25 mg/mL in PBS, 0.5 mL) were subjected to SEC at
a flow-rate of 0.3 mL/min using a Superose 6 10/300 GL column equilibrated in PBS. The A280
was continuously monitored and the elution profiles of the individual samples were overlayed for
analysis. PZP (360 kDa) and BSA (67 kDa) were included in the analysis as protein molecular
mass standards.

5.2.6

ThT assays of Aβ1-42 aggregation

Aβ1-42 (3 μM in PBS containing 25 μM ThT) was added to a clear 384-well plate (n = 3, 80
µL/well) in the absence or presence of PAI-2G or PAI-2NG (pre-treated with 0–200 µM NaOCl as
described in Section 5.2.2). PAI-2G or PAI-2NG were used at molar ratios of 1:2.5, 1:5, 1:7.5 or
1:10 (PAI-2:Aβ1-42). The plate was then incubated at 28°C with periodic shaking and ThT
fluorescence (excitation = 440 nm, emission = 480 nm) was measured at 5 min intervals using a
POLARstar OMEGA plate reader (BMG Labtech). In some instances, samples (n = 3, 80 µL/well)
were pooled, centrifuged at high speed (24,000 × g, 20 min, RT) and 30% of the supernatant
volume was subsequently subjected (in duplicate) to native Western blot analysis using the
relevant antibodies for either PAI-2 or Aβ1-42 detection (as described in Sections 2.3 and 2.4).

5.2.7

CPK aggregation assays

CPK (6.5 µM in PBS) was added to a clear 384-well plate (n = 3, 80 µL/well) in the absence or
presence of PAI-2G or PAI-2NG (pre-treated with 0–200 µM NaOCl as described in Section 5.2.2).
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PAI-2G or PAI-2NG were used at molar ratios of 1:1, 1:2.5 or 1:5 (PAI-2:CPK). The plate was then
incubated at 43°C with shaking and the turbidity of the solution was monitored at 5 min intervals
by recording the absorbance at 360 nm using a POLARstar OMEGA plate reader.

5.2.8

uPA activity assays of PAI-2 and PAI-1 protease inhibitory activity

The protease inhibitory activity of PAI-2G, PAI-2NG or PAI-1 was assessed against the target
protease uPA in the presence of a fluorogenic peptide containing a proteolytic cleavage motif
specific for uPA, essentially as previously described (Cochran et al. 2009). In brief, 1 nM uPA
(ADI, Stamford, USA) was added to the wells of a black 96-well plate containing 0.25 mM Z-GlyGly-Arg-AMC fluorogenic uPA substrate (Calbiochem, Bayswater, Australia) in HEPES buffer
(20 mM HEPES, 100 mM NaCl, 0.5 mM EDTA, 0.01% (v/v) Tween-20, pH 7.6) that was
supplemented with 0, 1 or 2 nM PAI-2G, PAI-2NG or PAI-1 pre-treated with 0, 100 or 200 µM
NaOCl (n = 3, 100 µL/well). Immediately after the addition of uPA, the fluorescence of the
samples (excitation = 355 nm, emission = 460 nm) was measured at 37°C in 30 sec cycles for 5 h
using a POLARstar OMEGA plate reader. Measurements were adjusted using a uPA fluorogenic
substrate/HEPES buffer blank (n = 3, 100 µL/well).

5.2.9

Bis-ANS assays

PAI-2G or PAI-2NG (pre-treated with 0–200 µM NaOCl as described in Section 5.2.2) were
incubated (37°C, 30 min) at a final concentration of 0.05 mg/mL with 20 µg/mL bis-ANS. The
protein solutions were dispensed into the wells of a clear 384-well plate (n = 3, 50 µL/well) and
the bis-ANS fluorescence (excitation = 355 nm, emission = 480 nm) indicative of surface-exposed
hydrophobicity was measured using a POLARstar OMEGA plate reader. Fluorescence values
were subtracted against a PBS/20 µg/mL bis-ANS blank (n = 3, 50 µL/well).

5.2.10 Spectrofluorometry
PAI-2G or PAI-2NG (pre-treated with 0–200 µM NaOCl as described in Section 5.2.2) were
dialysed extensively against 10 mM sodium phosphate buffer (pH 7.4) and diluted to 0.1 mg/mL.
The intrinsic fluorescence of the samples (excitation = 325 nm, emission = 420 nm; indicative of
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dityrosine cross-linkages) was measured at RT in a 10 mm quartz cuvette using a JASCO FP-8300
spectrofluorometer.

5.2.11 Aβ1-42 cytotoxicity assays
This assay was performed essentially as previously described in Section 4.2.7, except that PAI-2G,
PAI-2NG or ovalbumin were used (instead of PZP or A2M) at a 1:10 molar ratio of PAI2/Ovalbumin:Aβ1-42.

134

5.3 Results
5.3.1

Structural characteristics of purified PAI-2G and PAI-2NG

It has previously been reported that both wild type PAI-2G and PAI-2NG spontaneously form
oligomers in solution (Mikus et al. 1993; Wilczynska et al. 2003a; Wilczynska et al. 2003b).
Consistent with these observations, non-reducing SDS-PAGE showed that purified preparations
of wild type PAI-2G and PAI-2NG migrated as mixed populations of oligomers, specifically at sizes
corresponding to PAI-2G or PAI-2NG monomers (60 and 47 kDa, respectively), dimers (120 and
94 kDa, respectively) and trimers (180 and 141 kDa, respectively) (Figure 5.1A). Further analysis
using non-reducing SDS-PAGE Western blot showed that all PAI-2 oligomeric species were
immunoreactive with a commercially available PAI-2 polyclonal antibody, affirming the high
purity of these preparations (Figure 5.1B). Interestingly, the increased sensitivity provided by
Western blot analysis revealed that PAI-2 oligomer species could be at least as large as hexameric
in nature (Figure 5.1B). Native PAGE analysis further supported the conclusion that PAI-2G and
PAI-2NG existed in solution as mixed oligomeric populations including monomers, dimers and
higher-order oligomers, although the precise oligomeric states could not be unequivocally
determined due to the limitations of native PAGE mass standards (Figure 5.1C). In addition, PAI2G migrated faster than PAI-2NG by native PAGE despite the larger size of the former (Figure
5.1C), which was attributed to the lower pI of PAI-2G (pI = 4.4) in comparison to PAI-2NG (pI = 5)
(Kruithof et al. 1986). Further attempts to unravel the oligomeric state of the purified preparations
of PAI-2G and PAI-2NG using analytical SEC with molecular weight standards and native PAGE
with reduced PAI-2 monomer standards confirmed that the major species of PAI-2G and PAI-2NG
were indeed monomers (see Section 5.3.5). Additionally, PAI-2 oligomers were resistant to SDS
and boiling at 100°C as seen by SDS-PAGE, but all PAI-2 oligomers reverted to the monomeric
form upon addition of reducing agent, indicating that disulfide bonding was essential for PAI-2
oligomer formation (Figure 5.1D). CD spectroscopy analyses indicated that PAI-2G and PAI-2NG
were comprised of an essentially identical secondary structure content with approximately 25% αhelix, 20% β-sheet and 14% loop-turn (Figure 5.1E) in agreement with published values (Harrop
et al. 1999) (PDB ID: 1BY7). This suggests that production of these recombinant proteins using
two different organisms (CHO and E. coli cells, respectively) had not adversely altered the
secondary structure of either PAI-2G or PAI-2NG.
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Figure 5.1 Structural characteristics of purified PAI-2G and PAI-2NG as assessed by non-reducing or reducing
SDS-PAGE, Western blot, native PAGE and CD spectroscopy analyses. (A) PAI-2G and PAI-2NG were separated
by non-reducing SDS-PAGE using a 4–12% Bis-Tris gel. Protein molecular weight standards (lane M) are included
for comparison, with sizes as indicated in kDa. Positions of PAI-2G and PAI-2NG monomers (M), dimers (D) and
trimers (T) are marked. (B) A matched non-reducing SDS-PAGE gel was performed exactly as described in (A) and
subsequently transferred by Western blot to a nitrocellulose membrane for detection of PAI-2G and PAI-2NG with an
anti-PAI-2 antibody. (C) PAI-2G and PAI-2NG were separated by native PAGE using an 8% Tris-glycine gel.
NativeMark protein molecular weight standards (lane Mn) are included for comparison, with approximate sizes as
indicated in kDa. (D) PAI-2G and PAI-2NG were separated by SDS-PAGE using an 8% Tris-glycine gel in the presence
of SDS ± boiling at 100°C or treatment with reducing agent. (E) CD spectroscopy displayed as MRE of PAI-2G and
PAI-2NG measured between 190–250 nm at 24°C.
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5.3.2

uPA inhibitory activity of purified PAI-2G and PAI-2NG

Previous research has shown that both PAI-2G and PAI-2NG are capable of inhibiting uPA and tPA
protease activity with similar efficiency (Mikus et al. 1993). Additionally, the oligomerisation of
PAI-2 has been reported to be associated with an up to 4-fold reduction in PAI-2 protease
inhibitory activity (Wilczynska et al. 2003b). Considering these observations, it was important to
confirm the protease inhibitory capacity of the purified PAI-2G and PAI-2NG preparations obtained
for this study. PAI-2G and PAI-2NG were each able to achieve approximately 80% inhibition of
uPA proteolytic activity at a 1:1 molar ratio of PAI-2:uPA (when normalised to a uPA alone
positive control), as determined using a uPA activity assay (Figure 5.2). Under these conditions,
there was a small, but statistically significant difference between the uPA inhibitory activities of
PAI-2G and PAI-2NG (78 ± 2% versus 84 ± 4%, respectively; mean ± SD, n = 9) (Figure 5.2). When
a 2:1 molar ratio of PAI-2:uPA was used, PAI-2G and PAI-2NG each achieved approximately 95%
inhibition of uPA (Figure 5.2). Taken together, these results indicated that the purified PAI-2G and
PAI-2NG preparations obtained in this study were functionally intact with respect to protease
inhibitory activity and oligomerisation had not adversely affected their activity.

Figure 5.2 Analysis of PAI-2G and PAI-2NG uPA inhibitory activity. uPA was incubated for 5 h at 37°C with a
fluorogenic peptide substrate (excitation = 355 nm, emission = 460 nm) specific for uPA proteolysis ± PAI-2G or PAI2NG at molar ratios of 2:1 or 1:1 (PAI-2:uPA). The inhibitory activity of PAI-2G or PAI-2NG was calculated by
comparison with a uPA alone positive control incubated with the fluorogenic substrate in the absence of any inhibitors.
Data are means ± SD taken from three replicates in three independent experiments (n = 9). One-way ANOVA with
post-hoc Tukey’s HSD was used to identify non-significant (ns) and significant differences (*** = P < 0.001; ** = P
< 0.01; * = P < 0.05).
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5.3.3

PAI-2G exhibits enhanced chaperone activity in comparison to PAI-2NG against Aβ1–
42

aggregation

It has been shown that intracellular PAI-2NG has modest ability to bind to numerous misfolded
client proteins (including Aβ1-42) and attenuate their aggregation, as well as contribute to the
maintenance of intracellular proteostasis (Lee et al. 2015). Using a ThT assay, it was observed that
both PAI-2G and PAI-2NG inhibited the aggregation of Aβ1–42 in a dose-dependent fashion (Figure
5.3A and B). Strikingly, PAI-2G was substantially more effective than PAI-2NG at preventing the
aggregation of Aβ1–42 when examined at equivalent molar ratios (Figure 5.3A and B). Specifically,
PAI-2G increased the lag phase of Aβ1–42 aggregation and reduced the total aggregation at the
conclusion of the assay in a dose-dependent manner (Figure 5.3A). On the other hand, while PAI2NG also increased the lag phase of Aβ1–42 aggregation in a dose dependent manner, lower amounts
of PAI-2NG increased the total Aβ1–42 aggregation measured at the conclusion of the assay (Figure
5.3B). Co-incubation of Aβ1–42 with ovalbumin (a non-chaperone serpin structurally related to
PAI-2) at a 1:10 molar ratio (ovalbumin:Aβ1–42) did not markedly influence the aggregation of
Aβ1–42 (Appendix 8.4). PAI-2G and PAI-2NG incubated in the absence of Aβ1–42 did not produce
changes in ThT fluorescence at any of the concentrations tested (data not shown). Given that at
equivalent molar ratios the total mass of PAI-2G (60 kDa) would be higher than that of PAI-2NG
(47 kDa), the ability of both species to inhibit Aβ1–42 aggregation was also compared at equivalent
mass ratios of PAI-2:Aβ1–42. Under these conditions, PAI-2G was still markedly more efficacious
than PAI-2NG at attenuating Aβ1-42 aggregation (Figure 5.3C). This indicated that a mass bias effect
was unlikely to be responsible for the superior ability of PAI-2G to inhibit Aβ1–42 aggregation in
comparison to PAI-2NG.
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Figure 5.3. Effects of PAI-2G and PAI-2NG on Aβ1–42 aggregation as measured by ThT assay. Aβ1–42 (3 µM) was
incubated with 25 µM ThT in PBS at 28°C with shaking ± (A) PAI-2G or (B) PAI-2NG at molar ratios of 1:2.5, 1:5,
1:7.5 or 1:10 (PAI-2:Aβ1–42). Data shown are mean ThT fluorescence (AFU; excitation = 440 nm, emission = 480 nm)
± SEM (n = 3) and are representative of four independent experiments. One-way ANOVA with post-hoc Tukey’s
HSD was conducted on the assay endpoints to identify non-significant (ns) and significant differences (*** = P <
0.001; ** = P < 0.01; * = P < 0.05), with respect to the control containing Aβ1–42 alone. (B) The assay and statistical
analyses were repeated as described in (A) except using 19 µg/mL of each PAI-2G (purple squares; approximately
equivalent to a 1:10 molar ratio of PAI-2G:Aβ1–42) or PAI-2NG (blue triangles; approximately equivalent to a 1:7.5
molar ratio of PAI-2NG:Aβ1–42). Data are means ± SEM (n = 3) and are representative of three independent
experiments.
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5.3.4

PAI-2G exhibits enhanced chaperone activity in comparison to PAI-2NG against heatdenatured CPK

CPK was next employed to compare the chaperone activities of PAI-2G and PAI-2NG. Heating of
CPK at 43°C induced its aggregation over ~ 3 h, including a lag phase of ~ 0.5 h, as observed by
increases in absorbance at 360 nm indicative of the turbidity of the solution (Figure 5.4A, B and
C). Co-incubation of CPK with increasing molar ratios of PAI-2G (1:1 and 1:2.5 PAI-2G:CPK)
resulted in dose-dependent lengthening of the lag phase of CPK aggregation, as well as decreases
in the overall amount of CPK aggregation observed at the conclusion of the assay (Figure 5.4A).
However, at the lowest molar ratio tested (1:5 PAI-2G:CPK), PAI-2G appeared to promote CPK
aggregation after ~ 3 h despite a slight attenuation of CPK aggregation over the first ~ 1.5 h of the
assay (Figure 5.4A). In comparison, PAI-2NG failed to attenuate CPK aggregation at any molar
ratio (equivalent to molar ratios also tested for PAI-2G), with PAI-2NG instead appearing to
promote CPK aggregation over the length of the assay which was particularly apparent at the
highest molar ratio tested (1:1 PAI-2NG:CPK) (Figure 5.4B). PAI-2G and PAI-2NG incubated alone
at 43°C in the absence of CPK did not result in changes to absorbance at 360 nm at any of the
molar ratios tested (data not shown). To ensure that the more potent inhibition of CPK by PAI-2G
compared to PAI-2NG was not due to a mass bias effect (as discussed previously in Section 5.3.3),
the effect of equivalent mass amounts of PAI-2G and PAI-2NG on the aggregation of CPK was
examined and showed a similar disparity in the chaperone activities of PAI-2G and PAI-2NG (Figure
5.4C). Notably, PAI-2G was able to attenuate the aggregation of CPK for ~ 9 h, whereas PAI-2NG
appeared to instead promote the aggregation of CPK over the same time period Figure 5.4C).
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Figure 5.4. Effects of PAI-2G and PAI-2NG on the heat-induced aggregation of CPK. (A) CPK (6.5 µM) was
incubated at 43°C with shaking ± (i) PAI-2G or (ii) PAI-2NG at molar ratios of 1:1. 1:2.5 or 1:5 (PAI-2:CPK). Turbidity
indicative of CPK aggregation was monitored by measuring absorbance at 360 nm of the solution. Data are means ±
SEM (n = 3) and are representative of three independent experiments. One-way ANOVA with post-hoc Tukey’s HSD
was conducted on the assay endpoints to identify non-significant (ns) and significant differences (*** = P < 0.001; **
= P < 0.01; * = P < 0.05), with respect to the sample containing CPK alone. (B) The assay and statistical analyses
were repeated as described in (A) except using 530 µg/mL of each PAI-2G (purple squares; approximately equivalent
to a 1.4:1 molar ratio of PAI-2G:CPK) or PAI-2NG (blue triangles; approximately equivalent to a 1:7:1 molar ratio of
PAI-2NG:CPK). Data are means ± SEM (n = 3) and are representative of three independent experiments.
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5.3.5

Treatment of PAI-2G and PAI-2NG with NaOCl results in the formation of higher
molecular weight complexes

Hypochlorite is a powerful oxidant that is capable of functionally modifying proteins including
holdase-type chaperones (Müller et al. 2014; Ulfig et al. 2019; Winter et al. 2008; Wyatt et al.
2014), or damages proteins resulting in impaired functions (Hawkins et al. 2003; Hawkins &
Davies 1998). Treatment of PAI-2G and PAI-2NG with NaOCl induced the formation of higher
order oligomers and large complexes of indeterminate size in a dose-dependent fashion as seen by
native PAGE analysis (Figure 5.5A). Similar results were obtained by SEC, which further
indicated that NaOCl-modified PAI-2 oligomers may reach up to at least ~ 360 kDa in size when
compared with the elution profile of protein molecular weight standards (Figure 5.5B).
Furthermore, SEC revealed that NaOCl-treated PAI-2NG formed larger complexes than NaOCltreated PAI-2G (Figure 5.5B).
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Figure 5.5 Native PAGE and analytical SEC analyses of PAI-2G and PAI-2NG following NaOCl treatment. (A)
PAI-2G or PAI-2NG pre-treated with 0–200 µM NaOCl were separated by native PAGE using an 8% Tris-glycine gel.
A reduced, S-carboxymethylated sample (RCM monomer) is included as a standard to define the migratory position
of the monomer for each PAI-2G and PAI-2NG. High molecular weight oligomers and complexes (HMW) are marked.
(B) Samples of PAI-2G or PAI-2NG pre-treated with 0, 50, 100 or 200 µM NaOCl were each separately resolved by
analytical SEC on a Superose 6 10/300 GL column. The absorbance × 10-3 at 280 nm is displayed for each of the
elution profiles and overlayed. The elution position of 360 kDa PZP and 67 kDa BSA standards under these conditions
is shown.
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5.3.6

NaOCl-induced structural modifications of PAI-2G and PAI-2NG involve changes in
secondary structure

To further understand the changes occurring to PAI-2G and PAI-2NG upon NaOCl treatment, CD
spectroscopy was used. Analysis by CD spectroscopy indicated that treatment with NaOCl
perturbed the native secondary structures of PAI-2G and PAI-2NG (Figure 5.6Ai and ii). Notably,
treatment with increasing amounts of NaOCl yielded reductions in PAI-2G and PAI-2NG α-helical
content as evidenced by significant decreases in MRE minima at 208 and 222 nm (Figure 5.6Bii
and ii). This suggested that preparations of PAI-2G and PAI-2NG had adopted less-ordered
structures upon treatment with NaOCl. Apart from this, the overall secondary structures of both
PAI-2G and PAI-2NG remained comparable following oxidation (Figure 5.6A and B).
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Figure 5.6 The effect of NaOCl on PAI-2G and PAI-2NG secondary structure as determined by CD spectroscopy
analyses. MRE obtained by CD spectroscopy, measured between 190–250 nm at 24°C for (Ai) PAI-2G or (Aii) PAI2NG, each pre-treated with 0, 100 or 200 µM NaOCl. (B) MRE obtained by CD spectroscopy at 208 and 222 nm as a
measure of α-helical content for (Bi) PAI-2G or (Bii) PAI-2NG. Data are means ± SD (n = 3). One-way ANOVA with
post-hoc Tukey’s HSD was used to identify non-significant (ns) and significant differences (*** = P < 0.001; ** = P
< 0.01; * = P < 0.05) with respect to native PAI-2G and PAI-2NG.
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5.3.7

NaOCl-modified

PAI-2G

and

PAI-2NG

exhibit

enhanced

surface-exposed

hydrophobicity and dityrosine cross-linkages
Analysis using bis-ANS showed that PAI-2G or PAI-2NG pre-treated with 50, 100 or 200 µM
NaOCl had significantly increased surface-exposed hydrophobicity compared to untreated PAI-2G
or PAI-2NG (Figure 5.7A). However, PAI-2G and PAI-2NG had similar amounts of surface-exposed
hydrophobicity under equivalent treatment conditions (Figure 5.7A). In addition, intrinsic
fluorescence emission at 420 nm of PAI-2G and PAI-2NG upon excitation at 325 nm was found to
significantly increase with higher concentrations of NaOCl treatment in a dose-dependent fashion
(Figure 5.7B), supporting that NaOCl-induced oligomerisation of PAI-2 involved the formation of
dityrosine cross-linkages (Heinecke et al. 1993).
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Figure 5.7 The effect of NaOCl treatment on PAI-2G and PAI-2NG surface-exposed hydrophobicity and
dityrosine cross-linkage formation as determined by bis-ANS and intrinsic spectrofluorometric assays. (A) PAI2G or PAI-2NG (0.05 mg/mL in PBS) which had been pre-treated with 0, 100 or 200 µM NaOCl were incubated at
37°C for 30 min with 20 µg/mL bis-ANS. The bis-ANS fluorescence (AFU; excitation = 355 nm, emission = 480 nm)
was subsequently measured. Data are means ± SD (n = 3) and are representative of four independent experiments.
One-way ANOVA with post-hoc Tukey’s HSD was used to identify non-significant (ns) and significant differences
(*** = P < 0.001; ** = P < 0.01; * = P < 0.05). (B) PAI-2G or PAI-2NG which had been pre-treated with 0, 100 or 200
µM NaOCl were analysed for intrinsic fluorescence (AFU; excitation = 325 nm, emission = 420 nm). Data are means
± SD (n = 3) and are representative of three independent experiments. Statistical analysis was conducted as described
in (A).
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5.3.8

PAI-2G and PAI-2NG are more resistant than PAI-1 to NaOCl induced inactivation of
uPA inhibitory activity

The consequence of NaOCl treatment on PAI-2G and PAI-2NG uPA protease inhibitory activity
was next examined and directly compared with that of NaOCl-treated PAI-1. PAI-2G, PAI-2NG or
PAI-1 pre-treated with 50 or 100 µM NaOCl all had a significantly reduced uPA inhibitory activity
compared to untreated proteins (Figure 5.8Ai and ii). Relatively, the uPA inhibitory activity of
PAI-1 was significantly more reduced by 50 or 100 µM NaOCl treatment at either a 1:1 or 2:1
molar ratio of PAI:uPA compared to PAI-2G and PAI-2NG (Figure 5.8Bi and ii). Notably, PAI-1
exhibited a ~ 5.9-fold reduction in uPA inhibitory activity at a 1:1 molar ratio of PAI:uPA when
pre-treated with 100 µM NaOCl (Figure 5.8Bi), while PAI-2G and PAI-2NG displayed a ~ 2.1- and
~ 1.5-fold reduction in uPA inhibitory activity, respectively, under the same conditions (Figure
5.8Bi). In addition, the uPA inhibitory activity of PAI-2NG was slightly more resistant to NaOCl
inactivation compared to PAI-2G, which was statistically significant under all conditions tested
except at a 1:1 PAI:uPA ratio following 100 µM NaOCl treatment (Figure 5.8Bi and ii).
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Figure 5.8 Analysis of PAI-2G, PAI-2NG and PAI-1 uPA inhibitory activity in the absence or presence of NaOCl
treatment. uPA was incubated for 5 h at 37°C with a fluorogenic substrate specific for uPA proteolysis ± PAI-2G,
PAI-2NG or PAI-1 pre-treated with 0–100 µM NaOCl at molar ratios of (Ai) 1:1 or (Aii) 2:1 (PAI:uPA). The inhibitory
activity of PAI-2G, PAI-2NG and PAI-1 was calculated by normalisation with a uPA positive control incubated under
the same conditions with the fluorogenic substrate in the absence of any inhibitors. Data are means ± SD (n = 3) and
are representative of three independent experiments. One-way ANOVA with post-hoc Tukey’s HSD was used to
identify non-significant (ns) and significant differences (*** = P < 0.001; ** = P < 0.01; * = P < 0.05). As an extension
of the analysis as described in (A), the fold-reduction in uPA inhibitory activity was calculated following treatment
with 50 µM or 100 µM NaOCl at a (Bi) 1:1 or (Bii) 2:1 molar ratio of PAI:uPA. Fold reduction of uPA inhibition was
calculated by normalisation to 0 µM NaOCl treatments of PAI-2G, PAI-2NG or PAI-1 at respective molar ratios.
Statistical analysis was conducted as described in (A).
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5.3.9

The chaperone activity of PAI-2NG is enhanced by pre-treatment with NaOCl

The effect of NaOCl-induced modification on the chaperone activity of PAI-2G and PAI-2NG was
examined using Aβ1-42. Analysis by ThT assay showed that NaOCl-modified PAI-2G displayed a
similar ability to inhibit Aβ1-42 aggregation compared to native PAI-2G (Figure 5.9Ai). Conversely,
NaOCl-modified PAI-2NG displayed a markedly increased inhibition of Aβ1-42 aggregation
compared to native PAI-2NG (Figure 5.9Aii), such that NaOCl-modified PAI-2NG had similar
chaperone activity to PAI-2G. At the conclusion of the ThT assays, insoluble protein was pelleted
by centrifugation and the soluble protein fraction was subjected to native-Western blotting for
analysis of putative Aβ1-42:PAI-2 complex formation. Using a monoclonal anti-Aβ antibody, Aβ142

was undetectable in the absence of PAI-2 samples, indicating that the majority of Aβ1-42 had

formed insoluble amyloid fibrils when incubated in the absence of PAI-2 (Figure 5.9).
Comparatively, Aβ1-42 was detected at positions corresponding to high molecular weight
complexes when co-incubated with native PAI-2G, NaOCl-modified PAI-2G and NaOCl-modified
PAI-2NG (Figure 5.9Bi and ii), but Aβ1-42 was undetectable when co-incubated with native PAI2NG (Figure 5.9ii). These results correlated with ThT assays, in which the presence of a putative
stable PAI-2-Aβ1-42 high molecular weight complex (Figure 5.9B) was only observed where
endpoint reduction of Aβ1-42 aggregation had occurred in ThT assays (Figure 5.9A).
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Figure 5.9 The effect of NaOCl pre-treatment on PAI-2G and PAI-2NG chaperone activity as measured by Aβ1–
42 ThT aggregation assays and native Western blotting. (A) Aβ1–42 (3 µM) was incubated with 25 µM ThT in PBS
at 28°C with shaking ± 0.019 mg/mL (i) PAI-2G or (ii) PAI-2NG pre-treated with 0, 50, 100 or 200 µM NaOCl. Data
shown are mean ThT fluorescence (AFU; excitation = 440 nm, emission = 480 nm) ± SEM (n = 3) and are
representative of four independent experiments. One-way ANOVA with post-hoc Tukey’s HSD was conducted on
the assay endpoints to identify non-significant (ns) and significant differences (*** = P < 0.001; ** = P < 0.01; * = P
< 0.05), with respect to the control containing Aβ1–42 alone. (B) At the conclusion of the assay described in (A), each
of the treatments were pooled and centrifuged at high speed (24,000 × g, 20 min, RT) to pellet insoluble material.
Supernatants from each treatment (30% of the total volume) were subsequently loaded in duplicate and separated by
native PAGE using 8% Tris-glycine gels. After transferring the gels to nitrocellulose membranes by Western blotting,
the duplicate samples of each treatment were probed with either an anti-Aβ1-42 antibody or an anti-PAI-2 antibody (as
labelled). The results for (i) PAI-2G and (ii) PAI-2NG are shown (ox = µM NaOCl). The position of soluble high
molecular weight aggregates of Aβ1-42 (HMWA) and PAI-2 monomers (PAI-2 M) are marked on each blot.
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5.3.10 Native PAI-2G and PAI-2NG protect the SH-SY5Y cell line against Aβ1-42-induced
cytotoxicity
Considering that PAI-2G and PAI-2NG attenuated Aβ1-42 aggregation, the influence of PAI-2G and
PAI-2NG on Aβ1-42-induced cytotoxicity of SH-SY5Y cells was tested as described for A2M and
PZP in Chapter 4. Treatment of cells with Aβ1-42 in the presence of either PAI-2G or PAI-2NG at a
molar ratio of 1:10 (PAI-2:Aβ1-42) resulted in significantly reduced cell death compared to
corresponding samples treated with Aβ1-42 alone (Figure 5.10A). Comparatively, treatment of SHSY5Y cells with Aβ1-42 pre-incubated with ovalbumin (which does not influence Aβ1-42
aggregation in ThT assays; Appendix 8.4), had no protective effect against Aβ1-42 induced
cytotoxicity (Figure 5.10), suggesting that the protective effect of the PAI-2 proteins was
dependent on their ability to influence Aβ1-42 aggregation. Notably, PAI-2NG had a less potent
cytoprotective effect compared to PAI-2G. Specifically, PAI-2NG provided a significant protective
effect up until 32 h of incubation (Figure 5.10B), whereas PAI-2G maintained a significant
protective effect for the duration of the 48 h assay (Figure 5.10C).
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Figure 5.10 The effect of PAI-2G and PAI-2NG on Aβ1–42-induced cytotoxicity of SH-SY5Y cells as assessed by
Cytotox Green fluorescence assay. (A) SH-SY5Y cells were seeded into 96-well plates at 40% confluence in
DMEM/F-12 media supplemented with 10% FCS. The next day, cell media was aspirated and refreshed with
treatments (n = 3 technical replicates/100 µL/well) consisting of Aβ1-42 (10 µM) prepared in neurobasal medium ±
PAI-2G, PAI-2NG or ovalbumin at a 1:10 molar ratio of PAI-2/Ovalbumin:Aβ1-42. A cell viability control treatment of
neurobasal medium was also prepared (medium alone) which received equivalent volumes of PBS instead of protein
as a vehicle control. Negligible effects on cell viability were observed over the timeframe of the experiment. All
treatments were pre-incubated for 5 h at 37°C prior to addition to SH-SY5Y cell monolayers. Immediately following
addition of treatments, Cytotox Green fluorescent dye (excitation = 490 nm, emission = 524 nm) was added for
identification of dead cells and subsequently incubated under standard cell culture conditions for a further 48 h.
Microscope images were collected over the course of the experiment using an IncuCyte ZOOM (2016A) live cell
imager using the phase and green collection channels (excitation = 490 nm, emission = 524 nm; acquisition time =
400 ms) fitted with a 10 × objective. FOC indicative of cell death was calculated using an IncuCyte green object
analysis mask under a fixed threshold with a GCU of 100 and edge split turned on (set to 0). Data shown are means ±
SEM (n =3) and are representative of two independent experiments. One-way ANOVA with post-hoc Tukey’s HSD
was conducted on the (B) 32 h and (C) 48 h endpoints to identify non-significant (ns) and significant differences (***
= P < 0.001; ** = P < 0.01; * = P < 0.05). Significant and non-significant differences are shown for comparisons made
to the control containing Aβ1–42 alone.
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Representative microscope images of SH-SY5Y cells used to produce the analysis in Figure 5.10
are shown (Figure 5.11). After 48 h of incubation in medium alone, the majority of SH-SY5Y cells
displayed a generally healthy morphology and only a small amount of dead cells (Figure 5.11A),
which was consistent with earlier observations in Section 4.3.3. After approximately 24–48 h of
incubation with Aβ1-42, SH-SY5Y cells appeared to be completely non-viable, with only dead cells
visible (Figure 5.11B), which was identical to that observed with ovalbumin:Aβ1-42 for 24–48 h
(Figure 5.11B is representative). A mixed population of dead and healthy cells were observed in
SH-SY5Y cells treated with PAI-2G:Aβ1-42 up until 48 h of incubation (Figure 5.11C), which was
similar to images observed of SH-SY5Y cells treated with PAI-2NG:Aβ1-42 up until approximately
32 h of incubation (Figure 5.11C is representative).
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Figure 5.11 Representative microscope images showing the effect of PAI-2G on Aβ1–42-induced cytotoxicity and
cellular morphology of SH-SY5Y cells. Images for the 48 h endpoint from the experiment described in Figure 5.10
are shown for (A) medium alone, (B) Aβ1-42 and (C) PAI-2G:Aβ1-42 (1:10 molar ratio). Images in (B) are representative
for ovalbumin:Aβ1-42 (1:10 molar ratio) at 48 h, and images in (C) are representative for PAI-2NG:Aβ1-42 (1:10 molar
ratio) at 32 h.
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5.4 Discussion
For the first time, this study has shown that extracellular PAI-2G inhibits the aggregation of fibrillar
Aβ1-42 and amorphous CPK, and this holdase-type chaperone activity was more efficient than that
of the predominantly intracellular PAI-2NG. Consistent with having superior chaperone activity,
PAI-2G was also significantly more protective against Aβ1-42-induced cytotoxicity of SH-SY5Y
cells compared to PAI-2NG. Given that native PAI-2G and PAI-2NG have (i) similar surface-exposed
hydrophobicity by bis-ANS analysis (Figure 5.7A; which is the main force by which most holdasetype chaperones bind to misfolded proteins), and (ii) similar secondary structure by CD
spectroscopy (Figure 5.6), differences in chaperone activity are potentially linked to PAI-2G
glycosylation. For example, glycosylation may aid in keeping PAI-2G-misfolded protein
complexes soluble and thermodynamically stable, as increased thermostability has been reported
for glycosylated forms of α-chymotrypsin (Solá et al. 2007), β-lactoglobulin (Broersen et al.
2004), locust major peptide C protease inhibitor (Mer et al. 1996), and chicken ovomucoid (De
Koster & Robertson 1997). Similarly, other glycosylated proteins such as clusterin and seminal
plasma protein 109 have been shown to have superior chaperone activity in comparison to their
non-glycosylated counterparts (Rohne et al. 2014; Singh et al. 2019). Unconjugated sugars and
small sugar-nanoparticles have also been shown to influence the aggregation of misfolded proteins
including amyloid (Arakawa et al. 2006; Arora et al. 2004; Choudhary et al. 2015; Fung et al.
2005; Pradhan et al. 2017; Tanaka et al. 2004). Thus, the more potent chaperone activity of PAI2G may in part be due to the direct interaction of PAI-2G glycans with misfolded proteins. Although
PAI-2G appears to possess a more potent chaperone activity, previous research has shown that
intracellular PAI-2NG attenuates the aggregation of numerous misfolded proteins, promotes the
formation of cytoprotective inclusion bodies and binds to the proteasome (Fan et al. 2004; Lee et
al. 2015). Therefore, both PAI-2G and PAI-2NG may provide important contributions to
maintenance of proteostasis in the extracellular and intracellular environments, respectively.
Compared to other known extracellular chaperones, PAI-2G is unlikely to be a major contributor
to maintenance of extracellular proteostasis in human plasma under normal physiological
conditions. In general, relatively higher amounts of PAI-2G were required to inhibit protein
aggregation of Aβ1-42 or CPK compared to other extracellular chaperones including A2M,
haptoglobin and clusterin, which possess a more potent activity (French et al. 2008; Humphreys
et al. 1999; Poon et al. 2002a; Wyatt et al. 2013b; Yerbury et al. 2009; Yerbury et al. 2005a).
Furthermore, other extracellular chaperones are normally much more abundant in plasma (A2M,
2–4 mg/mL; haptoglobin, 0.3–2 mg/mL; clusterin, 0.03–0.1 mg/mL) (Bowman & Kurosky 1982;
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Murphy et al. 1988; Tunstall et al. 1975) in comparison to PAI-2G, which is usually lowly
expressed or undetectable in plasma under normal conditions (Lee et al. 2011; Medcalf 2011).
The chaperone activity of PAI-2G is thus more likely to be important under conditions when it is
upregulated, such as during pregnancy (Astedt et al. 1997; Kruithof et al. 1987; Lecander & Åstedt
1986), inflammation (Kruithof et al. 1995; Lee et al. 2011; Medcalf 2011; Medcalf &
Stasinopoulos 2005) and in localised tissues or exudates, such as amniotic fluid (Estellés et al.
1990; Uszynski et al. 1995), the placenta (Hofmann et al. 1994; Jonasson et al. 1989), saliva
(Virtanen et al. 2006) gingival crevicular fluid (Brown et al. 1995; Kinnby et al. 1991), pleural
effusions (Aleman et al. 2003), tears (Csutak et al. 2008) and peritoneal fluid (Scott‐Coombes et
al. 1995).
Reduced placental mRNA and plasma levels of PAI-2 have been found in pre-eclampsia patients
(Estelles et al. 1989; Grancha et al. 1996; He et al. 1996; Reith et al. 1993). PAI-2 has further been
found in microglia associated with senile plaques of Alzheimer’s disease brain (Akiyama et al.
1993). Both of these disorders feature aberrant misfolding and aggregation of Aβ1-42
predominantly in extracellular fluids as part of the pathophysiology (Buhimschi et al. 2014;
Murphy & LeVine III 2010), which is considered to be a generally toxic process in vivo
(Rajasekhar et al. 2015; Simmons et al. 1994; Yankner & Lu 2009). The exact mechanism(s) of
Aβ1-42 toxicity, however, remains controversial. A possibly protective role is thus proposed for
PAI-2G in vivo, whereby PAI-2G may bind and prevent the accumulation of cytotoxic species of
Aβ1-42 in disorders such as pre-eclampsia and Alzheimer’s disease. The mechanism by which PAI2G reduces Aβ1-42 aggregation and cytotoxicity could not be determined within the scope of the
present study. Based on previous structural analyses it is speculated that the hydrophobic pocket
within the A β-sheet of PAI-2 may be an important site for binding of misfolded proteins such as
Aβ1-42 (Jankova et al. 2001; Wilczynska et al. 2003b). Similar to cytoprotective mechanisms of
other extracellular chaperones, the mechanism of PAI-2G-Aβ1-42 cytoprotection may involve PAI2G preventing the formation of, or sequestering, toxic Aβ1-42 species (Wyatt et al. 2013c). Also, it
is possible that toxic PAI-2-Aβ1-42 complexes may be cleared from the extracellular space by
receptor-mediated endocytosis and degraded. However, considering that PAI-2 does not contain a
receptor binding site, clearance of the PAI-2-Aβ1-42 complexes would require interaction with
receptors specific for Aβ1-42 (of which there are some ~ 20 candidates) (Mroczko et al. 2018), or
alternatively, complex formation of PAI-2-Aβ1-42 with uPA or tPA following proteolytic cleavage
could facilitate clearance via LRP1 or mannose receptors (Al-Ejeh et al. 2004; Lee et al. 2010;
Narita et al. 1995; Orth et al. 1992; Otter et al. 1991). Furthermore, considering that the chaperone
157

activity of PAI-2G was only examined using one disease-relevant misfolding protein, it is of
interest in future work to examine if the chaperone activity of PAI-2G is broadly applicable to other
disease-associated misfolding proteins, such as those found in pre-eclampsia (as discussed in
Section 1.2.5).
Hypochlorite is a potent oxidant that is rapidly consumed in vivo by reactions with a broad range
of biological substrates, including DNA, lipids, cholesterol and proteins. In particular, proteins are
a major target for reaction with hypochlorite, which results in side-chain modifications, crosslinking, protein fragmentation, misfolding and aggregation (Hawkins et al. 2003)
Correspondingly, it is difficult to accurately estimate levels of hypochlorite in vivo. However, (i)
computational modelling predicts that proteins can be exposed to a 20-fold molar excess of
hypochlorite in their lifetime (Hazen & Heinecke 1997) and (ii) in vitro and ex vivo data support
the conclusion that hypochlorite levels may reach the high micromolar to low millimolar range in
vivo (Vlasova et al. 2011; Weiss 1989). Furthermore, two independent studies have demonstrated
that 1 × 106 stimulated neutrophils can produce 17–180 nmol of hypochlorite over a 2 h period in
vitro (Kalyanaraman & Sohnle 1985; Lampert & Weiss 1983). Given that 0.1 mL of fluid from
inflammatory tissue contains approximately 25 × 106 neutrophils (Weiss 1989), this suggests that
in vivo concentrations of unreacted hypochlorite could approach 4250–45000 µM in 2 h. The
experiments described in this thesis, therefore, attempt to mimic physiologically-relevant
hypochlorite-induced protein modification. For example, if the total protein concentration in
human plasma is assumed to be approximately 70 mg/mL (Busher 1990), with potential exposure
to 4250–45000 µM hypochlorite over 2 h, treatment of purified PAI-2 (present in pregnancy
plasma at ~ 0.25 mg/mL) is correspondingly scaled to 25–160 µM NaOCl. Therefore, the 50 and
100µM NaOCl treatments of 0.25 mg/mL PAI-2 as conducted in this study are considered
physiologically moderate, whereas 200 µM NaOCl represents a more extreme NaOCl treatment.
Hypochlorite-activated chaperones which counteract hypochlorite-induced protein misfolding
have previously been described in bacteria and humans (as discussed in Section 1.2.4). In the
present study, the chaperone activity of PAI-2NG, but not PAI-2G, was enhanced by treatment with
NaOCl, suggesting that PAI-2NG may also be a hypochlorite-activated chaperone. The reason for
this phenomenon is unknown, but it is speculated that the amino acids which are modified by
NaOCl treatment in PAI-2NG (which subsequently lead to an enhancement in chaperone activity)
are not modified in PAI-2G, possibly due to glycans acting as a preferential or competing site of
oxidation via base peeling reactions (Fischler & Orlando 2019). Given that hypochlorite is
typically extracellular, it is questionable whether the chaperone activity of PAI-2NG is enhanced
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by hypochlorite intracellularly. However, given that it has been observed that the intracellular pool
of PAI-2NG is exported to the extracellular space following inflammatory stimulation of leukocytes
(Ritchie & Booth 1998) and endothelial cells (Boncela et al. 2013), it is plausible that the
chaperone activity of PAI-2NG is enhanced extracellularly by hypochlorite during inflammation.
In conjunction with the observation that PAI-2G chaperone activity did not worsen upon NaOCl
treatment, these results support the notion that both PAI-2G and PAI-2NG may function as holdasetype chaperones in response to collateral damage to host proteins during inflammation.
It has been shown that treatment with oxidants including hypochlorite results in the inactivation
of many protease inhibitors, including alpha-1 antitrypsin, A2M, secretory leukocyte protease
inhibitor, antithrombin III, alpha-2 antiplasmin, neuroserpin, C1-inhibitor and the model Kunitztype soybean trypsin inhibitor (Gupta et al. 2017; Hawkins & Davies 2005; Kramps et al. 1988;
Reddy et al. 1989; Reddy et al. 1994; Stief et al. 1988; Swaim & Pizzo 1988; Travis & Salvesen
1983; Weiss 1989). Notably, PAI-1 is acutely sensitive to oxidation-induced inactivation
(Lawrence & Loskutoff 1986; Strandberg et al. 1991). Although oxidants are expected to produce
similar results, the specific effect of NaOCl on PAI-1 protease inhibitory activity has not
previously been investigated. Comparatively, PAI-2 has been shown to be resistant to NaOCl
inactivation of its protease inhibitory activity (Baker et al. 1990), but this study did not directly
compare PAI-2 to PAI-1 following NaOCl treatment and only examined the effect of NaOCl on
PAI-2NG. In the present study, it was shown that both PAI-2G and PAI-2NG are more resistant to
NaOCl inactivation of their uPA inhibitory activity when directly compared to PAI-1. This result
strongly suggests that PAI-2 could be critically important for inhibiting its target proteases uPA
and tPA during inflammation, when the corresponding activity of PAI-1 is inactivated by oxidative
stress. This could be an important consideration for numerous biological processes. For example,
it has been proposed that PAI-2 may be important for protecting against premature placental
separation by counteracting uPA- and tPA-mediated proteolysis, a role that might also be filled by
PAI-1 (Astedt et al. 1997; Brenner 2004; Kruithof et al. 1995; Reith et al. 1993). However,
considering that heightened hypochlorite generation has been reported in pregnancy plasma and
at the placenta (Fialova et al. 2006; Hammer et al. 2001), which is exacerbated in pre-eclampsia
(Gandley et al. 2008), PAI-2 is potentially more effective than PAI-1 during pregnancy as the
primary physiological inhibitor of uPA and tPA. It has also been proposed that PAI-2 acts as part
of the mucosal innate immune system due to its ability to inhibit proteases from bacteria associated
with periodontitis (Neilands et al. 2016). Intuitively, PAI-2 resistance to inflammatory conditions
of periodontitis which feature enhanced production of hypochlorite will be critical to PAI-2
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performing this defensive function (Cao & Smith 1989; Dagar et al. 2015). More generally,
resistance of PAI-2 to hypochlorite-induced modification may also be important for antifibrinolytic activity during inflammation, such as in the pathogenesis of atherosclerotic plaques
(Foy & Grant 1997; Li et al. 2015; Malle et al. 2000; Schroder et al. 2011a; Song et al. 2017).
Ultimately, PAI-2 is a rare example of a protease inhibitor that is partially resistant to oxidative
stress and this is likely to be an important consideration for defining the biological importance of
PAI-2 in vivo.
The best characterised serpinopathy is caused by the polymerisation of Z mutant alpha-1
antitrypsin, whereby the accumulation of alpha-1 antitrypsin polymers in hepatocyte inclusion
bodies leads to cirrhotic liver disease (gain of function) and emphysema (loss of function due to
lack of elastase inhibition) (Carrell & Lomas 2002). Most studies of serpin polymerisation in vitro
usually requires the use of mutants or harsh treatments to induce polymerisation, including high
heat, protease cleavage, chemical modification, chaotropic treatment or denaturation (Huntington
& Yamasaki 2011). In contrast, as observed in the present study (Figure 5.1) and by others (Mikus
et al. 1993; Wilczynska et al. 2003b), PAI-2 is a unique example of a serpin that spontaneously
polymerises under physiological conditions in the absence of mutations or harsh treatment. The
functional significance of PAI-2 polymerisation is unknown and has also not been linked to any
human disorders. A novel finding of the present study was that polymerisation of PAI-2 was
promoted by treatment with NaOCl, which suggests that polymerisation of serpins in general could
be promoted under conditions of inflammation or other oxidative stresses. This is of interest,
because Z mutant alpha-1 antitrypsin polymers have shown neutrophil chemotactic and activating
properties in vitro and in vivo, including increased release of myeloperoxidase, the enzyme
responsible for hypochlorite production (Mahadeva et al. 2005; Mulgrew et al. 2004; Parmar et
al. 2002). Synonymous with results observed in the present study for PAI-2, if hypochlorite is
capable of promoting alpha-1 antitrypsin polymerisation, this may produce a pro-inflammatory
positive feedback loop which contributes to the pathology of emphysema.
It has been proposed that serpins form polymers by a mechanism involving RCL insertion of one
monomer into the open A β-sheet of another (Ekeowa et al. 2010; Lomas et al. 1992; Lomas et al.
1993). However, alternative models of serpin polymerisation including domain swapping have
also been proposed (Yamasaki et al. 2008; Yamasaki et al. 2010). It is unknown precisely how
PAI-2 polymerises, but previous work using RCL peptides is strongly suggestive that PAI-2
polymerises predominantly via the RCL-β-sheet A mechanism (Mikus & Ny 1996; Wilczynska et
al. 2003b). As such, it is possible that NaOCl treatment enhances the formation of PAI-2 polymers
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via the RCL-β-sheet A insertion mechanism. For example, NaOCl-induced polymers of PAI-2
displayed an increase in surface-exposed hydrophobicity (Figure 5.7A), which is a feature also
reported for alpha-1 antitrypsin RCL-β-sheet A insertion polymers formed by treatment at 65°C
(James & Bottomley 1998). Considering the active site of PAI-2 does not contain residues
sensitive to NaOCl inactivation (Baker et al. 1990), RCL-β-sheet A insertion could also explain
the reduction in uPA inhibitory activity upon NaOCl treatment (Wilczynska et al. 2003b).
However, in the present study there is also evidence that PAI-2 polymers form through a
mechanism independent of RCL-β-sheet A insertion. For example, NaOCl-treated PAI-2 polymers
display dityrosine cross-link formation (Figure 5.7B), and the reduction in PAI-2 protease
inhibitory activity upon NaOCl treatment could also be explained by changes in secondary
structure elements required for protease inhibition (Figure 5.6). Taken together, the data suggests
that polymers of NaOCl-treated PAI-2 form through multiple mechanisms, including RCL-β-sheet
A insertion and dityrosine cross-link formation.
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6 Conclusions and future directions
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6.1 Overview of pregnancy-associated chaperones
The overarching goal of this project was to characterise the extracellular holdase-type chaperone
activity of PZP and PAI-2 in vitro. The data presented in this thesis supports a model in which
PZP and PAI-2 inhibit protein aggregation and reduce the cytotoxicity of misfolded proteins
(Figure 6.1). This protective chaperone mechanism potentially has important implications for
maintenance of proteostasis in vivo during pregnancy and non-pregnancy associated inflammatory
states. It is also possible that PZP and PAI-2 holdase-type chaperone activity interconnects or is
regulated by other functions such as protease inhibition or receptor interactions (Figure 6.1), but
this will need to be investigated in future studies. Of the two proteins, PZP is likely to be a major
pregnancy-associated extracellular chaperone, given its marked upregulation in maternal plasma
(Ekelund & Laurell 1994; Petersen et al. 1990), and more potent chaperone activity compared to
PAI-2 and the bona fide extracellular chaperone A2M. Conversely, the chaperone activity of
extracellular PAI-2G is likely to be more relevant at localised sites where it is highly expressed
such as the placenta (Hofmann et al. 1994; Jonasson et al. 1989), given its comparatively lower
abundance in maternal plasma (Kruithof et al. 1987). Considering that mild endoplasmic reticulum
stress underlies normal pregnancy (Kyathanahalli et al. 2015), the chaperone activity of
intracellular PAI-2NG could also be impactful in the placenta. It is currently unknown whether other
pregnancy-associated plasma proteins, which are normally undetectable in blood plasma but are
markedly upregulated during gestation, contribute to stabilisation of misfolded proteins during
human pregnancy. Other well-characterised HSP family chaperones including HSP70 and
HSP10/early pregnancy factor are detectable in extracellular fluids during pregnancy but only in
small amounts (< 25 ng/mL) (Anraku et al. 2012; Fukushima et al. 2005; Molvarec et al. 2007),
and so it is doubtful that these predominantly intracellular proteins will be impactful for stabilising
extracellular misfolded proteins, especially given the low extracellular concentration of ATP and
other cofactors required for their function.
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Figure 6.1 Proposed mechanisms of PZP and PAI-2 extracellular proteostasis. PZP and PAI-2 are upregulated in
extracellular fluids during pregnancy and inflammation, which are states involving elevated stresses which can induce
protein misfolding and aggregation. (1) PZP or PAI-2 bind misfolded proteins and subsequently reduce their
aggregation and cytotoxicity. (2) Clearance of PZP- or PAI-2-misfolded protein complexes may occur through LRP1
(PZP), or mannose or LRP1 receptors (PAI-2), following cleavage by relevant proteases (light purple receptors), or
through (3) receptors specific for the misfolded protein, such as scavenger receptors (grey receptors). (4) Intracellular
PAI-2 may be important for stabilising misfolded proteins and interacting with proteostasis networks, particularly in
tissues such as the placenta, or (5) following its release to the extracellular environment during inflammation, where
hypochlorite modification enhances its chaperone activity. (6) PAI-1 (pink) is more sensitive to hypochlorite-induced
inactivation of its protease inhibitory activity compared to PAI-2 (purple) during pregnancy and inflammation.
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6.2 Significance of pregnancy-associated chaperones in pre-eclampsia
The demonstration that pregnancy-associated proteins have holdase-type chaperone activity has
potential significance for understanding the pathophysiology of pre-eclampsia. Numerous proteins
have been identified in the misfoldome of pre-eclampsia, including transthyretin, alpha-1
antitrypsin, ceruloplasmin, albumin, IgG k-free light chains and Aβ (Buhimschi et al. 2014;
Buhimschi et al. 2008; Kalkunte et al. 2013; Millen et al. 2018; Schuster et al. 2020; Tong et al.
2017). Aggregates found in pre-eclampsia are also implicated in other human diseases, including
systemic amyloidosis (transthyretin, IgG k-free light chains), liver cirrhosis co-morbid with
emphysema (alpha-1 antitrypsin) and Alzheimer’s disease (Aβ). Analogous to other PDDs, the
proteins which misfold in pre-eclampsia are expected to elicit toxic loss of function, as well as
toxic gain of function (Gerasimova et al. 2019; Phipps et al. 2016). The present study suggests
that both PZP and PAI-2 are important for inhibiting the aggregation and corresponding
cytotoxicity of pre-eclampsia-associated Aβ using a neuronal cell model in vitro. It will thus be of
interest to determine whether PZP and PAI-2 are able to inhibit the aggregation and cytotoxicity
of other misfolded proteins associated with pre-eclampsia and other human diseases detailed
above. Given that misfolded proteins circulate throughout the bloodstream in pre-eclampsia
(Cheng et al. 2016; Gerasimova et al. 2019; Millen et al. 2018), potentially a large number of
maternal organs are damaged by protein aggregate toxicity. In particular, the placenta (where
deposits of misfolded proteins have been identified) and the kidneys (which excrete misfolded
proteins in urine), are particularly susceptible to damage during pre-eclampsia (Buhimschi et al.
2014; Kalkunte et al. 2013; Millen et al. 2018). As such, determining whether PZP and PAI-2 can
protect placental or kidney cell lines from cytotoxicity induced by the accumulation of misfolded
proteins in future studies will be of high interest. It will also be important to determine whether
PZP or PAI-2 co-localise with misfolded proteins in the placenta or urine of pre-eclampsia
patients. The fate of misfolded proteins in complex with PZP or PAI-2 is further unknown, but it
is speculated that they are cleared by LRP1 (PZP), or mannose or LRP1 (PAI-2) receptor-mediated
endocytosis upon reaction with proteases, or by receptors that preferentially bind to misfolded
proteins such as scavenger receptors (Bamberger et al. 2003) (Figure 6.1). Ultimately, further work
concerning the chaperone and clearance mechanisms of PZP and PAI-2 is desirable and will be
important for enhancing our understanding of the role of pregnancy-associated chaperones in preeclampsia pathology.
In concordance with the proposed protective mechanism of PZP and PAI-2 chaperone activity, it
is possible that a plasma deficiency of extracellular chaperones may render individuals at an
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increased risk of developing or suffering exacerbated pre-eclampsia due to uncontrolled toxicity
of misfolded proteins. Although animal models of pre-eclampsia are available, mouse models are
unsuitable for studying the corresponding effect of PZP and PAI-2 chaperone deficiencies in the
pathophysiology of human pre-eclampsia. For example, PAI-2 is expressed differently in mice to
humans, including platelet-specific expression in mice (Schroder et al. 2019b), and a lack of
expression during mouse pregnancy by the trophoblast cells of the placenta until very late in
gestation (Chern et al. 2010; Kawata et al. 1996). Moreover, a dimeric alpha-macroglobulin which
increases during mouse pregnancy, analogous to human PZP, does not exist in mice (Overbergh
et al. 1995; Tayade et al. 2005). A recent study suggests the common marmoset (Callithrix
jacchus) could be a suitable model to study chaperone functions of human PZP during pregnancy,
due to the existence of an analogous pregnancy-associated alpha-macroglobulin with 90%
homology with PZP (Kashiwagi et al. 2020). Due to the lack of in vivo models, most studies of
PZP and PAI-2 chaperone activity in pre-eclampsia pathophysiology are currently limited to
human fluids or tissues. So far, reduced plasma levels of PAI-2 have been observed in preeclampsia patients (Estelles et al. 1989; Reith et al. 1993). In addition, the available data, including
that generated in this study, suggests that a reduced level of PZP in maternal plasma is associated
with pre-eclampsia (Auer et al. 2010; Griffin 1983; Horne et al. 1972; Nguyen et al. 2019; Rasanen
et al. 2010). Previous reports that PZP is elevated in pre-eclampsia plasma (Armstrong et al. 1986;
Blumenstein et al. 2009) are potentially due to A2M cross-reactivity, which was ruled out in the
present study. Other well-known extracellular chaperones including clusterin, A2M and
haptoglobin are reportedly dysregulated in pre-eclampsia plasma, but due to conflicting results it
is currently unclear if this relates to a deficiency (Auer et al. 2010; Blumenstein et al. 2012;
Blumenstein et al. 2009; Hsu et al. 2015; Kim et al. 2016; Mary et al. 2017; Mlambo et al. 2020;
Weissgerber et al. 2013; Weissgerber et al. 2012). As such, it is recommended that future studies
attempt to measure the levels of multiple extracellular chaperones simultaneously (PZP, PAI-2,
clusterin, haptoglobin and A2M), as it is possible that deficiencies in one extracellular chaperone
are compensated for by others. In addition, there is a need to consider the level of extracellular
chaperones in specific subtypes of pre-eclampsia in future studies, because pre-eclampsia is a
highly heterogeneous disorder and the diagnostic utility of maternal plasma PZP improved slightly
for pre-eclampsia patients co-morbid with IUGR in the present study. Together, a concerted
approach which investigates the levels of multiple extracellular chaperones across subtypes of preeclampsia could potentially lead to improved diagnostic strategies for the disorder.
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6.3 PZP- and PAI-2-Aβ proteostasis in Alzheimer’s disease and possible links
with pre-eclampsia
Several links between Alzheimer’s disease and pre-eclampsia have already been made, including
that both of the disorders involve misfolding and deposition of the Aβ peptide as a pathological
hallmark (Cheng 2014; Cheng et al. 2016; Gerasimova et al. 2019). Extracellular Aβ plaques are
a hallmark of Alzheimer’s disease brain (Serrano-Pozo et al. 2011), whereas deposits of Aβ have
been detected in the urine and placenta of women with pre-eclampsia (Buhimschi et al. 2014). It
has previously been reported that each PZP and PAI-2 co-localise with Aβ plaques in Alzheimer’s
disease brain (Akiyama et al. 1993; Nijholt et al. 2015). PZP has also been reported to be elevated
in plasma of women with presymptomatic Alzheimer’s disease (IJsselstijn et al. 2011), possibly
as a response to the inflammatory pathology of Alzheimer’s disease, given the expression of PZP
is induced by inflammation in many other disorders (as discussed in Section 1.4.3). In conjunction
with data presented herein, it is plausible that both PZP and PAI-2 participate in neuronal Aβ
homeostasis in vivo by sequestering misfolded Aβ and inhibiting its aggregation, eliciting a
reduced cytotoxicity. Given women with a past history of pre-eclampsia are at an increased risk
of Alzheimer’s disease mortality (Theilen et al. 2016), it is possible that aberrant Aβ produced
during pregnancy may act as a seed for pathological events in later life Alzheimer’s disease.
Examining the regulation of PZP and PAI-2 during pre-eclampsia, and whether it relates to later
diagnosis of Alzheimer’s disease, is thus an interesting concept.
The discovery that protein misfolding and aggregation occurs in early-life women with preeclampsia is a rare exception to the trend that PDDs are typically age-related. Interestingly, there
are numerous similarities between early-life pre-eclampsia and old age PDDs, with both involving
chronically elevated stresses, including endoplasmic reticulum dysfunction (Lian et al. 2011;
Pereira 2013; Yung et al. 2008), oxidative stress (Lévy et al. 2019; Raijmakers et al. 2004),
disruption of the unfolded protein response (Burton et al. 2009; Burton & Yung 2011; Gao et al.
2012; Remondelli & Renna 2017) and inflammation (Harmon et al. 2016; Hook et al. 2015), as
well as the accumulation of similar types of protein aggregates (as discussed in Section 6.2). Data
showing that women with pre-eclampsia are at an increased risk of dementia (Basit et al. 2018),
Alzheimer’s disease (Theilen et al. 2016), and cognitive impairment later in life (Fields et al.
2017), are further suggestive that the same processes which contribute to neurodegeneration may
contribute to pre-eclampsia. Similarly, it has been identified that premature placental aging is
implicated in early-onset pre-eclampsia (Mayne et al. 2017), and it has thus been suggested that
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the placenta may be a tractable tissue model for studying human senescence (Maiti et al. 2017).
Pregnancy and particularly the placenta, which is a readily available tissue post-pregnancy, may
thus offer unique opportunities to study the processes which influence protein misfolding and
aggregation in many age-related PDDs. As such, further work which elucidates mechanisms of
proteostasis in pregnancy, such as that described for PZP and PAI-2 in this study, could potentially
lead to novel therapeutic strategies not only for pre-eclampsia, but for numerous human disorders
involving protein misfolding and aggregation.

6.4 PZP and PAI-2 as chaperones during inflammation
Inflammation is a state which can contribute to protein misfolding and aggregation, particularly
through the generation of free radicals such as nitric oxide and reactive oxygen species. The –OCl
reactive oxygen species is particularly powerful at inducing protein misfolding and aggregation,
and hypochlorite-damaged proteins have been implicated in numerous protein-misfolding
disorders including Alzheimer’s disease (Green et al. 2004), atherosclerosis (Hazell et al. 1994),
kidney disease (Malle et al. 1997), rheumatoid arthritis (Stamp et al. 2012), osteoarthritis
(Steinbeck et al. 2007) and pre-eclampsia (Huang et al. 2013). As a means to offset the collateral
damage caused by hypochlorite during inflammation, organisms have evolved proteostasis
mechanisms which are activated in the presence of hypochlorite. For example, hypochlorite
enhances the chaperone activity of human serum albumin, A2M and unfractionated blood plasma
proteins (Ulfig et al. 2019; Wyatt et al. 2014). Hypochlorite-enhanced chaperones have also been
described in E. coli (Müller et al. 2014; Winter et al. 2008). In general, hypochlorite modification
of protein amino acids results in increased surface-exposed hydrophobicity through structural
disruption or conformational modification, which may either promote the accumulation of
susceptible proteins, or enhance the chaperone activity of others (Chao et al. 1997; Ulfig et al.
2019; Winter et al. 2008). PAI-2 appears to fall into the latter category, as both PAI-2NG and PAI2G increased in hydrophobicity upon NaOCl treatment and maintained their solubility in the
present study. The reason for PAI-2NG but not PAI-2G enhancement in chaperone activity upon
NaOCl treatment is unknown, but may relate to the differences in glycosylation between the
proteins (as discussed in Section 5.4). Unfortunately, similar studies testing the effect of NaOCl
on the chaperone activity of PZP could not be undertaken in the present study due to limited
availability of purified protein, but are of interest, especially given the enhancement of A2M
chaperone activity following NaOCl modification (Wyatt et al. 2014). Considering that both PZP
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and PAI-2 are upregulated during inflammation, further examination of hypochlorite-induced
modification on the chaperone activity of these proteins and their substrates will be beneficial to
understanding the contributions of PZP and PAI-2 to proteostasis during inflammatory stress.

6.5 The importance of PZP and PAI-2 as protease inhibitors
Although PZP and PAI-2 were both originally characterised as protease inhibitors, there has been
much debate whether this is an important physiological function. In the latter case, the
predominantly intracellular location of PAI-2, and the existence of PAI-1 (a more abundant and
efficient inhibitor), has confounded the role of PAI-2 as a genuine inhibitor of uPA and tPA in
vivo (as discussed in Section 1.5.4). For the first time, this study has shown in a direct comparison
that both the intracellular and extracellular forms of PAI-2G and PAI-2NG were relatively more
resistant to oxidative NaOCl inactivation of their protease inhibitory activity compared to PAI-1.
This supports a role for PAI-2 as an oxidation-resistant inhibitor of uPA and tPA during pregnancy
and inflammation, when oxidants including hypochlorite that reduce PAI-1 activity are generated
(Fialova et al. 2006; Gandley et al. 2008; Hammer et al. 2001; Klebanoff 2005; Weiss 1989). This
may potentially have further implications for understanding how PAI-1 and PAI-2 influence
fibrinolysis in the pathology of human disorders which involve hypochlorite generation, such as
atherosclerosis and cancer (Pan et al. 2012; Zhang et al. 2020), where the pathology of PAImediated fibrinolysis is under investigation (Croucher et al. 2008; Li et al. 2015; Ploplis 2011).
On the other hand, it is still unclear whether the protease trapping activity of PZP is important
alongside more abundant and efficient protease inhibitors such as A2M (as discussed in Section
1.4.4). The results of this study are supportive of PZP providing some supplemental inhibition of
endogenous or exogenous proteases in human plasma, but it is proposed that an absence of PZP
protease inhibitory activity is unlikely to be of major detriment to human physiology, and perhaps
this is a redundant function. Furthermore, PZP protease inhibitory activity is unlikely to be
resistant to hypochlorite, given its bait region contains oxidation-susceptible methionine residues
which are involved in hypochlorite-induced inactivation of A2M protease inhibitory activity
(Reddy et al. 1994). As such, it is recommended that studies which investigate other functions of
PZP, including immunomodulatory and chaperone activities, should be prioritised.
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6.6 PZP as an immunomodulatory factor
There is evidence that PZP functions as an immunomodulatory factor in vivo through interaction
with cytokines, but so far PZP has only been demonstrated to bind a handful of cytokines in vitro.
This study has demonstrated a novel binding interaction of PZP with TNFα, which, like shown for
A2M and TNFα, resulted in an increased cytotoxicity in a murine cell line. However, due to the
limitations of the L929 cell line in accurately modelling human TNFα receptor interactions, and
the fact that TNFα has a diverse functional output which is often cell type-dependent, it is unknown
whether A2M or PZP potentiate TNFα toxicity in vivo. Instead, studies of A2M-TNFα interactions
in the context of arthritis suggest that alpha-macroglobulins may instead suppress TNFα-mediated
damage and inflammation in vivo (as discussed in Section 4.4). Further investigations which
elucidate the precise effects of PZP-TNFα immunomodulation both in vitro and in vivo are thus
warranted, considering that aberrant expression or dysregulation of PZP and TNFα has been
implicated in multiple diseases. More broadly, it is possible that PZP interacts with other important
immune system cytokines such as those reported to bind A2M, including IL-2 and IL-6 (LaMarre
et al. 1991; Wu et al. 1998), but this is in need of investigation. Together, these studies will lead
to a better understanding of how PZP participates in regulation of the human immune system in
vivo.

6.7 Conclusion
In conclusion, the present study has shed much needed light on the likely biological functions of
PZP and PAI-2. In part, this was possible due to the development of an improved protocol for the
purification of endogenous PZP from pregnancy plasma. The groundwork completed here to
develop a recombinant PZP expression system is also expected to aid future studies of PZP.
Although both PZP and PAI-2 have protease inhibitory activity and holdase-type chaperone
function in vitro, the importance of these functions in vivo is yet to be resolved. The results
presented in this study support that the biological importance of PZP is not exclusively related to
its protease inhibitory activity, and instead PZP may function as a major-pregnancy associated
holdase-type chaperone. Comparatively, the data presented here supports the idea that PAI-2 plays
a more modest role in stabilising proteins, such as locally at the placenta. However, PAI-2 is likely
to be an important inhibitor of uPA and tPA during conditions of oxidative stress that inactivates
PAI-1. The work presented in this thesis will in time serve as an important landmark in our
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understanding of extracellular proteostasis during pregnancy, an exciting area of research in which
few studies have focused on to date. Furthermore, the functions of PZP and PAI-2 described here
are potentially relevant to inflammatory states independent of pregnancy. Future studies of PZP
and PAI-2 may ultimately lead to the development of novel diagnostic or therapeutic strategies for
numerous human disorders involving protein misfolding or dysfunctions in fibrinolysis.
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8 Appendices
8.1 Plasmid DNA maps and sequences

Appendix figure 8.1 SnapGene map (above) and sequence (below) of p-PZP-6His

5’GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGT
GTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGT
TTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA
GCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTA
TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT
ATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGT
ACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAG
TCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTC
ACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCGCCACCATGCGGAAAGACAGACTTCTTCATTTATGT
CTTGTGCTACTTCTTATCCTGCTTTCTGCCAGTGACTCAAACTCTACAGAACCGCAGTATATGGTGCTGGTCCCCTCCCTGCTCCACACTGAGGCCC
CTAAGAAGGGCTGTGTCCTTCTGAGCCACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGGCAGGGAAAACAGGAGCCTCTTCACTGA
CCTGGTGGCGGAGAAGGACTTATTCCACTGTGTCTCCTTCACTCTCCCAAGGATCTCAGCCTCTTCAGAGGTGGCATTCCTTAGCATCCAGATAAAG
GGGCCTACGCAAGATTTCAGGAAGAGGAACACAGTTCTGGTACTGAACACCCAAAGTCTGGTCTTTGTCCAGACAGACAAACCCATGTATAAACCAG
GACAGACAGTAAGATTCCGTGTTGTCTCCGTGGATGAAAATTTTCGCCCTCGAAATGAACTGATTCCACTGATATACCTTGAGAACCCAAGAAGAAA
TCGAATTGCACAATGGCAGAGTCTCAAGCTAGAAGCTGGCATCAATCAGTTGTCCTTTCCCCTCTCATCAGAGCCCATTCAGGGCTCCTACAGGGTG
GTGGTACAGACAGAATCAGGTGGAAGGATACAGCACCCCTTCACCGTGGAGGAATTTGTGCTTCCCAAGTTTGAGGTCAAAGTTCAGGTGCCAAAGA
TAATCAGTATCATGGATGAAAAAGTGAACATAACAGTCTGTGGAGAATACACTTATGGGAAGCCTGTCCCAGGACTTGCAACTGTGAGCCTGTGTAG
AAAATTATCTCGTGTTCTTAATTGTGACAAGCAGGAGGTCTGTGAGGAATTCAGTCAACAGCTTAACAGCAATGGCTGCATCACCCAACAAGTACAC
ACCAAAATGCTCCAGATTACAAATACGGGCTTTGAAATGAAGCTTAGAGTGGAAGCCAGGATCAGAGAAGAGGGGACAGACCTGGAAGTCACTGCAA
ACAGGATCAGTGAAATCACAAACATTGTATCCAAACTCAAATTCGTGAAAGTGGATTCACACTTTAGACAAGGAATCCCCTTTTTTGCACAGGTGCT
TCTGGTGGATGGAAAAGGTGTGCCCATCCCCAATAAACTCTTCTTCATCTCTGTGAATGACGCCAATTATTACTCCAATGCAACCACCAATGAGCAG
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GGTCTTGCACAGTTTTCAATCAATACTACCAGTATCTCGGTTAATAAACTTTTTGTCCGGGTTTTCACTGTGCATCCCAACTTGTGTTTTCACTATT
CATGGGTAGCAGAAGACCACCAGGGTGCTCAGCACACTGCAAATCGTGTTTTCTCCTTAAGTGGAAGTTACATTCACCTGGAGCCTGTGGCTGGTAC
CCTGCCCTGTGGCCACACGGAGACTATCACGGCACACTATACACTGAATAGACAGGCCATGGGAGAGTTATCGGAGCTCAGTTTCCATTACCTGATC
ATGGCTAAGGGAGTCATCGTCAGATCTGGAACCCACACTCTGCCTGTGGAGTCAGGAGACATGAAAGGCAGTTTTGCCTTATCCTTCCCTGTGGAGT
CAGACGTTGCCCCCATTGCACGAATGTTCATCTTTGCCATTTTACCAGATGGAGAAGTTGTTGGAGACTCTGAAAAATTTGAGATTGAAAACTGTCT
AGCCAACAAGGTGGATTTGAGCTTCAGCCCAGCACAAAGTCCCCCAGCCTCACATGCCCACCTGCAAGTAGCAGCTGCTCCGCAGTCCCTCTGTGCC
CTTCGTGCTGTGGACCAAAGTGTGCTGCTCATGAAGCCTGAGGCTGAGCTCTCTGTGTCCTCAGTATATAATCTGCTAACTGTGAAGGATCTCACCA
ATTTTCCTGACAATGTGGACCAGCAGGAGGAAGAACAAGGACACTGTCCCCGTCCTTTCTTCATTCATAATGGAGCCATCTATGTTCCCTTATCAAG
TAATGAAGCAGATATTTATAGCTTCCTCAAGGGGATGGGATTGAAGGTGTTCACTAACTCAAAAATCCGAAAACCAAAGTCGTGTTCAGTCATCCCT
TCCGTGTCTGCAGGAGCAGTAGGTCAAGGATACTATGGAGCAGGTCTAGGAGTAGTAGAGAGACCATATGTTCCTCAATTAGGCACATATAATGTGA
TACCCTTAAATAATGAACAAAGTTCAGGGCCAGTCCCTGAAACGGTGCGAAGCTATTTTCCTGAGACTTGGATCTGGGAGTTGGTGGCAGTGAACTC
ATCAGGTGTGGCTGAGGTAGGAGTAACAGTCCCTGACACCATCACCGAGTGGAAGGCAGGGGCCTTCTGCCTGTCCGAAGATGCTGGACTTGGTATC
TCTTCCACTGCCTCTCTCCGAGCCTTCCAGCCCTTCTTTGTGGAGCTCACAATGCCTTACTCTGTGATTCGTGGAGAGGTCTTCACACTCAAGGCCA
CGGTCCTAAACTACCTTCCCAAATGCATCCGGGTCAGTGTGCAGCTGAAAGCCTCTCCAGCCTTCCTAGCTTCCCAAAATACAAAGGGAGAAGAATC
CTATTGTATCTGTGGAAATGAGAGACAAACCTTGTCTTGGACAGTGACTCCTAAAACTCTGGGGAATGTGAACTTCTCAGTGAGTGCAGAGGCAATG
CAGTCCTTAGAACTCTGTGGAAATGAGGTTGTTGAGGTCCCTGAGATTAAAAGAAAAGACACAGTCATCAAAACCCTGTTGGTGGAGGCTGAAGGTA
TTGAGCAAGAAAAGACTTTCAGTTCTATGACCTGTGCCTCAGGTGCTAATGTGTCTGAGCAGTTGTCCTTGAAGCTCCCATCAAATGTGGTCAAAGA
ATCTGCCAGAGCTTCTTTCTCAGTTCTGGGTGACATATTAGGTTCTGCTATGCAAAATATACAAAATCTCCTCCAGATGCCATATGGCTGTGGAGAA
CAGAACATGGTCCTATTTGCTCCTAACATCTATGTCTTGAACTATCTGAATGAAACCCAGCAGCTGACGCAGGAGATCAAGGCCAAGGCCGTTGGCT
ATCTCATCACTGGTTACCAGAGACAGCTGAACTACAAACACCAAGATGGCTCCTACAGCACCTTTGGGGAACGATATGGCAGGAACCAGGGCAACAC
TTGGCTCACAGCTTTTGTACTGAAGACTTTCGCCCAGGCTCGATCCTACATCTTCATTGATGAAGCACACATTACCCAATCTCTCACGTGGCTCTCC
CAGATGCAGAAGGACAATGGCTGTTTCAGGAGCTCTGGGTCACTGCTCAACAATGCCATAAAGGGAGGTGTAGAAGATGAAGCGACCCTCTCCGCCT
ATGTTACTATTGCCCTTCTGGAAATTCCTCTCCCAGTCACTAACCCTATTGTTCGCAATGCCCTGTTCTGCCTGGAGTCAGCCTGGAATGTAGCAAA
GGAGGGGACCCATGGGAGCCATGTCTACACCAAGGCATTGCTGGCCTATGCTTTTTCCCTACTGGGAAAGCAAAATCAGAATAGAGAAATACTGAAC
TCACTTGATAAGGAAGCTGTGAAAGAAGACAACCTCGTCCATTGGGAGCGCCCTCAGAGACCCAAGGCACCAGTGGGGCATCTTTACCAAACCCAGG
CTCCCTCTGCTGAGGTGGAGATGACATCCTATGTGCTCCTCGCTTATCTCACGGCCCAGCCAGCCCCCACCTCAGGGGACCTGACCTCTGCAACTAA
CATTGTGAAGTGGATCATGAAGCAGCAGAACGCCCAAGGTGGTTTCTCCTCCACCCAGGACACAGTGGTGGCTCTCCATGCCCTGTCCAGGTATGGA
GCAGCCACTTTCACCAGAACTGAGAAAACTGCACAGGTCACCGTTCAGGATTCACAGACCTTTTCTACAAATTTCCAAGTAGACAACAACAACCTCC
TATTACTGCAGCAGATCTCATTGCCAGAGCTCCCTGGAGAATATGTCATAACAGTAACTGGGGAAAGATGTGTGTATCTTCAGACATCCATGAAATA
CAATATTCTTCCAGAGAAAGAGGACTCCCCATTTGCTTTAAAAGTGCAGACTGTGCCCCAAACTTGCGATGGACACAAAGCCCACACCAGCTTTCAG
ATCTCACTGACCATCAGTTACACAGGAAACCGTCCTGCTTCCAATATGGTGATTGTTGATGTAAAGATGGTATCTGGTTTTATTCCCCTGAAACCAA
CAGTAAAAATGCTTGAAAGATCTAGCTCTGTGAGCCGGACAGAAGTGAGCAACAACCATGTCCTCATTTATGTGGAACAGGTGACAAATCAGACGCT
AAGTTTTTCCTTCATGGTTCTGCAAGACATCCCAGTAGGAGACTTGAAGCCAGCAATTGTTAAAGTCTATGATTACTATGAGACAGATGAGTCTGTG
GTTGCTGAGTATATCGCCCCCTGCAGCACAGATACAGAGCATGGAAATGTTGGTGGAGGTGGCTCTCATCATCACCATCACCATTGATAAACCCGCT
GATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCT
TTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGG
GAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCT
GTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCC
TTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCC
AAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTG
GACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAA
TGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTA
TGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTC
AGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATT
TATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAG
CTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTG
GGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTT
TTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTG
TGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAA
AGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCA
CGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGC
GCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTG
TGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTC
GTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGAC
CGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGC
TGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCA
TCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGAC
CTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATA
AAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGC
TGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCG
GCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAG
CAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGA
GGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATA
CCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGC
TGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGG
CAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAAC
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGT
TTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAA
ACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTAT
ATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTC
CCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTAT
CAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG
AGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGC
TCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTC
AACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAA
GTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACT
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GATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATG
TTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAAT
AAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC
-3’

Appendix figure 8.2 SnapGene map (above) and sequence (below) of p-PZP-FLAG

5’GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGT
GTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGT
TTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA
GCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTA
TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT
ATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGT
ACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAG
TCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTC
ACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCGCCACCATGCGGAAAGACAGACTTCTTCATTTATGT
CTTGTGCTACTTCTTATCCTGCTTTCTGCCAGTGACTCAAACTCTACAGAACCGCAGTATATGGTGCTGGTCCCCTCCCTGCTCCACACTGAGGCCC
CTAAGAAGGGCTGTGTCCTTCTGAGCCACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGGCAGGGAAAACAGGAGCCTCTTCACTGA
CCTGGTGGCGGAGAAGGACTTATTCCACTGTGTCTCCTTCACTCTCCCAAGGATCTCAGCCTCTTCAGAGGTGGCATTCCTTAGCATCCAGATAAAG
GGGCCTACGCAAGATTTCAGGAAGAGGAACACAGTTCTGGTACTGAACACCCAAAGTCTGGTCTTTGTCCAGACAGACAAACCCATGTATAAACCAG
GACAGACAGTAAGATTCCGTGTTGTCTCCGTGGATGAAAATTTTCGCCCTCGAAATGAACTGATTCCACTGATATACCTTGAGAACCCAAGAAGAAA
TCGAATTGCACAATGGCAGAGTCTCAAGCTAGAAGCTGGCATCAATCAGTTGTCCTTTCCCCTCTCATCAGAGCCCATTCAGGGCTCCTACAGGGTG
GTGGTACAGACAGAATCAGGTGGAAGGATACAGCACCCCTTCACCGTGGAGGAATTTGTGCTTCCCAAGTTTGAGGTCAAAGTTCAGGTGCCAAAGA
TAATCAGTATCATGGATGAAAAAGTGAACATAACAGTCTGTGGAGAATACACTTATGGGAAGCCTGTCCCAGGACTTGCAACTGTGAGCCTGTGTAG
AAAATTATCTCGTGTTCTTAATTGTGACAAGCAGGAGGTCTGTGAGGAATTCAGTCAACAGCTTAACAGCAATGGCTGCATCACCCAACAAGTACAC
ACCAAAATGCTCCAGATTACAAATACGGGCTTTGAAATGAAGCTTAGAGTGGAAGCCAGGATCAGAGAAGAGGGGACAGACCTGGAAGTCACTGCAA
ACAGGATCAGTGAAATCACAAACATTGTATCCAAACTCAAATTCGTGAAAGTGGATTCACACTTTAGACAAGGAATCCCCTTTTTTGCACAGGTGCT
TCTGGTGGATGGAAAAGGTGTGCCCATCCCCAATAAACTCTTCTTCATCTCTGTGAATGACGCCAATTATTACTCCAATGCAACCACCAATGAGCAG
GGTCTTGCACAGTTTTCAATCAATACTACCAGTATCTCGGTTAATAAACTTTTTGTCCGGGTTTTCACTGTGCATCCCAACTTGTGTTTTCACTATT
CATGGGTAGCAGAAGACCACCAGGGTGCTCAGCACACTGCAAATCGTGTTTTCTCCTTAAGTGGAAGTTACATTCACCTGGAGCCTGTGGCTGGTAC
CCTGCCCTGTGGCCACACGGAGACTATCACGGCACACTATACACTGAATAGACAGGCCATGGGAGAGTTATCGGAGCTCAGTTTCCATTACCTGATC
ATGGCTAAGGGAGTCATCGTCAGATCTGGAACCCACACTCTGCCTGTGGAGTCAGGAGACATGAAAGGCAGTTTTGCCTTATCCTTCCCTGTGGAGT
CAGACGTTGCCCCCATTGCACGAATGTTCATCTTTGCCATTTTACCAGATGGAGAAGTTGTTGGAGACTCTGAAAAATTTGAGATTGAAAACTGTCT
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AGCCAACAAGGTGGATTTGAGCTTCAGCCCAGCACAAAGTCCCCCAGCCTCACATGCCCACCTGCAAGTAGCAGCTGCTCCGCAGTCCCTCTGTGCC
CTTCGTGCTGTGGACCAAAGTGTGCTGCTCATGAAGCCTGAGGCTGAGCTCTCTGTGTCCTCAGTATATAATCTGCTAACTGTGAAGGATCTCACCA
ATTTTCCTGACAATGTGGACCAGCAGGAGGAAGAACAAGGACACTGTCCCCGTCCTTTCTTCATTCATAATGGAGCCATCTATGTTCCCTTATCAAG
TAATGAAGCAGATATTTATAGCTTCCTCAAGGGGATGGGATTGAAGGTGTTCACTAACTCAAAAATCCGAAAACCAAAGTCGTGTTCAGTCATCCCT
TCCGTGTCTGCAGGAGCAGTAGGTCAAGGATACTATGGAGCAGGTCTAGGAGTAGTAGAGAGACCATATGTTCCTCAATTAGGCACATATAATGTGA
TACCCTTAAATAATGAACAAAGTTCAGGGCCAGTCCCTGAAACGGTGCGAAGCTATTTTCCTGAGACTTGGATCTGGGAGTTGGTGGCAGTGAACTC
ATCAGGTGTGGCTGAGGTAGGAGTAACAGTCCCTGACACCATCACCGAGTGGAAGGCAGGGGCCTTCTGCCTGTCCGAAGATGCTGGACTTGGTATC
TCTTCCACTGCCTCTCTCCGAGCCTTCCAGCCCTTCTTTGTGGAGCTCACAATGCCTTACTCTGTGATTCGTGGAGAGGTCTTCACACTCAAGGCCA
CGGTCCTAAACTACCTTCCCAAATGCATCCGGGTCAGTGTGCAGCTGAAAGCCTCTCCAGCCTTCCTAGCTTCCCAAAATACAAAGGGAGAAGAATC
CTATTGTATCTGTGGAAATGAGAGACAAACCTTGTCTTGGACAGTGACTCCTAAAACTCTGGGGAATGTGAACTTCTCAGTGAGTGCAGAGGCAATG
CAGTCCTTAGAACTCTGTGGAAATGAGGTTGTTGAGGTCCCTGAGATTAAAAGAAAAGACACAGTCATCAAAACCCTGTTGGTGGAGGCTGAAGGTA
TTGAGCAAGAAAAGACTTTCAGTTCTATGACCTGTGCCTCAGGTGCTAATGTGTCTGAGCAGTTGTCCTTGAAGCTCCCATCAAATGTGGTCAAAGA
ATCTGCCAGAGCTTCTTTCTCAGTTCTGGGTGACATATTAGGTTCTGCTATGCAAAATATACAAAATCTCCTCCAGATGCCATATGGCTGTGGAGAA
CAGAACATGGTCCTATTTGCTCCTAACATCTATGTCTTGAACTATCTGAATGAAACCCAGCAGCTGACGCAGGAGATCAAGGCCAAGGCCGTTGGCT
ATCTCATCACTGGTTACCAGAGACAGCTGAACTACAAACACCAAGATGGCTCCTACAGCACCTTTGGGGAACGATATGGCAGGAACCAGGGCAACAC
TTGGCTCACAGCTTTTGTACTGAAGACTTTCGCCCAGGCTCGATCCTACATCTTCATTGATGAAGCACACATTACCCAATCTCTCACGTGGCTCTCC
CAGATGCAGAAGGACAATGGCTGTTTCAGGAGCTCTGGGTCACTGCTCAACAATGCCATAAAGGGAGGTGTAGAAGATGAAGCGACCCTCTCCGCCT
ATGTTACTATTGCCCTTCTGGAAATTCCTCTCCCAGTCACTAACCCTATTGTTCGCAATGCCCTGTTCTGCCTGGAGTCAGCCTGGAATGTAGCAAA
GGAGGGGACCCATGGGAGCCATGTCTACACCAAGGCATTGCTGGCCTATGCTTTTTCCCTACTGGGAAAGCAAAATCAGAATAGAGAAATACTGAAC
TCACTTGATAAGGAAGCTGTGAAAGAAGACAACCTCGTCCATTGGGAGCGCCCTCAGAGACCCAAGGCACCAGTGGGGCATCTTTACCAAACCCAGG
CTCCCTCTGCTGAGGTGGAGATGACATCCTATGTGCTCCTCGCTTATCTCACGGCCCAGCCAGCCCCCACCTCAGGGGACCTGACCTCTGCAACTAA
CATTGTGAAGTGGATCATGAAGCAGCAGAACGCCCAAGGTGGTTTCTCCTCCACCCAGGACACAGTGGTGGCTCTCCATGCCCTGTCCAGGTATGGA
GCAGCCACTTTCACCAGAACTGAGAAAACTGCACAGGTCACCGTTCAGGATTCACAGACCTTTTCTACAAATTTCCAAGTAGACAACAACAACCTCC
TATTACTGCAGCAGATCTCATTGCCAGAGCTCCCTGGAGAATATGTCATAACAGTAACTGGGGAAAGATGTGTGTATCTTCAGACATCCATGAAATA
CAATATTCTTCCAGAGAAAGAGGACTCCCCATTTGCTTTAAAAGTGCAGACTGTGCCCCAAACTTGCGATGGACACAAAGCCCACACCAGCTTTCAG
ATCTCACTGACCATCAGTTACACAGGAAACCGTCCTGCTTCCAATATGGTGATTGTTGATGTAAAGATGGTATCTGGTTTTATTCCCCTGAAACCAA
CAGTAAAAATGCTTGAAAGATCTAGCTCTGTGAGCCGGACAGAAGTGAGCAACAACCATGTCCTCATTTATGTGGAACAGGTGACAAATCAGACGCT
AAGTTTTTCCTTCATGGTTCTGCAAGACATCCCAGTAGGAGACTTGAAGCCAGCAATTGTTAAAGTCTATGATTACTATGAGACAGATGAGTCTGTG
GTTGCTGAGTATATCGCCCCCTGCAGCACAGATACAGAGCATGGAAATGTTGATTACAAGGATGACGACGATAAGTGATAAACCCGCTGATCAGCCT
CGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATA
AAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAAT
AGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCG
CATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCT
CGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTT
GATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGT
TCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGAT
TTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCA
TGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAT
AGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAG
GCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATAT
CCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAG
GCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAG
ACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACG
TTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCAT
CATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGG
ATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCG
ACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCT
GGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTAC
GGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGC
GACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATC
CTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATT
TCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTA
GAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAA
GCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAAT
GAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCG
AGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCC
AGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA
ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGC
CTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC
GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCA
CTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTT
TGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTT
AAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTA
AACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTG
TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAA
ACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAG
TTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCC
CAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAG
TGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATC
ATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAG
CATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACT
CATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATA
GGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC
-3’
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Appendix figure 8.3 SnapGene map (above) and sequence (below) of p-PZP-twST

5’GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGT
GTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGT
TTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA
GCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTA
TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT
ATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGT
ACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAG
TCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTC
ACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCGCCACCATGCGGAAAGACAGACTTCTTCATTTATGT
CTTGTGCTACTTCTTATCCTGCTTTCTGCCAGTGACTCAAACTCTACAGAACCGCAGTATATGGTGCTGGTCCCCTCCCTGCTCCACACTGAGGCCC
CTAAGAAGGGCTGTGTCCTTCTGAGCCACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGGCAGGGAAAACAGGAGCCTCTTCACTGA
CCTGGTGGCGGAGAAGGACTTATTCCACTGTGTCTCCTTCACTCTCCCAAGGATCTCAGCCTCTTCAGAGGTGGCATTCCTTAGCATCCAGATAAAG
GGGCCTACGCAAGATTTCAGGAAGAGGAACACAGTTCTGGTACTGAACACCCAAAGTCTGGTCTTTGTCCAGACAGACAAACCCATGTATAAACCAG
GACAGACAGTAAGATTCCGTGTTGTCTCCGTGGATGAAAATTTTCGCCCTCGAAATGAACTGATTCCACTGATATACCTTGAGAACCCAAGAAGAAA
TCGAATTGCACAATGGCAGAGTCTCAAGCTAGAAGCTGGCATCAATCAGTTGTCCTTTCCCCTCTCATCAGAGCCCATTCAGGGCTCCTACAGGGTG
GTGGTACAGACAGAATCAGGTGGAAGGATACAGCACCCCTTCACCGTGGAGGAATTTGTGCTTCCCAAGTTTGAGGTCAAAGTTCAGGTGCCAAAGA
TAATCAGTATCATGGATGAAAAAGTGAACATAACAGTCTGTGGAGAATACACTTATGGGAAGCCTGTCCCAGGACTTGCAACTGTGAGCCTGTGTAG
AAAATTATCTCGTGTTCTTAATTGTGACAAGCAGGAGGTCTGTGAGGAATTCAGTCAACAGCTTAACAGCAATGGCTGCATCACCCAACAAGTACAC
ACCAAAATGCTCCAGATTACAAATACGGGCTTTGAAATGAAGCTTAGAGTGGAAGCCAGGATCAGAGAAGAGGGGACAGACCTGGAAGTCACTGCAA
ACAGGATCAGTGAAATCACAAACATTGTATCCAAACTCAAATTCGTGAAAGTGGATTCACACTTTAGACAAGGAATCCCCTTTTTTGCACAGGTGCT
TCTGGTGGATGGAAAAGGTGTGCCCATCCCCAATAAACTCTTCTTCATCTCTGTGAATGACGCCAATTATTACTCCAATGCAACCACCAATGAGCAG
GGTCTTGCACAGTTTTCAATCAATACTACCAGTATCTCGGTTAATAAACTTTTTGTCCGGGTTTTCACTGTGCATCCCAACTTGTGTTTTCACTATT
CATGGGTAGCAGAAGACCACCAGGGTGCTCAGCACACTGCAAATCGTGTTTTCTCCTTAAGTGGAAGTTACATTCACCTGGAGCCTGTGGCTGGTAC
CCTGCCCTGTGGCCACACGGAGACTATCACGGCACACTATACACTGAATAGACAGGCCATGGGAGAGTTATCGGAGCTCAGTTTCCATTACCTGATC
ATGGCTAAGGGAGTCATCGTCAGATCTGGAACCCACACTCTGCCTGTGGAGTCAGGAGACATGAAAGGCAGTTTTGCCTTATCCTTCCCTGTGGAGT
CAGACGTTGCCCCCATTGCACGAATGTTCATCTTTGCCATTTTACCAGATGGAGAAGTTGTTGGAGACTCTGAAAAATTTGAGATTGAAAACTGTCT
AGCCAACAAGGTGGATTTGAGCTTCAGCCCAGCACAAAGTCCCCCAGCCTCACATGCCCACCTGCAAGTAGCAGCTGCTCCGCAGTCCCTCTGTGCC
CTTCGTGCTGTGGACCAAAGTGTGCTGCTCATGAAGCCTGAGGCTGAGCTCTCTGTGTCCTCAGTATATAATCTGCTAACTGTGAAGGATCTCACCA
ATTTTCCTGACAATGTGGACCAGCAGGAGGAAGAACAAGGACACTGTCCCCGTCCTTTCTTCATTCATAATGGAGCCATCTATGTTCCCTTATCAAG
TAATGAAGCAGATATTTATAGCTTCCTCAAGGGGATGGGATTGAAGGTGTTCACTAACTCAAAAATCCGAAAACCAAAGTCGTGTTCAGTCATCCCT
TCCGTGTCTGCAGGAGCAGTAGGTCAAGGATACTATGGAGCAGGTCTAGGAGTAGTAGAGAGACCATATGTTCCTCAATTAGGCACATATAATGTGA
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TACCCTTAAATAATGAACAAAGTTCAGGGCCAGTCCCTGAAACGGTGCGAAGCTATTTTCCTGAGACTTGGATCTGGGAGTTGGTGGCAGTGAACTC
ATCAGGTGTGGCTGAGGTAGGAGTAACAGTCCCTGACACCATCACCGAGTGGAAGGCAGGGGCCTTCTGCCTGTCCGAAGATGCTGGACTTGGTATC
TCTTCCACTGCCTCTCTCCGAGCCTTCCAGCCCTTCTTTGTGGAGCTCACAATGCCTTACTCTGTGATTCGTGGAGAGGTCTTCACACTCAAGGCCA
CGGTCCTAAACTACCTTCCCAAATGCATCCGGGTCAGTGTGCAGCTGAAAGCCTCTCCAGCCTTCCTAGCTTCCCAAAATACAAAGGGAGAAGAATC
CTATTGTATCTGTGGAAATGAGAGACAAACCTTGTCTTGGACAGTGACTCCTAAAACTCTGGGGAATGTGAACTTCTCAGTGAGTGCAGAGGCAATG
CAGTCCTTAGAACTCTGTGGAAATGAGGTTGTTGAGGTCCCTGAGATTAAAAGAAAAGACACAGTCATCAAAACCCTGTTGGTGGAGGCTGAAGGTA
TTGAGCAAGAAAAGACTTTCAGTTCTATGACCTGTGCCTCAGGTGCTAATGTGTCTGAGCAGTTGTCCTTGAAGCTCCCATCAAATGTGGTCAAAGA
ATCTGCCAGAGCTTCTTTCTCAGTTCTGGGTGACATATTAGGTTCTGCTATGCAAAATATACAAAATCTCCTCCAGATGCCATATGGCTGTGGAGAA
CAGAACATGGTCCTATTTGCTCCTAACATCTATGTCTTGAACTATCTGAATGAAACCCAGCAGCTGACGCAGGAGATCAAGGCCAAGGCCGTTGGCT
ATCTCATCACTGGTTACCAGAGACAGCTGAACTACAAACACCAAGATGGCTCCTACAGCACCTTTGGGGAACGATATGGCAGGAACCAGGGCAACAC
TTGGCTCACAGCTTTTGTACTGAAGACTTTCGCCCAGGCTCGATCCTACATCTTCATTGATGAAGCACACATTACCCAATCTCTCACGTGGCTCTCC
CAGATGCAGAAGGACAATGGCTGTTTCAGGAGCTCTGGGTCACTGCTCAACAATGCCATAAAGGGAGGTGTAGAAGATGAAGCGACCCTCTCCGCCT
ATGTTACTATTGCCCTTCTGGAAATTCCTCTCCCAGTCACTAACCCTATTGTTCGCAATGCCCTGTTCTGCCTGGAGTCAGCCTGGAATGTAGCAAA
GGAGGGGACCCATGGGAGCCATGTCTACACCAAGGCATTGCTGGCCTATGCTTTTTCCCTACTGGGAAAGCAAAATCAGAATAGAGAAATACTGAAC
TCACTTGATAAGGAAGCTGTGAAAGAAGACAACCTCGTCCATTGGGAGCGCCCTCAGAGACCCAAGGCACCAGTGGGGCATCTTTACCAAACCCAGG
CTCCCTCTGCTGAGGTGGAGATGACATCCTATGTGCTCCTCGCTTATCTCACGGCCCAGCCAGCCCCCACCTCAGGGGACCTGACCTCTGCAACTAA
CATTGTGAAGTGGATCATGAAGCAGCAGAACGCCCAAGGTGGTTTCTCCTCCACCCAGGACACAGTGGTGGCTCTCCATGCCCTGTCCAGGTATGGA
GCAGCCACTTTCACCAGAACTGAGAAAACTGCACAGGTCACCGTTCAGGATTCACAGACCTTTTCTACAAATTTCCAAGTAGACAACAACAACCTCC
TATTACTGCAGCAGATCTCATTGCCAGAGCTCCCTGGAGAATATGTCATAACAGTAACTGGGGAAAGATGTGTGTATCTTCAGACATCCATGAAATA
CAATATTCTTCCAGAGAAAGAGGACTCCCCATTTGCTTTAAAAGTGCAGACTGTGCCCCAAACTTGCGATGGACACAAAGCCCACACCAGCTTTCAG
ATCTCACTGACCATCAGTTACACAGGAAACCGTCCTGCTTCCAATATGGTGATTGTTGATGTAAAGATGGTATCTGGTTTTATTCCCCTGAAACCAA
CAGTAAAAATGCTTGAAAGATCTAGCTCTGTGAGCCGGACAGAAGTGAGCAACAACCATGTCCTCATTTATGTGGAACAGGTGACAAATCAGACGCT
AAGTTTTTCCTTCATGGTTCTGCAAGACATCCCAGTAGGAGACTTGAAGCCAGCAATTGTTAAAGTCTATGATTACTATGAGACAGATGAGTCTGTG
GTTGCTGAGTATATCGCCCCCTGCAGCACAGATACAGAGCATGGAAATGTTGGGAGCGCTTGGAGCCACCCGCAGTTCGAAAAAGGTGGAGGTTCTG
GCGGTGGATCGGGAGGTTCAGCGTGGAGCCACCCGCAGTTCGAGAAATGATAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATC
TGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTG
AGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTAC
GCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAA
GCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGC
CATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTAT
CTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTC
TGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTG
TGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCG
CCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTAT
TCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGG
ATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAG
ACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAAC
TGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCT
GCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCAT
ACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATG
ATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGG
CGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATA
GCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCA
TCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTC
GATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGT
TCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCA
TTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTG
TTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAAC
TCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGG
TTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTA
ATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGG
CGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGC
GTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTT
TCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCG
CCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTA
TGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACC
TTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAA
AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAA
AAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTA
ATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTAC
CATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAG
AAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTT
GTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCC
CCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACT
GCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCG
AGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAAC
TCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGG
GTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGA
AGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAG
TGCCACCTGACGTC
-3’
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8.2 Quality control of anti-PZP and anti-A2M antibody cross-reactivity
Purified PZP and purified A2M (500 ng each) were probed by dot blot or native PAGE Western
blot using the relevant antibodies as described in Sections 2.3 and 2.4. The anti-PZP antibody
displayed good reactivity for PZP and no cross-reactivity for A2M by dot blot (Appendix figure
8.4Ai) and native Western blot (Appendix figure 8.4Bi). The anti-A2M antibody displayed good
reactivity for A2M and some cross-reactivity for PZP by dot blot (Appendix figure 8.4Aii) and
native Western blot (Appendix figure 8.4Bii).

Appendix figure 8.4 Quality control of anti-PZP and anti-A2M antibody cross-reactivity. Purified PZP and
purified A2M (500 ng each) were probed by either (A) dot blot or (B) native PAGE Western blot, using (i) an antiPZP or (ii) an anti-A2M antibody, as labelled.
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8.3 Optimisation of Aβ1-42 cytotoxicity in the SH-SY5Y cell line
Using the method described in Section 4.2.7, SH-SY5Y treatment with 10 µM Aβ1–42 was the
minimum required to achieve significant cytotoxicity (Appendix figure 8.5A). Incubation of 10
µM Aβ1–42 for 5 h at 37°C significantly improved SH-SY5Y cytotoxicity, compared to
preparations of 10 µM Aβ1–42 incubated for 0, 1 or 24 h at 37°C (Appendix figure 8.5B).
Preparations of 10 µM Aβ1–42 incubated for 5 h at 37°C in cell medium remained soluble, as no
increase in ThT fluorescence compared to the 0 h treatment was observed (Appendix figure 8.5C).

Appendix figure 8.5 Determination of optimal conditions for Aβ1-42 cytotoxicity in SH-SY5Y cells. (A) The effect
of 0, 5, 10 or 20 µM Aβ1-42 on SH-SY5Y cytotoxicity as assessed by Cytotox Green assay after 48 h. (B) The effect
of 10 µM Aβ1-42 on SH-SY5Y cytotoxicity following pre-incubation for 0, 1, 5 or 24 h at 37°C in cell medium, as
assessed by Cytotox Green assay after 48 h. (C) A corresponding ThT assay of 10 µM Aβ1-42 incubated at 37°C over
24 h in cell medium, with arrows indicating relevant time points to the analysis in (B). Data are means ± SD (n = 3).
One-way ANOVA with post-hoc Tukey’s HSD was conducted to identify non-significant (ns) and significant
differences (*** = P < 0.001; ** = P < 0.01; * = P < 0.05).
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8.4 ThT assay of Aβ1-42 aggregation in the presence of ovalbumin
Using the ThT assay method described in Section 5.2.6, co-incubation of Aβ1–42 with ovalbumin
at a 1:10 molar ratio (ovalbumin:Aβ1–42) did not markedly influence the aggregation of Aβ1–42
(Appendix figure 8.6).

Appendix figure 8.6 The effect of ovalbumin on Aβ1-42 aggregation. (A) Aβ1-42 (3 μM in PBS) was incubated at
28°C in the absence or presence of ovalbumin (1:10 molar ratio of ovalbumin:Aβ1-42) and analysed by ThT assay.
Data are means ± SD (n = 3).
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